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SUMMARY
Nucleotide sequences of the structural protein genes 
(5'-capsid-E3-E2-6K-El-3') of the virulent Trinidad donkey (TRD) 
strain of Venezuelan equine encephalitis (VEE) virus and its 
attenuated vaccine derivative, strain TC-83, were determined from 
cDNA clones containing the 3 '-one-third (26S RNA) region of the 42S 
RNA genomes of these viruses. The capsid, E3, and 6K genes
contained no mutations, and therefore are not involved in the 
attenuation of TC-83 virus. One and five amino acid mutations in El 
and E2, respectively, and a single nucleotide deletion in the 
3 '-noncoding region of TC-83 virus were detected. The E2 mutations, 
which affected predicted secondary structure and hydropathicity, are 
probable determinants of the attenuated phenotype. TRD and TC-83 E2 
proteins apparently are equally glycosylated at three sites.
The structural protein genes of VEE TRD and TC-83 viruses were 
expressed in vaccinia virus under control of the vaccinia 7.5K 
promoter. Expression of seven E2-specific and two of four
El-specific epitopes was shown by indirect immunofluorescence using 
monoclonal antibodies. Mice immunized with recombinant virus
developed VEE virus-specific neutralizing antibodies and survived 
intraperitoneal challenge with virulent TRD, P676, 3880, and
Everglades VEE viruses. However, unlike TC-83 vaccine virus,
recombinant virus did not protect mice from intranasal challenge with 
TRD virus. These results suggest that the recombinant vaccine may
be a vaccine candidate for equines and humans at risk of
mosquito-transmitted VEE, but perhaps not for laboratory workers at 
risk of aerosol infection with VEE virus.
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CHAPTER 1
LITERATURE REVIEW
PART 1: VENEZUELAN EQUINE ENCEPHALITIS VIRUS
I. Taxonomic Setting
A. Arboviruses
The term arbovirus (arthropod-borne virus) was 
introduced in 1942 to designate those animal viruses that 
are maintained in a cycle of biological transmission between 
haematophagus arthropod vectors and vertebrate hosts. The 
arthropod becomes infected by feeding on a viraemic 
vertebrate. After an extrinsic incubation period during 
which virus replicates in tissues of the arthropod, the 
vector is able to transmit the virus to another vertebrate 
host. Arthropod vectors, including mosquitoes, ticks, 
Gulicoides species (midges), and Phlebotomus species (flies) 
utilize a wide variety of vertebrates as hosts (World Health 
Organization Technical Report, 1967).
The first recognized arboviruses were those that cause 
significant epidemics or epizootics. Yellow fever, sandfly 
fever, and Rift Valley fever viruses as well as eastern.
—2—
western, Japanese, St. Louis, and Murray Valley encephalitis 
viruses were isolated before or during the 1930's (World 
Health Organization Technical Report, 1967). By 1950, 
thirty-five arboviruses had been identified (Berge, 1975).
In the late 1950's the Rockefeller Foundation instituted a 
worldwide program of arbovirus investigation by establishing 
laboratories in Poona, India; Port-of-Spain, Trinidad;
Belem, Brazil; Johannesburg, South Africa; Cairo, Egypt; 
Ibadan, Nigeria; and Cali, Colombia (Theiler and Downs, 
1973). As a result of these activities, many new viruses 
were isolated from arthropods, trapped and sentinel animals, 
and humans. By 1960 about 140 different arboviruses or 
possible arboviruses were recognized (Theiler and Downs, 
1973), and by 1975, 334 were recognized (Berge, 1975). The 
1985 edition of The International Catalogue of Arboviruses 
contains 504 registered viruses, 32 of which are designated 
as probably not or not arthropod-borne, but which are of 
interest to arbovirologists (Karabatsos, 1985). Most 
registered virus isolates are from South America (152 
isolates) and Africa (130), followed by North America (107), 
Asia (105), Australasia (68), and Europe (47).
Arboviruses are, by definition, grouped together on the 
basis of their transmission by haematophagous arthropods. 
Relationships among arboviruses were established by 
serological methods. The first recognized groups of 
antigenically related arboviruses were initially designated 
A, B, and C (Casals, 1957). These three groups were 
designated later as alphaviruses and flaviviruses of the
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family Togaviridae (Porterfield et al., 1978) and Group C of 
the family Bunyaviridae (Porterfield et al.,1975/76), 
respectively. Registered arboviruses are presently 
separated antigenically into 63 serogroups (Karabatsos, 
1985).
In 1984 the International Committee on Taxonomy of 
Viruses (ICTV) approved the recommendation of the ICTV 
Togavirus Study Group to transfer flaviviruses from 
Togaviridae into a new family taxon - Flaviviridae 
(Karabatsos, 1975; Westaway et al., 1985a, 1985b). This 
recommendation resulted from the realization that 
alphaviruses and flaviviruses differ in size, morphology, 
morphogenesis, and replication strategy. The structural 
genes of flaviviruses (Rice et ^., 1985a) and alphaviruses 
are located at the 5’-end and 3'-end of the viral genomic 
RNA, respectively. Serological relationships established 
among the arboviruses have so far been supported by both 
morphological and molecular evidence. This correlation 
ensures the continued importance of conventional serological 
techniques in the identification and classification of the 
arboviruses.
One hundred twenty-four of the registered arboviruses 
cause natural or laboratory related disease in humans. 
Severity of disease ranges from minor episodes of febrile 
illness to more serious haemorrhagic fevers and 
encephalitides. Antigenic groups of arboviruses that 
contain the largest number of viruses associated with 
natural or laboratory acquired human disease are
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classified in virus families Bunyaviridae, i, - ■ ■  : ■ . ■ ',   ^
Flaviviridae, and Togaviridae j
(Karabatsos, 1985).
B. Toeaviruses
Four genera of viruses are included in the Togaviridae 
family: Alphavirus. Rubivirus. Pestivirus. and Arterivirus.
Members of this family contain an icosahedral nucleocapsid 
30 - 35 nm in diameter composed of a capsid protein and a 
single-stranded, positive-sense RNA genome of approximately 
4 X 10^ daltons. The nucleocapsid is
enclosed within a lipid envelope containing two or three 
polypeptides that are usually glycosylated.
The Rubivirus and Arterivirus genera each contain a 
single virus species, rubella virus and equine arteritis 
virus, respectively. Pestivirus contains three viruses: 
mucosal disease-bovine virus diarrhoea virus, hog cholera 
(swine fever) virus, and border disease virus. Alphavirus. 
which contains 26 members, is the largest genus. Although 
viruses within each genus are serologically related, 
serological relationships do not extend across genera. 
Lactic dehydrogenase and carrot mottle viruses are possible 
members of the Togaviridae (Westaway et al., 1985a).
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C. Alphaviruses
Serological grouping of 26 arboviruses in the 
Alphavirus genus is based on antigenic relationships 
demonstrated by haemagglutination-inhibition (HI) using 
hyperimmune antisera. The original grouping by HI was 
proposed by Casals and Brown (1954). Twenty-two viruses are 
grouped by HI into three antigenic complexes of viruses: (i) 
Venezuelan equine encephalitis (Venezuelan equine 
encephalitis, Everglades, Mucambo, Pixuna, and Cabassou 
viruses), (ii) western equine encephalitis (western equine 
encephalitis, Sindbis, Whataroa, Kyzylagach, Highlands J, 
Fort Morgan, Aura, and Y62-33 viruses), and (iii) Semliki 
Forest (Semliki Forest, Chikungunya, O'nyong-nyong, Getah, 
Sagiyama, Bebaru, Ross River, Mayaro, and Una viruses). 
Eastern equine encephalitis (EEE), Ndumu, Middelburg, and 
Barmah Forest viruses have not been grouped into any 
alphavirus complex (Calisher et ^ . , 1980a; Shope, 1985). 
Complement-fixation, immunofluorescence, and enzyme-linked 
immunosorbent assays are less cross-reactive among 
alphaviruses than HI, and neutralization (Nt) is specific 
for agents within antigenic complexes (Karabatsos, 1975; 
Chanas et ^., 1976; Shope, 1985).
The geographic distribution of alphaviruses includes 
the Americas (the Venezuelan equine encephalitis complex, 
and western equine encephalitis, EEE, Highlands J, Fort 
Morgan, Aura, Mayaro, and Una viruses), the Soviet Union 
(Kyzylagach and Y62-33 viruses), Australia (Barmah Forest
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virus), New Zealand (Whataroa virus), Africa (Semliki 
Forest, Chikungunya, O'nyong-nyong, Ndumu, and Middelburg 
viruses), Asia (Chikungunya, Getah, Sagiyama, Bebaru, and 
Ross River viruses), the Pacific (Ross River virus), and 
throughout the Old World (Sindbis virus) (Shope, 1985).
Except for Fort Morgan virus, which has been isolated 
only from cliff swallow bugs (Calisher et al., 1980b), all 
of the alphaviruses have been isolated from mosquitoes. 
Western equine encephalitis (WEE), EEE, Sindbis (SIN), 
Mayaro, Chikungunya, and Tonate (variant of Mucambo) viruses 
have also been isolated from other arthropods (Karabatsos, 
1985). Chikungunya, Mayaro, O ’nyong-nyong, Ross River (RR), 
and SIN viruses have caused human epidemics (Karabatsos, 
1985). Venezuelan equine encephalitis (VEE), WEE, and EEE 
viruses are major veterinary pathogens that can cause 
encephalitis in equines and humans (Monath and Trent, 1981; 
Shope, 1985).
D. Venezuelan Equine Encephalitis Virus Complex
VEE virus was first isolated and characterized by Kubes 
and Rios (1939) and Beck and Wyckoff (1938) from the brain 
of a horse that died of a previously unrecognized disease 
during an epizootic that occurred between 1936 and 1938 in 
Venezuela. Subsequent isolations of VEE virus-related 
strains were made in Venezuela, Colombia, Peru, the island 
Trinidad (northeast coast of South America), Brazil,
Surinam, Argentina, Panama, Mexico, and the United States.
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The VEE virus serological complex was first defined by Shope 
et al. (1964), who demonstrated reciprocal relationships 
between classical VEE, Mucambo (Causey et al., 1961), and 
Pixuna viruses. Young and Johnson (1969a) and Scherer and 
Pancake (1970) demonstrated cross-protection among these 
three viruses in heimsters and spiny rats, respectively. 
Scherer and Pancake (1970) suggested that classical VEE, 
Mucambo (MUC), and Pixuna (PIX) viruses should be designated 
as VEE virussubtypes 1, 2, and 3 to simplify nomenclature. 
Young and Johnson (1969b) further classified many VEE virus 
isolates by short-incubation HI reactions using spiny rat 
(Prpechimys spinpsus) immune sera. The classification 
scheme devised by these investigators forms the basis of 
current classification. VEE viruses were classified as VEE 
virus subtypes 1 - 4 .  Subtype 1 contained all classical 
epizootic VEE virus strains, and was subdivided further into 
five variants, designated lA - IE. Everglades (EVE), MUC, 
and PIX viruses were designated as VEE virus subtypes 2, 3, 
and 4, respectively. Testing of many VEE virus isolates 
demonstrated that short-incubation HI testing does not 
reliably differentiate the closely related A, B, and C 
variants of subtype 1 virus (Johnson and Martin, 1974).
These authors suggested that these serological variants of 
VEE virus should therefore be grouped together as virus 
subtype-variant lABC.
The immunological analysis of agents in the VEE virus 
complex, including several new VEE virus isolates, was 
extended by HI and Nt using antisera from rabbits that had
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been immunized with. E2 envelope glycoproteins purified from 
VEE viruses (France et al., 1979; Kinney et al., 1983; 
Calisher et al., 1982). As a result of this work, several 
new VEE viruses (78V-3531, Tonate, 71D-1252, and Cabassou) 
were added to the classification scheme of Young and Johnson 
(1969b) as shown in Table 1. VEE Trinidad donkey (TRD) and 
PTF-39 viruses are now considered to be strains of VEE 
variant lAB virus, while P676 virus is a separate, 
differentiable 1C variant (France et al., 1979).
II. Importance of VEE Virus Disease
Probable or confirmed epizootics of VEE virus disease
occurred in 17 of the 34 years between 1935 and 1968 in
Venezuela, Colombia, Peru, Trinidad, Panama, and/or Mexico.
Most of the outbreaks occurred in Colombia and Venezuela. A
wide-spread epizootic that was caused by VEE subytpe lAB
virus occurred between 1969 and 1971 in Colombia, Venezuela,
Peru, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua,
Costa Rica, and Mexico (Groot, 1972). This outbreak spread
into the United States (Texas) for the first time in the
summer of 1971.
Over 150,000 equine deaths were attributed to VEE virus
infection between 1967 and 1971 (Groot, 1972). Equine 
^frequencies
mortality""''-^ .^ ,.--''(l00 X number of dead equines/total number
of equines in area) in VEE virus epizootics have varied from
frequencies
19% to 40% (Groot, 1972), while fatality"T'-.^--''''( 100 X number 
of dead equines/number of sick equines) ranged from 35% in
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1969 in Guatemala (Scherer et a^ , , 1972a) to 83% in 1943 in 
Trinidad (Tigertt and Downs, 1962). Thus, VEE virus is an 
important veterinary pathogen that can cause severe economic 
disruption in nonmechanized societies (Groot, 1972).
Epidemics of VEE virus infection in humans occurred in 
association with concurrent equine epizootics. VEE virus 
disease generally produced mild influenza-like disease in 
humans, with fatality rates of 1% or less. However, in 
severe epidemics where large numbers of humans, particularly 
children, became infected, morbidity and mortality were 
significant. In the 1962 - 1964 VEE virus outbreak in 
Venezuela, 960 of more than 23,000 cases suffered overt 
central nervous system infection, with 156 deaths (0.7% 
fatality). In the 1969 VEE virus epizootic-epidemic in
Ecuador, 310 fatalities occurred out of an estimated 31,000 
human cases (Groot, 1972).
The last recognized cases of epizootic VEE virus 
infection in horses occurred in 1972 in Nicaragua (Scherer 
et al., 1976a; Dickerman and Scherer, 1983). Epizootic VEE 
virus has been quiescent for sixteen years, but given the 
epidemic pattern of sporadic, often explosive outbreaks, it 
remains a potential problem.
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III. Natural History of VEE Virus
A. Epizootic and Enzootic VEE Viruses
The etiologic agents of VEE virus epizootic-epidemics, 
when identified, have invariably been VEE subtype lAB or 1C 
viruses (Young and Johnson, 1969b; Johnson and Martin,
1974). Furthermore, subtype lAB and 1C viruses have been 
isolated only during VEE virus outbreaks, and have not been 
isolated from rodents or mosquitoes involved in cycles of 
endemic transmission in nature, despite intensive field 
investigations (Franck and Johnson, 1971; Johnson and 
Martin, 1974; Sudia and Newhouse, 1975; Cupp et al., 1986; 
Walder et al., 1984a, 1984b; Wiebe et al., 1983; Scherer 
et , 1976b) .
Infection of horses with epizootic VEE virus strains 
resulted in severe disease (Henderson et al., 1971; Walton 
et al.. 1973; Mackenzie et al., 1976). Viraemias in subtype
o
lAB and 1C virus-infected horses reached 10 infectious 
units/ml, indicating that equines are efficient amplifying 
hosts for the epizootic VEE viruses. High viraemias 
correlated well with encephalitis and death in equines 
(Walton et al,, 1973). On the other hand, horses infected 
with enzootic strains developed viraemias of less than 10^ 
plaque forming units (PFU)/ml (Walton et al., 1973; Johnson 
and Martin, 1974). Similarly, VEE subtype lAB and 1C 
viruses, but not ID virus, caused clinical disease in rhesus 
monkeys (Monath et ^., 1974).
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Enzootic VEE viruses occur in limited geographic foci 
located in warm wet forest or shaded fresh water swamp 
habitats. Enzootic foci have been studied in Brazil, Panama 
(Grayson and Galindo, 1969), Mexico (Scherer et al,, 1964; 
Scherer and Dickerman, 1972), and the Everglades in southern 
Florida in the United States (Chamberlain et ^., 1964, 
1969). Epizootic VEE viruses, on the other hand, have been 
isolated during epizootics during rainy seasons in drier 
regions that are normally devoid of VEE virus activity 
(Johnson and Martin, 1974).
B. Mosquito Vectors and Vertebrate Hosts
Enzootic VEE viruses have been isolated from a wide 
variety of mosquitoes (more than 40 species in 11 genera). 
Most of these isolations were from Culex. subgenus 
Melanoconion mosquito species (Sellers et si,, 1965; Galindo 
et al.. 1966; Sudia et 1971, Martin et ^., 1972; Sudia
and Newhouse, 1975). Epizootic VEE viruses have been 
isolated from a variety of other mosquito species, commonly 
Aedes species and Psoronhora species (Johnson and Martin, 
1974; Scherer et al., 1986).
Melanoconion mosquitoes apparently feed on wild rodents 
(Galindo et 1966; Grayson and Galindo, 1968), which
appear to be the major vertebrate reservoirs of enzootic VEE 
viruses (Johnson and Martin, 1974). Enzootic VEE virus 
disappeared from the Bush Bush Forest of Trinidad after the 
rodent population was inexplicably decimated (Jonkers
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et al., 1968). Enzootic VEE viruses or VEE virus-specific 
antibodies have been found in marsupials, rabbits, bats, 
raccoons, and monkeys (Johnson and Martin, 1974; Bowen, 
1976), but infrequently in birds (Dickerman et al., 1972,
1976). However, VEE virus infection in birds can result in 
viraemias sufficient to infect mosquitoes (Bowen and McLean,
1977). Possible wide vector and host specificities of 
epizootic VEE virus may have contributed to the widespread 
epizootic-epidemic of 1969 - 1971 and the propensity of the 
virus to circumvent established immune barriers (Lord,
1974). Cattle, pigs, and various other mammals are thought 
not to be important epizootic hosts of VEE virus due to low 
viraemia or low susceptibility to infection (Walton and 
Johnson, 1972a; Bowen, 1976).
C. Human Infection with Enzootic VEE Viruses
Mosquito-transmitted human disease has occurred with 
enzootic VEE subtype ID (Johnson et ^., 1968; Franck and 
Johnson, 1970; Young and Johnson, 1969b) and subtype 2 
(Ehrenkranz et al., 1970) viruses. The prototype ID virus, 
strain 3880, was isolated from a fatal human case in Panama 
(Johnson et al., 1968). Subtype ID virus was isolated from 
soldiers on manoeuvres in the Panama Canal Zone (Franck and 
Johnson, 1970). Seminole Indians in the Everglades region 
of Florida had a high prevalence of anti-VEE virus 
(subtype 2) antibodies (Work, 1964). More recently, human 
intrusion into an enzootic focus of VEE virus resulted in
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VEE virus infection of 9 individuals (Adames et 1979).
Laboratory infection with Mucambo virus (subtype 3A) has 
also been reported (de Mucha-Macias and Sanchez-Spindola, 
1965).
D. Origin of Epizootic VEE Viruses
The origin of epizootic VEE virus or the mechanism for 
maintenance of the virus in nature is an important question 
in the natural history of VEE virus. Johnson and Martin 
(1974) summarized five possibilities for consideration:
(i) virus is maintained in undiscovered mosquito-vertebrate 
cycles, (ii) epizootic strains arise from enzootic strains 
by mutation, (iii) the virus is maintained in mosquito-horse 
populations where most horses are immune or mosquito 
populations are low, (iv) the virus resides as a latent 
infection in wild vertebrates, and (v) epizootics result 
from the use of inadequately inactivated VEE virus 
vaccines. The second possibility was investigated by 
Rico-Hesse et (1988a, 1988b), who demonstrated genetic 
and antigenic diversity of subtype ID strains by 
oligonucleotide fingerprinting of viral RNAs and monoclonal 
antibody analysis, respectively. The 3880 strain (ID) is 
closely related to epizootic VEE strains by tryptic peptide 
mapping (Kinney and Trent, 1982). Although laboratory 
rodents are highly susceptible to lethal challenge with 
subtype ID virus, wild rodents were not killed by this virus 
(Zarate and Scherer, 1969). It seems plausible that wild
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rodents might serve as vertebrate reservoirs for subtype ID 
viruses that occasionally mutate to equine-virulent forms.
IV. Pathogenesis of VEE Virus Disease
A. Humans
Laboratory accidents have resulted in at least 150 
human infections with VEE virus (American Committee on 
Arthropod-Borne Viruses, 1980). Details of VEE virus 
disease in humans have been obtained from observations of 
infections incurred in the laboratory (Casals et ^., 1943; 
Lennette and Koprowski, 1943; Koprowski and Cox, 1947; 
Johnson and Martin, 1974) or in natural settings 
(Sanmartin-Barberi et ^ . , 1954; Briceno Rossi, 1967; Hinman 
et al.. 1971; Scherer et al., 1972a, 1972b; Bowen, 1972; 
Bowen et al., 1976). Symptoms of illness developed quickly 
after an incubation period of 2 - 5 days. Patients suffered 
malaise, fever, chills, retro-orbital or occipital pain, and 
myalgia in the thighs and lower back. Nausea and vomiting 
were common symptoms. Upon examination, patients presented 
fever, tachycardia, inflamed throat, and leukopenia. Virus 
could be isolated from the blood and from throat swabs for 3 
days after onset of symptoms (Briceno Rossi, 1967; Scherer 
et al.. 1972b; Bowen and Calisher, 1976). Viraemias of up 
to 10^ suckling mouse median intracranial lethal units of 
VEE virus have been reported (Suarez and Bergold, 1968; 
Martin et al., 1972; Calisher and Maness, 1975; Bowen and
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Calisher, 1976). Central nervous system (CNS) symptoms of 
somnolence, mild confusion, and photophobia were seen in 
fewer than half of the cases. Severe CNS involvement, 
manifested by convulsions and coma, have been reported in 4% 
of infected children under 15 years of age (Sanmartin,
1972). Clinical symptoms usually subsided 4 - 6  days after 
onset. Biphasic illness, in which the complete clinical 
picture recurs 4 - 8  days following the first episode, has 
also been reported (Koprowski and Cox, 1947; Bowen, 1972).
Autopsies performed on 21 people who suffered fatal 
infection with VEE virus during the 1962 - 1963 VEE virus 
epidemic in Zulio, Venezuela, demonstrated moderate to 
severe congestion and oedema with haemorrhage in many 
organs, but especially in the brain, gastrointestinal tract, 
and lungs (de la Monte al., 1985). The extensive hepatic 
degeneration and interstitial pneumonia that was found has 
not been reported in experimental animal models. However, 
the central nervous system and reticuloendothelial 
cytopathology observed in these human fatalities were 
typical of VEE virus-induced lesions in experimentally 
infected animals. Pathology included depletion of 
lymphocytes, vascular thrombosis, and necrosis of follicles 
in lymph nodes, spleen, and gastrointestinal tract. In the 
CNS, mild or focal inflammatory cell infiltrates occurred in 
the leptomeninges and perivascular spaces, and 
meningoencephalitis with necrotizing vasculitis occurred in 
two of the patients (de la Monte et al»» 1985).
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Marker and Ascher (1976) isolated sensitized populations 
of lymphocytes from the peripheral circulation of individuals 
immunized with a live, attenuated VEE virus (strain TC-83). 
These cells were stimulated to proliferate in vitro by 
inactivated VEE TC-83 virus antigen. Such sensitized 
lymphocytes may play a role in the inflammatory lesions 
induced by local virus replication in the CNS during 
infections with VEE virus.
Asymptomatic infection with epizootic VEE virus was 
apparently rare in humans (Bowen, 1972). The presence in 
serum of VEE virus-specific antibodies correlated well with 
a history of illness (Hinman et al., 1971; Scherer et al.. 
1972b; Martin et al., 1972).
Enzootic VEE viruses, which have not caused obvious 
disease in equines, have caused human illness that is like 
epizootic VEE virus-induced disease (Scherer et ^ . , 1972b; 
Causey et al., 1961; de Mucha-Macias and Sanchez-Spindola, 
1965). Human infection with enzootic subtype ID virus has 
resulted in abrupt onset of fever, muscle pains, leukopenia 
and vomiting (Dietz et al., 1979).
B. Monkevs
Although Gochenour (1972) reported fatalities in rhesus 
monkeys, with severe necrotizing encephalitis, leukocytic 
infiltration, and neuronal destruction, after infection 
monkeys with a Colombian-Venezuelan epizootic strain (VE-9) 
of VEE virus, monkeys infected with epizootic VEE virus
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usually only show symptoms of leu openia and mild fever 
(Gleiser et 1962; Monath et al., 1974). Involvement of
the pancreas following VEE virus infection in hamsters 
(Gorelkin and Jahrling, 1974) led to investigation of a 
possible diabetic effect of this virus in monkeys (Bowen 
et al.. 1980). Rhesus monkeys infected with the virulent 
TRD virus developed mild illness (cough, biphasic fever, 
viraemia) accompanied by low insulin and high glucose levels 
in the blood. Infection with the attenuated VEE TC-83 
virus, however, did not cause viraemia or signs of illness 
and did not exhibit any potential diabetic effect (Bowen 
et al.. 1980). Ryder and Ryder (1983) found no evidence to 
support a causal relationship between epizootic VEE virus 
infection and diabetes in human patients during the 1969 VEE 
virus epidemic in Venezuela.
VEE TRD virus infection of rhesus monkeys produced 
early destruction of lymphocytes in the lymph nodes and 
spleen, but no evidence of myeloid pathology in the bone 
marrow. Although clinical CNS symptoms were absent, glial 
proliferation and perivascular cuffing, without neuronal 
damage, were detected in the CNS (Victor et ^., 1956; 
Gleiser et al., 1962). Lesions were absent 10 weeks after 
infection. Danes et al.(1973a, 1973b) detected VEE virus in 
the olfactory bulb after 2 days postinfection (PI). These 
investigators demonstrated haematogenous spread of VEE virus 
to the CNS in virus-infected monkeys in which the cribriform 
plate of the ethmoid bone, through which unmyelinated
-19-
olfactory nerve fibers enter the olfactory bulb of the 
brain, had been replaced with a bone graft.
C. Equines
Infection of equines with epizootic VEE virus has 
resulted in (i) mild fever, (ii) more severe fever, 
tachycardia, depression, anorexia, and sometimes diahrroea, 
or (iii) encephalitis manifested by CNS symptoms such as 
circling, ataxia, head pressing, and hyperexcitability 
(Kissling and Chamberlain, 1967). Equines infected 
experimentally with epizootic VEE virus developed mild 
leukopenia 2 days after infection. Signs of CNS dysfunction 
appeared by 5 days, and most deaths occurred between 6 - 8  
days, postinfection (Kissling et al., 1956). Biphasic 
fevers have occurred, and the second episode invariably 
signaled rapid deterioration and death of the animal. 
Epizootic VEE viruses replicated to high viraemia in equines 
and, unlike enzootic VEE viruses, were recovered from nasal, 
oral, and conjunctival washings (Johnson and Martin, 1974). 
Epizootic virus was not recovered from the urine or faeces of 
infected horses (Johnson and Martin, 1974). Virus was 
recovered from cerebrospinal fluid of equines infected with 
epizootic or enzootic VEE viruses, although enzootic strains 
do not produce encephalitis in horses (Shope et al., 1964; 
Walton et al., 1973). Epizootic VEE virus strains grew to 
high titre in donkey macrophages and lymphocytes, whereas 
enzootic Muc, Fix, and 71D-1252 viruses did not (Liprandi
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et al.. 1986). Jochim et al. (1973) reported abortions in 
two horses following infection with epizootic VEE virus in 
Texas, but normal foetuses were also found in infected 
equines (Johnson and Martin, 1974).
Histopathology resulting from infection with the TRD 
strain of VEE subtype lAB virus included massive destruction 
of lymphocytes in lymph nodes, myeloid depletion of the bone 
marrow, and necrosis in pancreatic acinar cells (Kissling 
et al., 1956; Gleiser et al,, 1962; Gochenour et al..
1962). Johnson and Martin (1974) reported that infection of 
equines with other epizootic strains resulted in slight 
haematopoietic cytopathology. Walton et (1973) 
recovered no virus from the pancreas of infected horses, and 
VEE virus was recovered from the brain in only one-half of 
the fatal cases studied. Infection in horses ranged from 
mild infiltration of the basal ganglia to diffuse 
inflammation, perivascular cuffing, vasculitis, and neuronal 
degeneration (Walton et al., 1973).
D. Rodents
Laboratory rodents are highly susceptible to VEE virus 
infection. VEE lAB and 1C viruses are uniformly fatal by 
peripheral or intracerebral (i.e.) routes for adult mice, 
rats, guinea pigs, hamsters, and for weanling rabbits. 
Enzootic strains show variable virulence for these animals.
In mice, infection resulted in destruction of 
lymphocytes in spleen and lymph nodes, with neutrophil
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infiltration and endothelial swelling, by the first day PI.
By day 4, marked lymphocytic depletion and necrosis occurred 
in the spleen, nodes, and bone marrow; and primary 
encephalitic lesions, including perivascular cuffing, 
oedema, and necrosis of the cerebral cortex, were evident.
At 6 days PI, immature blast cells and primitive 
reticuloendothelial cells infiltrated lymph nodes; necrosis 
of the bone marrow was more severe; and encephalitis 
involved the entire brain, spinal cord, and meninges, with 
severe perivascular cuffing, gliosis, and necrosis of 
neurons, especially the large motor neurons in the spinal 
cord (Gleiser et al., 1962; Gochenour, 1972; Gorelkin, 1973).
Virus accumulated more slowly in the mouse brain than 
in peripheral tissues, but eventually replicated to the 
highest level in the brain and resulted in hind limb 
paralysis and death within 8 days PI (Gleiser et al., 1962). 
The contribution of host immunity in VEE virus-induced 
encephalitis was investigated by Dal Canto et (1981), 
who showed that VEE virus infection of Balb/c mice resulted 
in extensive inflammation and demyelination of the white 
matter of the spinal cord. In athymic nude mice, however, 
inflammation of the spinal cord was not seen, and the onset 
of clinical signs was delayed for 2 days compared to 
infected Balb/c mice. Nude mice developed grey matter 
pathology in the CNS, but the lesions were not as severe as 
those seen in immunocompetent mice. Thus, it appeared that 
VEE virus initiated grey matter cytopathology by a cytopathic 
mechanism, but the host inflammatory response was involved
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in the severe lesions and extensive necrosis observed in 
infected animals. Similar results were obtained in VEE 
virus-infected mice treated with antithymocyte serum 
(Woodman et 1975). Epizootic VEE virus infection of
pregnant rats resulted in inflammatory reactions in the 
placenta and infection and death of embryos (Garcia-Tamayo 
et al., 1981).
Epizootic VEE viruses killed guinea pigs 2 - 4  days 
PI. The massive and rapid cytopathology that occurred in 
the lymphoid and bone marrow tissues resulted in death 
before CNS lesions developed (Gochenour, 1972, Victor 
et al.. 1956; Gleiser et al., 1962). Partially immunized 
guinea pigs endured epizootic VEE virus challenge long 
enough to develop encephalitis (Victor et al., 1956). 
Enzootic VEE viruses were usually not lethal for guinea 
pigs, although subtype ID virus infection was fatal (Scherer 
and Chin, 1977). A Guatemalan guinea pig species was 
susceptible to fatal infection with VEE subtype IE virus 
(Scherer et §1., 1979).
Viruses of all VEE subtypes except those of subtype 4 
caused fatal infection in hamsters (Zarate and Scherer,
1969; Jahrling and Scherer, 1973a, 1973b). Infection with 
subtype lAB, IE and 2 viruses caused massive necrosis of 
lymphoid tissues and bone marrow within 2 days PI, resulting 
in death from peripheral cytopathology before development of 
significant CNS symptoms (Austin and Scherer, 1971; Jahrling 
and Scherer, 1973a; Walker et al,, 1976). Subtype 3 virus
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caused less severe haematopoietic pathology and resulted in 
delayed death (14 days) with minimal CNS cytopathology.
V. VEE Virus Vaccines
A. Inactivated Vaccines
The first VEE vaccine, which was used in Venezuela, 
Colombia, and Ecuador, was an inactivated preparation of 
virus that was grown in chicken embryos (Johnson and Martin,
1974). Although Randall et (1949) successfully 
immunized humans with VEE TRD virus that had been 
inactivated with 0.2% formaldehyde, this vaccine produced 
clinical illness in 14 of 327 vaccinees, and live VEE virus 
was recovered from 8 of these patients (Smith et ^., 1956). 
These infections occurred despite extensive testing of the 
vaccine for infectivity in laboratory rodents. Virus 
inactivated with 4% formaldehyde was found to be safe for 
human use, but failed to induce immunity (Berge et al.. 
1961a).
Cole et (1973) used an improved technique to 
prepare a formaldehyde-inactivated preparation of VEE TRD 
virus. These investigators maintained that TRD virus grown 
in cell culture and harvested before development of 
significant cytopathic effect (CPE) was more completely 
inactivated by low concentrations of formaldehyde (0.05% - 
0.1%) than were earlier vaccines prepared from crude chick 
embryo cultures. The use of adjuvants potentiated the
— 24—
antibody response of mice and monkeys immunized with 
inactivated VEE vaccine (Harrington et 1979; Harrington
et al., 1981).
Because of the reluctance to use inactivated vaccines 
derived from virulent VEE virus, Cole et al. (1974) developed 
a formaldehyde-inactivated preparation of the attenuated 
TC-83 strain of VEE virus. Formaldehyde-inactivated TC-83 
virus (C-84 vaccine) protected hamsters from peripheral TRD 
virus challenge, but not from intranasal challenge (Jahrling 
and Stephenson, 1984). Foster et al. (1983) purified and 
concentrated formaldehyde-inactivated TC-83 virus in sucrose 
gradients to enable vaccination of guinea pigs and horses 
with a larger antigenic mass of this nonreplicating antigen. 
Protection of guinea pigs against challenge with the 
virulent 71-180 No. 4 subytpe IB, 1971 isolate from Texas 
correlated with high vaccine dose. Horses receiving two 
doses of 32,000 haemagglutination units of inactivated 
vaccine developed VEE virus-specific HI reciprocal titres of 
40 - 160 and survived challenge with the 71-180 virus, which 
caused 90% mortality in unimmunized animals (Foster et , 
1983).
Gamma-irradiated VEE virus has also been shown to
protect guinea pigs from virulent VEE virus challenge, but
this vaccine has not been evaluated in humans or equines
»
(Reitman e^ ^ . , 1970).
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B. Attenuated Vaccines
Virulent VEE virus that was serially passaged 65 or 74 
times in HeLa or Maitland-type chicken embryo cell cultures, 
respectively, lost virulence for adult mice by peripheral 
routes, but not by the i.e. route (Koprowski and Lennette, 
1946; Murphy, 1955). A mouse fibroblast cell adapted strain 
of TRD virus retained virulence for suckling mice, but 
showed little evidence of replication in the brains of adult 
mice after s.c. inoculation (Kundin et al., 1966). However, 
the attenuated virus was still lethal by i.e. inoculation 
(Kundin, 1966).
The most promising vaccine was developed by Berge 
et al. (1961). The virulent TRD strain of VEE virus, which 
was isolated in 1943 from the brain of an infected donkey 
that died during a VEE virus epizootic on the island of 
Trinidad (Randall and Mills, 1949; Tigertt and Downs, 1962), 
was passaged in primary cultures of foetal guinea pig heart 
cells (Berge et ^ . , 1961; McKinney, 1972). After 45 
passages the virus was almost completely attenuated for 
adult mice by both peripheral and i.e. routes, and protected 
adult mice from virulent VEE virus challenge by either route 
(Berge et al., 1961). The TC-45 virus was still virulent 
for suckling and weanling mice by both i.p. and i.e. routes. 
Burros immunized with TC-50 virus (50th guinea pig heart 
cell passage) developed minimal fever and viraemia, produced 
anti-VEE virus Nt antibodies, and survived challenge with 
virulent virus (Gochenour et , 1962).
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In humans, TC-50 and TC-80 viruses produced viraemias
2 9of 10 ’ PFU/ml or less and reactogenicity rates of 40% or 
85% in vaccinees with or without prior immunization with 
formaldehyde-inactivated VEE vaccine, respectively (McKinney 
et al.. 1963). Due to this high rate of reactogenicity, a 
substrain was derived by plaque purifying the 78th-passage 
virus in chicken fibroblast cell culture (McKinney et al..
1963). The resulting virus clone was grown again in guinea 
pig heart cells. The new TC-80 strain was completely 
avirulent for weanling mice by both peripheral and i.e. 
routes, was nonfatal for newborn mice by intraperitoneal 
(i.p.) inoculation, and immunized guinea pigs, rhesus 
monkeys, and burros against virulent virus challenge 
(McKinney, 1972; Johnson and Martin, 1974). The 
81st-passage virus was used to prepare stock virus (TC-82) 
from which the TC-83 vaccine was prepared.
Since 1964, more than 6000 humans at risk of VEE virus
3
infection have been vaccinated with 5 X 10 guinea pig 
median i.p. immunizing doses of TC-83 virus. Clinical 
reactions, ranging from mild symptoms to more serious 
influenza-like illness requiring several days of bed rest 
occurred in 25% - 40% of vaccinees (McKinney, 1972; 
Alevizatos et ^., 1967; Johnson and Martin, 1974). The 
more serious symptoms, which occurred in 5% of vaccinees, 
included fever, myalgia, and leukopenia. Reactogenicity did 
not approach the severe form of natural VEE virus disease. 
TC-83 virus was recovered from blood and throat washings of 
human recipients, but viraemias were insufficient to infect
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mosquitoes (McKinney, 1972). Over 90% of human recipients 
of the TC-83 vaccine developed HI and Nt antibodies within 2 
weeks of vaccination, and immunity has been reported to be 
long lived, lasting as long as 6 - 10 years (McKinney, 1972, 
Burke et al., 1977). Immunization with TC-83 virus elicited 
Nt antibodies of high titre against the homologous virus, 
somewhat lower and more variable titres against other 
subtype lAB and subtype 1C strains, and low or absent titres 
against enzootic VEE viruses in humans, equines, and mice 
(McKinney, 1972; Burke et al., 1977; Fillis and Calisher, 
1979; Walton et al., 1973). No epizootic virus illness has 
been reported in humans vaccinated with TC-83 virus, but 
several cases have been reported in immunized personnel 
working with enzootic strains (de Mucha-Macias and 
Sanchez-Spindola, 1965; Johnson and Martin, 1974).
Reactogenicity of the TC-83 vaccine in equines included 
fever, mild to moderate leukopenia, and viraemia of less 
than 10^*^ PFU/ml (Jochim e t ^ . ,  1973; Spertzel and Kahn, 
1971; Gochenour et ^., 1962). Walton et (1972a) 
measured antibody titres versus TC-83 virus in vaccinated 
horses. All immunized animals had anti-lAB and anti-lC 
virus Nt antibodies that lasted for at least 14 months, by 
which time the low anti-ID and anti-IE virus titres had 
disappeared. Challenge with epizootic VEE virus 14 months 
following immunization resulted in neither clinical symptoms 
nor viraemia, although postchallenge antibody levels 
increased greatly against TC-83 virus and moderately against 
all other VEE virus strains (Walton et al,, 1972). Anti-VEE
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virus Nt antibodies have been shown to last at least 30 
months in horses (Walton and Johnson, 1972b).
More than ten million doses of the TC-83 vaccine have 
been administered to equines (McKinney, 1972; Walton et al.. 
1971; Eddy et al., 1972; Sharman, 1972). The TC-83 vaccine 
proved invaluable in controlling the 1969 - 1970 VEE 
epizootic in Central America (Walton et al., 1972) and later 
in Mexico and the southern United States (Lord, 1974; 
Ferguson et al., 1978; Henderson et al., 1971; Sharman, 
1972).
C. Problems Associated with the TC-83 Virus Vaccine
Although the attenuated, live TC-83 vaccine is of 
proven efficacy in experimental models and under actual 
field conditions during VEE virus epizootics, concerns 
remain regarding the use of this vaccine. The high rate of 
reactogenicity, particularly in humans has been documented. 
TC-83 virus has been shown to cause stillbirths, decreased 
litter sizes, and decreased birth-to-weanling survival in 
mice (Spertzel et al., 1972). Intracerebral inoculation of 
rhesus monkey foetuses caused congenital cerebral and ocular 
malformations (London et al., 1977).
Thus, the TC-83 vaccine may have 
teratogenic potential in humans. Mice, humans, and lower 
primates, which possess haemochorial placentas, may be more 
susceptible to foetal infection than equines, which have 
epitheliochorial placentas.
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As with any attenuated live vaccine, reversion of TC-83 
virus to the virulent parental phenotype is a major 
concern. Serial passage of TC-83 virus in horses resulted 
in higher viraemias and increased frequency and severity of 
clinical manifestations (Luedke et al., 1972). However, 
there was no evidence of serious nervous system infection in 
these same experimental animals after autopsy (Monlux 
et al.. 1972) or of reversion of the vaccine virus to 
lethality for small laboratory animals (Luedke et ^., 1972).
Berge et al. (1961) demonstrated that attenuated TC-50 
virus regained the capacity to kill mice by i.e. inoculation 
after three serial mouse brain passages. During the plaque 
purification of the TC-78 virus in chick fibroblast culture,
9 of 12 plaque-purified viruses killed 3% to 23% of 
challenged mice. The TC-83 vaccine virus was derived from 
one of the 3 plaque-purified viruses that did not kill mice 
(McKinney et al,, 1963). Although the TC-83 virus was more 
than 99% homogeneous for hamster avirulence, virulent virus 
was selected by passage in hamsters; virus isolated from
Q
hamsters that died after high challenge dose (10 PFU 
subcutaneously) of TC-83 vaccine virus was virulent for 
5- to 7-week-old hamsters (Jahrling and Scherer, 1973c).
Although Sudia et al. (1971) were unable to demonstrate 
infection of mosquitoes fed upon TC-83 virus-immunized 
horses, Pedersen et (1972) isolated the TC-83 vaccine 
virus from a pool of Psorophora confinnis mosquitoes 
collected in the United States (Louisiana) during the large 
scale immunization campaign in 1971. Thus, introduction of
-30-
vaccine virus into a mosquito-rodent maintenance cycle and 
possible reversion of this virus to the virulent phenotype 
are possibilities.
VI. Comparisons of Virulent and Avirulent VEE Viruses
A. In Vivo Comparisons
TC-83 and avirulent VEE subtype 4 viruses replicated to 
lower titres than virulent VEE virus in the blood and brain 
of mice infected by peripheral inoculation (Le Blanc et al..
1978). Both TC-83 and virulent VEE viruses replicated to 
similar titres following i.e. inoculation in hamsters, but 
TC-83 virus failed to produce the pathological lesions 
typical of virulent VEE virus infection (Austin and Scherer, 
1971). Avirulent VEE virus was generally cleared more 
rapidly from the plasma of infected hamsters (Jahrling and 
Scherer, 1973b; Marker and Jahrling, 1979, Jahrling and 
Gorelkin, 1975) and rhesus monkeys (Jahrling et al., 1977a) 
than were virulent strains. Jahrling and Gorelkin (1975) 
reported that avirulent virus was more efficiently 
phagocytized by endothelial and Kupffer cells in the hamster 
liver.
The preceding studies indicated that differences in 
cell adsorption or tissue tropism may correlate with 
virulent and avirulent phenotypes of VEE virus. However, 
three avirulent VEE strains were cleared slowly, like 
virulent strains, from the blood of guinea pigs (Jahrling
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et al.. 1977b). Temperature-sensitive mutants of VEE virus 
that produce lethal infection but cause low viraemia in 
infected animals have been reported (Krieger et al., 1979). 
Thus, restricted replication of virus in target tissues also 
appears to be a factor in resistance to infection with 
avirulent VEE virus.
Splenectomy or pretreatment with cyclophosphamide 
increased the pathogenicity of TC-83 virus in hamsters 
(Jahrling et al., 1974). In these animals, alteration of 
the host immune response may have been a factor in the 
virulent and avirulent phenotypes of VEE viruses. In nude 
mice, however, TC-83 and Pix viruses did not cause increased 
mortality, although Nt titres were decreased and greater 
replication of the virus occurred, relative to 
immunocompetent mice infected with these viruses (Le Blanc 
et al.. 1978). The increased sensitivity of immuno­
compromised hamsters to infection with avirulent VEE virus 
may be related to the exquisite sensitivity of cells of the 
reticuloendothelial system to VEE virus replication.
Avirulent VEE viruses also may be more sensitive to the 
effects of interferon in the infected host (Jahrling, 1975; 
Jahrling et al., 1976).
B. In Vitro Comparisons
The virulent phenotype of VEE virus has been associated 
with both small (Heam and Jameson, 1971; Franck and Johnson, 
1971; Johnson and Martin, 1974) and large (Heydrick et al..
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1966; Hearn and Soper, 1967; Heam et 1969) plaque
sizes in various cell monolayers. Lack of correlation of 
virulence with plaque size has also been reported (Zarate 
and Scherer, 1968; Hruskova et al., 1970; Walder and Bradish,
1975). Marker and Jahrling (1979) demonstrated a 
correlation between rate of virus clearance from plasma in 
vivo and optimum pH of virus adsorption to cells in vitro. 
Avirulent strains had an attachment pH optimum that was 
close to physiologic pH, whereas virulent virus showed a 
more acidic pH optimum. Elution profiles of epizootic and 
enzootic VEE viruses differed by hydroxylapatite column 
chromatography, indicating
consistent differences in virion surface charge. The elution 
profiles of TC-83 and TRD viruses were slightly different 
(Jahrling and Eddy 1977).
Trent e_t (1979) determined that the ribonuclease T1 
oligonucleotide fingerprint of TC-83 genomic 42S RNA 
contained three unique oligonucleotide spots relative to 
that of the TRD parent and was missing three spots that were 
present in the parent. These oligonucleotide differences 
were all located in the 26S messenger RNA (mRNA) molecules 
of TRD and TC-83 viruses; and tryptic peptide mapping of 
capsid, El, and E2 proteins detected differences between the 
E2 envelope glycoproteins of TRD and TC-83 viruses (Mecham 
and Trent, 1982a). The E2 glycoproteins of TRD and TC-83 
viruses differed also in the number of glycosylated sites, 
as indicated by tryptic peptide mapping of sugar-labelled 
proteins (Mecham and Trent, 1982b). These investigators
-33-
further reported that, compared to TRD virus, TC-83 virus 
produced less virus-specific RNA and a higher ratio of 42S 
to 26S mRNA during the first 4 - 8 h PI in Vero cells. More 
infectious TRD virus than TC-83 virus was produced during 
the first 12 h PI in Vero cells, although maximum virus 
yields were similar for both viruses (Mecham and Trent,
1983).
VII. Molecular Bioloev of VEE Virus
A. Replication Cvcle
Alphavirus infection of the cell is initiated by 
electrostatic adsorption to the external cell membrane 
(Hruskova et al., 1970), which may be mediated by viral 
surface projections (Mussgay and Weibel, 1963; Mussgay and 
Rott, 1964). VEE virus may bind to a specific cell 
receptor. TC-83 virus adsorbed to cells at O^C and was 
internalized at 37®C. Pretreatment of the cells with 
proteolytic enzymes decreased the virus binding capacity, 
which returned after further incubation of the cells in the 
absence of proteases (Huggins et al., 1983). Protease 
treatment of virus particles also destroyed infectivity 
(Kennedy, 1974). Alphavirus nucleocapsids obtained by 
detergent disruption of virus did not adsorb to or infect 
cells (Bose and Sagik, 1970; Dobos and Faulkner, 1970).
Penetration of VEE virus occurs within 30 min at 37®C, 
and virus-induced inhibition of host cell RNA and protein
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synthesis is evident by 2 h PI (Lust, 1966). VEE virus has 
a latent period of 3 - 4 h, and virus-specific protein is 
evident by indirect immunofluorescence by 4 h PI. Release 
of mature virus rapidly increases 8 - 14 h PI and remains 
constant for up to 80 h (Hanon, 1970; Yershov and Zhdanov, 
1968; Hardy and Brown, 1961; Scherer et ^., 1971). 
Cytopathic effect is observed late in the period of constant 
release (Hardy and Brown, 1961). Mature virions are formed 
by budding of nucleocapsids through the plasma membrane 
containing virus-specific envelope glycoproteins (Murphy and 
Harrison, 1972). The alphavirus capsid protein appears to 
interact with the carboxyl-terminal portion of the viral 
glycoproteins on a one-to-one basis (Enzmann and Weiland,
1979).
B. Genome Organization
Alphavirus genome organization has been defined to a 
large extent by molecular investigations of SIN and Semliki 
Forest (SF) viruses. The 42S - 49S single-stranded viral 
genomic RNA of the virion functions directly as messenger 
RNA, and the naked molecule is infectious (Wecker, 1959; 
Friedman et ^., 1966; Simmons and Strauss, 1972). The 42S 
RNA genome, which is 11,703 and 11,442 nucleotides long in 
SIN and SF viruses, respectively (Strauss, et ^ . , 1984; 
Takkinen, 1986; Garoff et al., 1980a, 1980b), contains two 
coding regions (Fig. 1). The 5’-terminal two-thirds of the 
genome encodes the nonstructural proteins (nsP) nsPl, nsP2,
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Figure 1. Organization of the 42S genomic RNA of 
alphaviruses. Protein coding regions of the nonstructural 
(ns) genes (nsPl, nsP2, nsP3, and nsP4) and structural genes 
(C, E3, E2, 6K, and El) are shown as open rectangles. The 
short noncoding regions at the S’- and 3’-termini and 26S 
junction region are shown as solid lines (42S mRNA diagram 
at top of figure). The structural proteins (solid 
rectangles: C, El, and E2) of mature virions result from 
proteolytic processing of a structural polyprotein precursor 
(130 kd) that is translated from an intracellular 26S mRNA 
that is identical to the 3’-one-third end of the 42S genomic 
RNA. The E3 polypeptide is also incorporated into SF virus.
C = nucleocapsid protein, El and E2 = envelope glycoproteins.
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nsP3, and nsP4 that are involved in intracellular 
replication of the virus (Lachmi and Kaâriainen, 1976;
Collins et al., 1982; Takkinen, 1986; Ranki and Kaâriainen, 
1979;; Kerânen and Kaâriainen, 1979; Gomatos et al,, 1980). 
These nonstructural polypeptides are translated as a 
polyprotein precursor molecule that is initiated at a 5'-end 
AUG codon which occurs after a short 5'-terminal noncoding 
region (Strauss and Strauss, 1986). The polyprotein is 
processed by proteolytic cleavage to produce the final 
polypeptide products.
The 5'-nonstructural coding regions of both SIN and SF 
viruses have been sequenced (Strauss et ^.,1984; Takkinen,
1986). Regulation of SIN and Middelburg virus translation 
appears to occur in part by means of an in-frame read-through 
opal termination codon (UGA) that occurs between nsP3 and 
nsP4, thereby limiting translation of the full-length 
nonstructural polyprotein precursor molecule and, therefore, 
nsP4 (Strauss et al., 1983, 1984). The nsPl, nsP2, and nsP4 
polypeptides possess amino acid homologies with the 
replicases of other positive strand RNA viruses, and 
translation of the T2 polypeptide of tobacco mosaic virus, 
which shows homology with the alphavirus nsP4, appears also 
to be regulated by the presence of a preceding, in-frame 
termination codon (Strauss and Strauss, 1986). SF virus, 
which does not possess this in-frame regulatory termination 
codon and which has a deletion of 73 amino acids at the 
carboxyl terminus of nsP3 relative to the nsP3 of SIN virus.
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presumably differs from SIN virus in some aspect of 
intracellular replication (Takkinen, 1986).
The 5’-translated region of the 42S RNA is terminated 
by one or more in-frame stop codons at the 26S junction 
region, where genes encoding the structural proteins of the 
virus begin. Although the initiation site for translation 
of the structural proteins is present in the 42S RNA, it is 
apparently inactive (Bonatti et al., 1980; Cancedda and 
Shatkin, 1979; Glanville et ^ . , 1976). Rather, the 
structural proteins are translated as a polyprotein 
precursor from a separate intracellular 26S mRNA that is 
transcribed from the negative sense 42S RNA and is identical 
to the 3’-one-third portion of the 42S mRNA genome (Simmons 
and Strauss, 1972; Wengler and Wengler, 1976; Pettersson 
et al.. 1980; Strauss and Strauss, 1986). Both 42S and 26S 
mRNA molecules are polyadenylated at their 3’-termini and 
possess a 5’-terminal cap structure (Dubin et al., 1979;
Frey et 1978; Clegg and Kennedy, 1974). Although both
RNA species are associated with ribosomes, the 26S mRNA is 
the major species (Martire et al., 1977; Soderlund et al.. 
1974 ; Wengler and Wengler, 1975).
C. Processing of Structural Proteins
The structural proteins of alphaviruses are translated 
from the 26S mRNA as a polyprotein in the order 5’-capsid- 
E3-E2-6K-E1-3’ (Fig. 1) (Strauss and Strauss, 1986).
Protease inhibitors and temperature sensitive mutants that
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are defective in proteolytic processing of the precursor 
polyprotein at nonpermissive temperatures have permitted 
identification of polyproteins of 130 kilodaltons (kd) 
(corresponding to all of the structural polypeptides), 100 
kd (E3-E1), and 65 kd (E3-E2 or pE2) (Morser and Burke,
1974; Bracha and Schlesinger, 1976; Schlesinger and 
Schlesinger, 1973; Lachmi et al., 1975; Bracha et ^ . , 1976; 
Kerânen and Kââriâinen, 1975).
Cell-free translation systems lacking membranes produce 
only capsid protein from the 26S mRNA (Wengler et al., 1974). 
Addition of membranes results in production of capsid, pE2 
(E3-E2), and El polypeptides (Garoff et ^., 1978; Bonatti 
et al.. 1979). The capsid protein itself appears to be an 
autoprotease that performs the capsid-E3 cleavage in the 
nascent polyprotein (Aliperti and Schlesinger, 1978; Hahn 
et al.. 1985). Following cleavage of the capsid protein, a 
signal sequence in the pE2 region inserts the polyprotein 
into the membrane of the endoplasmic reticulum. The pE2-El 
cleavage occurs after insertion into the endoplasmic 
reticulum (Writh et al., 1977; Garoff et ^., 1978). 
Completion of El and E2 glycosylation, which begins before 
the release of these proteins from the polyribosomes, occurs 
during protein migration through the rough endoplasmic 
reticulum and Golgi apparatus en route to the plasma 
membrane (Garoff and Soderlund, 1978; Sefton and Burge,
1973; Sefton, 1977). The cleavage of pE2 to E2 occurs on 
the external surface of the plasma membrane (Ziemiecki 
et al., 1980) and is necessary for the release of mature
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virions (Smith and Brown, 1977). The E3 cleavage product 
remains associated with the envelope of SF virus (Garoff 
et al.. 1974). It has not been found in the virions of 
other alphaviruses, although a glycoprotein of similar 
molecular mass (9800 daltons) has been detected in the 
medium of SIN virus-infected cells (Welch and Sefton, 1979).
D. Structural Proteins of VEE Virus
Alphavirus interrelationships defined by HI and Nt 
indicated that the viral type-specific antigens are located 
on the virion surface (Dalrymple et al., 1972, 1973;
Compans, 1971). Pedersen and Eddy (1974) demonstrated that . 
VEE virions consist of a capsid protein and two
envelope glycoproteins. This protein composition was 
confirmed for VEE subtype lA-F, 2, 3, 4, and 5 viruses 
(France et , 1979; Kinney et ^., 1983). Wiebe and 
Scherer (1979, 1980) reported the presence of 3 large 
molecular weight envelope glycoproteins in the virions of 
several VEE virus strains. Discrepancies in the reported 
number of envelope proteins of VEE viruses may be due to the 
use of variable quantities of sodium dodecyl sulphate (SDS) 
and 2-mercaptoethanol in the dénaturation of virion proteins 
(Kaluza and Pauli, 1980; Kinney et ^ . , 1983). Pulse-chase 
studies of VEE virus-infected cells showed that the 
nucleocapsid protein is rapidly processed, followed by the 
appearance of the El glycoprotein and E2, which was cleaved
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from a 65 kd precursor (pE2) (France et 1979; Kinney
et al.. 1983). The envelope glycoproteins of the 
alphaviruses are designated
by their precursor-product relationships (Baltimore et , 
1976). The capsid protein and glycoproteins El and E2 have 
molecular weights of 35 - 36 kd, 48 - 51 kd, and 51 - 58 kd, 
respectively, in polyacrylamide gels cross-linked with 
N ’-N’-diallyltartardiamide (France et al., 1979; Kinney 
et al., 1983). The relative molecular weights of the 
envelope glycoproteins of various VEE virus strains do not 
correlate uniformly with serological classification or 
virulence of these viruses (Pederson and Eddy, 1975; France 
et al.. 1979). VEE viruses of different antigenic subtypes 
are readily differentiated by fingerprinting of the 
ribonuclease Tl-resistant oligonucleotides of the genomic 
42S RNA (Trent et al.* 1979). Mapping of tryptic peptides 
of the purified structural proteins of VEE viruses indicated 
that the capsid, El, and E2 proteins are highly conserved 
among VEE subtype lAB, 1C, ID, and 2 viruses, whereas 
subtype IE, 3, and 4 viruses appear to be more unique 
(Kinney and Trent, 1982).
E. Biological Activities of VEE Virus Glycoproteins
Mice immunized with vaccines prepared from the 
envelopes of VEE, EEE, and WEE viruses were protected from 
peripheral challenge with the virulent homologous virus 
(Pedersen, 1976). Antibodies with HI or Nt activity were
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induced by immimization with SIN virus El or E2 envelope 
glycoprotein, respectively (Dalrymple et 1976).
Purified E2 envelope glycoprotein of VEE viruses, on the 
other hand, elicited both HI and Nt antibodies in immunized 
animals (France et ^ . , 1979; Kinney ^., 1983).
Twelve epitopes, four El and eight E2, have been 
identified on the envelope glycoproteins of VEE virus 
(Roehrig et al., 1982; Roehrig and Mathews, 1985). The 
E2^ epitope defines a critical domain on the surface of 
the virus. Monoclonal antibodies (3B4C-4 and 1A4A-1) that 
define this site possess high-titre HI and Nt activity 
against subtype lAB, 1C, and 2 viruses and high-titre HI, 
but lower Nt activity, against ID virus. Depending on their 
topological relationships to the E2^ epitope, the E2^,
f p
E2 , E2 , and E2 epitopes are defined by monoclonal 
antibodies that have variable HI and Nt activities. 
Antibodies defining the E2^, E2^, and E2^ epitopes 
have little or no Nt or HI activity (Roehrig and Mathews, 
1985). Of the four epitopes identified on the El protein, 
the anti-El^ antibody (3B2A-9) has minimal Nt and barely 
measurable HI activities. Anti-El^ monoclonal antibody is 
broadly cross reactive with other VEE viruses and 
alphaviruses (Roehrig et al., 1982; Hunt and Roehrig, 1985). 
The monoclonal antibodies that are most efficient at 
blocking virus attachment to cells in vitro are those which 
define epitopes that are spatially close to the E2^ 
epitope (Roehrig et ^., 1988).
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Passive transfer of anti-El or anti-E2 polyvalent
rabbit serum or anti-E2^, anti-El^, anti-El^, or
anti-El^ monoclonal antibody in 3-week old mice protected
these animals from virulent VEE virus challenge (Mathews and
Roehrig, 1982). Anti-E2 polyvalent and monoclonal antibodies
protected animals more effectively than did anti-El
antibodies, and low-avidity monoclonal antibodies of either
specificity failed to protect animals after passive
immunization. The ability of anti-El, nonneutralizing
also
antibodies to protect animals in vivo has^been demonstrated 
for SIN virus (Schmaljohn et al., 1982; Chanas
et al., 1982) .
Rabinowitz and Adler (1973) reported that passive 
transfer of polyvalent anti-TC-83 antibody protected normal, 
thymectomized, or anti-thymocyte serum-treated mice.
Mathews et al. (1985) demonstrated that anti-E2^ F(ab')2 
polyvalent serum neutralized VEE TRD virus in vitro, but did 
not protect mice in vivo by passive transfer, indicating a
critical function of the Fc domain of the antibody molecule
b cfor in vivo protection. Intact anti-El or anti-E2
monoclonal antibody protected mice in complement-deficient
mice. Although both antibodies bound complement, other Fc
effector functions are probably necessary for in vivo
protection (Mathews and Roehrig, 1985).
During the last VEE virus epizootic in which millions
of equines were immunized with the TC-83 vaccine, field
isolations of both epizootic subtype lAB and vaccine viruses
were made. Differentiation of these isolates required
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testing their virulence in rodents, since subtype lAB 
viruses cannot be differentiated reliably by using 
conventional polyvalent antisera (Calisher and Maness, 
1975). The monoclonal antibody (5B4D-6) that defines the 
E2^ epitope, and which is specific for TC-83 virus by 
enzyme-linked immunosorbent assay (ELISA), now provides the 
basis for a rapid diagnostic test that can be performed by 
indirect immunofluorescence or ELISA. However, this 
antibody has no HI or Nt activity (Roehrig and Mathews, 
1985).
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PART 2: RECOMBINANT VACCINIA VIRUS
I. Vaccinia Virus and the Eradication of Smallpox
The last outbreak of smallpox occurred in October, 1977 
in Somalia. In May of 1980, the Thirty-Third World Health 
Assembly of the World Health Organization declared the 
successful global eradication of this long-time human 
scourge (World Health Organization, 1980). The Global 
Commission on the Eradication of Smallpox recommended in 
1979 that only a few laboratories should hold and work with 
smallpox (variola) virus, and by 1984 the only laboratories 
that still stored and handled smallpox virus presumably were 
two World Health Organization Collaborating Centers, the 
Centers for Disease Control in the United States and the 
Research Institute for Viral Preparations in Moscow, both of 
which have maximum containment laboratories. In 1981, the 
Thirty-Fourth World Assembly removed smallpox from the 
International Health Regulations, and by 1984 all countries 
had ceased smallpox vaccination of civilians (Jezek et al.. 
1987).
Due to the potential use of smallpox virus in 
biological warfare. United States military personnel 
continued to be vaccinated at five year intervals, although 
smallpox vaccination of military personnel in the United 
Kingdom and Finland was discontinued in 1981. Vaccination 
of United States military recruits has resulted in
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accidental infection of unvaccinated civilians by contact 
spread of vaccinia virus (Behbehani, 1983; Williams et al..
1984). In 1986 the Committee on Orthopox Infections 
recommended the cessation of smallpox vaccination of 
military personnel.
Although smallpox vaccination was generally safe, 
severe complications did occur in rare cases. One death 
(5 deaths in children less than 1 year old) per million 
vaccinees has been attributed to severe complications of 
primary smallpox vaccination. Approximately 10 of every 
million vaccinees required hospitalization due to severe 
complications of postvaccinial encephalitis, eczema 
vaccinatum (secondary infection of vaccinia virus on 
pre-existing skin diseases), and "generalized vaccinia" 
(progressive vaccinia or vaccinia necrosum, vaccinia 
gangrenosa). Complications occurred with 10-fold decreased 
frequency in individuals who received secondary smallpox 
immunization. Eczema vaccinatum was more severe in contacts 
of vaccinees than in vaccinees themselves, perhaps resulting 
from multiple inoculation sites. Progressive vaccinia 
occurred in those vaccinees who had underlying humoral or 
cell mediated immunological deficiencies (Redfield et al..
1987). Over 500 complications involving vaccinia infection 
of the eye or superinfection of skin conditions occurred per 
million vaccinees. The introduction of vaccinia immune 
globulin (Nanning, 1962) and thiosemicarbazone (Appleyard 
et al.. 1965) for treatment of vaccinia virus-induced 
complications proved to be therapeutically beneficial and to
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decrease the fatality rate associated with those conditions 
(Lane et al., 1969). With the global eradication of 
smallpox, the low, but definite risk of universal 
immunization with smallpox vaccine outweighed the 
insignificant benefit of the vaccine in a smallpox-free 
world (Behbehani, 1983; Lane et al., 1969, 1971; Ferry,
1977; Goldstein et ^., 1975). However, due to the advances 
in molecular biology during the 1980*s, the bidding of 
"farewell to smallpox vaccination" (Arita, 1979) may prove 
to be premature.
II. Recombinant Vectors as Immunogens
A. Small Virus Vectors
Heterologous genes have been expressed in a variety of 
recombinant constructs involving the use of adenoviruses, 
papovaviruses, papillomaviruses, and retroviruses as 
eukaryotic cloning and expression vectors (reviewed by 
Rigby, 1983). The genomes of these viruses are small enough 
to permit insertion of foreign genes by direct in vitro 
splicing manipulations. Use of small expression vectors is 
affected by limitations involving the packaging of the 
genome in an icosahedral nucleocapsid, which in turn limits 
the size of foreign genes that can be expressed, and by 
restricted host ranges of these vectors. Small genomes 
contain little information that is nonessential to virus 
replication. Therefore insertion of foreign DNA often
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necessitates coinfection of cells with wild-type helper 
virus to achieve expression.
B. Advantages of Vaccinia Virus as a Vector
As eukaryotic cloning and expression vectors, the 
larger genomes of herpes and vaccinia (VACC) viruses permit 
the insertion of large foreign genes without crippling the 
replication of the carrier virus (Mackett and Smith, 1986). 
Large regions of the VACC virus genome appear to be 
nonessential for virus replication (Moss et ^ . , 1981), and 
infectious poxviruses can express at least 25,000 base pairs 
of foreign DNA (Smith and Moss, 1983). The World Health 
Organization has shown interest in the use of recombinant 
VACC viruses as potential vaccines for a variety of diseases 
(World Health Organization, 1985).
The global eradication of smallpox is a clear 
indication of the efficacy of the smallpox vaccine, and as a 
result of the smallpox campaign, there exists a great deal 
of expertise in the manufacture, stabilization, 
distribution, and use of the vaccine in all areas of the 
world (World Health Organization, 1966). Other advantages 
of using recombinant VACC viruses as vaccines include the 
low cost of manufacture and delivery, which is especially 
important in underdeveloped countries; the capability of 
vaccine administration by unskilled personnel; the stability 
of rehydrated VACC virus without refrigeration; the potency 
of a single VACC virus dose in humans ; lack of splicing in
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VAC C virus mRNA transcripts; lack of animal reservoirs for 
VACC virus; and lack of chronic infection by VACC virus. In 
addition, VACC virus has a broad host range, which permits 
analysis of expression of foreign genes in a variety 
of cell lines and analysis of the immunogenicity of the 
expressed heterologous proteins or epitopes in different 
animal species. VACC virus itself induces both humoral and 
cell mediated immunity (Bennink et al,, 1984, 1986; Wiktor 
et al., 1984, Yewdell et al., 1985).
III. Molecular Biology of Vaccinia Virus
VACC virus is the prototype virus of the Orthopox
genus. The virion is about 320 nm X 230 nm in size and
contains more than 100 polypeptides (Essani and Dales,
1979). The structure and replication of poxviruses have
been reviewed by Holowczak (1982), Dales and Pogo (1981),
Moss (1985), and Fenner (1985). The VACC virus genome
consists of approximately 1 8 6 , 0 0 0  base pairs of l inear
double-stranded DNA that contains inverted terminal repeats
cova len tly
of 10,000 base pairs. The DNA strands are^linked
at the genome termini.
VACC virus is a complex virus that replicates in the 
cytoplasm of infected cells, although a maturation 
requirement for the host cell nucleus has been demonstrated 
(Moyer, 1987). The virus rapidly inhibits cell protein 
synthesis within 1 - 4 h PI, depending on multiplicity of 
infection (Moss, 1968; Rice and Roberts, 1983). The virus
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encodes enzymes that are involved in virus replication, 
including RNA polymerase and enzymes involved in capping, 
méthylation, and polyadenylation of mRNA. Transcription of 
mRNA from the VACC virus genome is accomplished by 
virus-specific RNA polymerases that recognize a variety of 
promoter sequences that are unique to the poxvirus genome. 
These promoter sequences are rich in adenylate and 
thymidylate residues and do not share consensus recognition 
sequences with eukaryotic or prokaryotic promoters 
(Venkatesan et al., 1981; Weir and Moss, 1983, 1984; 
Bertholet et al., 1985; Rosel and Moss, 1985). VACC virus 
RNA polymerase does not recognize promoter sequences used by 
eukaryotic RNA polymerase II, and eukaryotic RNA polymerase 
II does not recognize VACC promoters (Puckett and Moss,
1983; Rohrmann and Moss, 1985; Fogelsong, 1985; Golin and 
Kates, 1985).
Poxvirus replication is temporally regulated at the 
level of transcription. This regulation results in the 
expression of different genes early in infection before DNA 
replication, when enzymes packaged in the virion transcribe 
early genes, and in the late phase of infection after DNA 
replication. Unlike the late genes, transcription of early 
genes via viral enzymes present within the virion is not 
blocked by inhibitors of either protein synthesis or DNA 
replication (Moss, 1985).
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IV. Insertion of Heterologous Genes
VACC virus was established as a viable vector for the 
cloning and expression of foreign sequences after Sam and 
Dumbell (1981) and Nakano et al. (1982) demonstrated marker 
rescue of subgenomic VACC virus DNA fragments transfected 
into cells infected with VACC virus, and Mackett et al. 
(1982) and Panicali and Paoletti (1982) demonstrated that 
foreign DNA (herpes simplex virus thymidine kinase gene) 
could be introduced into VACC virus. Since then, 
heterologous genes encoding polypeptides from many viral 
pathogens have been expressed successfully in cell cultures 
or animals infected with recombinant VACC virus (Table 2).
Because the VACC virus genome is too large to permit 
insertion of foreign genes by in vitro restriction and 
ligation, and because purified VACC virus DNA itself is not 
infectious (the virion contains enzymes to initiate 
replication), recombinant VACC virus genomes are obtained by 
transfection of calcium phosphate-precipitated recombinant 
DNA plasmids, "insertion vectors", into cells infected with 
the wild-type VACC virus. The insertion vector consists of 
a VACC virus promoter sequence that is followed by unique 
restriction enzyme sites which permit insertion of foreign 
DNA by in vitro splicing procedures. The promoter and 
foreign DNA insert are flanked on both sides by VACC virus 
DNA, which is derived from a region of the genome that is 
nonessential for VACC virus replication.
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The flanking DNA is usually derived from the VACC virus 
thymidine kinase (TK) gene, which is located in the 
approximately 5-kilobase-pair Hind III J endonuclease 
restriction fragment of the VACC virus genomic DNA (Weir 
et al., 1982; Hruby and Ball, 1982; Hruby et ^., 1983). 
Other known nonessential regions of the VACC virus genome 
include a region near the left end of the genome (Moss 
et al.. 1981; Panicali et ^ . , 1981) and a region within the 
Hind III F restriction fragment (Panicali and Paoletti, 
1982). The insertion vector contains an antibiotic 
resistance gene, usually encoding ampicillinase, that 
permits selection of recombinant plasmid-containing 
Escherichia coli (E. cpli) cells grown in the presence of 
the antibiotic.
VACC virus-infected cells are transfected by calcium 
phosphate-precipitated, chimeric insertion vector DNA, and 
the heterologous gene is inserted by homologous 
recombination mediated by crossover between the TK arms of 
the insertion plasmid and the homologous sequences within 
the VACC virus TK gene (Mackett et al., 1982, 1984, Mackett 
and Smith, 1986; Ball, 1987). Recombination in poxviruses 
was shown initially by coinfection of cells with two 
distinct viruses and the demonstration that plaques of 
progeny virus expressed a combination of genetic markers 
(Fenner, 1959; Fenner and Comben, 1958).
Thymidine kinase phosphorylates 5-bromo-2-deoxyuridine 
(BUDR) to the 5’-monophosphate form, which is then converted 
to the 5’-triphosphate analogue of deoxythymidine.
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Incorporation of the analogue during DNA replication 
prevents the correct development of the virus. Insertional 
inactivation of the TK gene by a heterologous DNA insert 
prevents the incorporation of the mutagen. Therefore, 
recombinant VACC viruses containing foreign gene inserts in 
the TK gene can be selectively plaque-purified in monolayers 
of thymidine kinase negative (TK ) cells in the presence 
of BUDR, which inactivates wild-type virus. BUDR selection 
of recombinant VACC viruses containing foreign DNA inserts 
in the VACC virus TK gene has been a nearly universal 
practice (Table 2).
V. Vaccinia Virus Promoters
A. Seldom Used Promoters
Insertion and expression of foreign genes have been 
accomplished without the direct engineering of promoters 
(Panicali and Paoletti, 1982; Panicali et al., 1983;
Paoletti et ^ . , 1984; Perkus et al,, 1985). This method 
requires using the local promoter present within a 
nonessential region of the VACC virus genome, without the 
opportunity of using genetic engineering to optimize 
expression. Furthermore, foreign genes are usually 
expressed as fusion proteins (Mackett and Smith, 1986). 
Promoters of VACC virus genes that are expressed late in 
VACC virus infection have been used. These include the IIK, 
4b, and 28K promoters (Bertholet et al., 1985; Weir and
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Moss, 1983, 1984; Esposito et al., 1987; Coupar et al..
1987; Cantin al., 1987; McLanghlin-Taylor et ^ . , 1988; 
Mackett et al., 1985; Stunnenberg et ^ . , 1988; Browne 
et al.. 1988; Deubel et , 1988). Insertion of foreign 
genes behind these promoters usually involves stringent 
requirements for splicing the genes in correct reading 
frame, using the ATG initiation codon for the VACC 
polypeptide product that is normally controlled by the 
promoter. These promoters are useful for foreign genes that 
need to have an initiation codon provided (Esposito et al..
1987).
B. 7.5K Earlv-Late Promoter
The early-late 7.5K promoter, obtained from a region 
near the left end of the VACC virus genome, and which 
controls expression of a 7.5-kd VACC virus polypeptide, is 
the promoter that has been utilized most often (Table 2).
The most common insertion vector used has been pGS-20 
(Mackett et al., 1984) or one of its derivatives, pGS-62.
The 7.5K gene is controlled by two separate, but closely 
spaced (about 55 nucleotides apart) RNA start sites, both of 
which control transcription of mRNAs that translate into the 
same 7.5-kd polypeptide. One promoter is operative during 
the early phase of VACC virus replication, while the other 
controls late expression of the 7.5-kd gene product (Cochran 
et al.. 1985). The 7.5K gene, therefore, is operative 
throughout the replication cycle of VACC virus. Mackett
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et al. (1984) demonstrated that expression of the enzyme 
chloramphenicol acetyltransferase was 30-fold more efficient 
when controlled by the 7.5K promoter than when controlled by 
the early TK gene promoter.
Several investigators have utilized the pSCll insertion 
vector (Chakrabarti et , 1985), in which the foreign DNA 
is inserted behind the VACC 7.5K promoter, and the coli 
beta-galactosidase gene is expressed under control of the 
VACC virus IIK late promoter in the same plasmid (Elango 
et al., 1986; Chakrabarti et al., 1986; Willey et al., 1988; 
Whitton et al., 1988a, 1988b; Cranage et al., 1988; Zhao 
et al.. 1987; Olmstead et al., 1986; Rodriguez et al..
1988). Identification of plaques formed by recombinant 
viruses are easily identified by the blue colour that 
develops when the expressed beta-galactosidase hydrolyzes 
the 5-bromo-4-chloro-3-indolyl galactoside substrate that is 
included in the culture medium. Both promoters and 
heterologous genes are bracketed in the pSCll plasmid by 
VACC TK arms, and selection of recombinant VACC plaques is 
usually accomplished in TK cells (143 B cells) in the 
presence of BUDR. The advantage of beta-galactosidase in 
this system lies in the fact that spontaneous TK mutants 
of wild-type VACC virus appear with high frequency; 10% - 
80% of plaques that develop in the presence of BUDR are due 
to recombinant virus (Chakrabarti, 1985).
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VI. Expression of Heterologous Genes
A. Survey
Recombinant VACC viruses have been used to express 
genes derived from many other viruses, including SIN virus, 
human respiratory syncytial virus (RSV), influenza A virus, 
hepatitis B virus, vesicular stomatitis virus, rabies virus, 
rotavirus, polyomavirus, human papilloma virus. Lassa fever 
virus. Rift Valley fever virus, human immunodeficiency virus 
(HIV), human T cell lymphotropic virus type 1 (HTLV-1), 
infectious bronchitis virus, lymphocytic choriomeningitis 
(LCM) virus, human and murine cytomegalovirus (CMV), Hantaan 
virus, parainfluenza virus, dengue virus types 2 and 4, 
Epstein Barr virus, murine leukaemia virus, adenovirus, and 
measles virus (Table 2). The sporozoite antigen of the 
malaria parasite also has been expressed in recombinant VACC 
virus (Smith et al*> 1984; Langford et al., 1986). Almost 
without exception, cells infected with these recombinant 
viruses expressed authentic heterologous polypeptides 
derived from the foreign gene inserts as judged by 
electrophoretic migration, glycosylation, and antigenicity. 
The sporozoite (S) antigen expressed by recombinant VACC 
virus had a lower than expected molecular weight. The 
fusion protein of RSV (Wertz et ^., 1987) and envelope 
glycoprotein of HIV were not proteolytically cleaved in 
infected cells, although cleavage of the HIV envelope
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protein did occur in lymphoid cells that supported HIV 
replication (Chakrabarti et al., 1985).
B. Protection of Immunized Animals
In those studies where appropriate test animals were 
available, immunization of animals with recombinant viruses 
by one of several routes elicited ELISA, Nt, and/or 
radioimmune assay-detectable (hepatitis B) antibodies 
against the heterologous pathogens (Table 2). Animals 
generally have been immunized with 10^ to 3 X 10^ PFU of 
recombinant VACC virus, the usual dose being approximately 
10® PFU.
Several studies have demonstrated cell mediated immune 
responses to foreign polypeptides expressed via recombinant 
VACC virus vaccines. Animals generally were protected 
completely or to a significant extent from challenge with 
the wild-type heterologous pathogen (Table 2). Although 
recombinant VACC viruses expressed structural proteins of 
dengue virus in cell culture, the recombinants were neither 
immunogenic nor protective in mice, cotton rats, hamsters, 
or cynomolgus monkeys (Zhao et al., 1987; Deubel et al..
1988). Zhang et al. (1988), however, were able to protect 
dengue virus-susceptible mice from dengue virus encephalitis 
by immunization with dengue virus structural proteins and 
nonstructural protein NSl that were expressed by recombinant 
baculovirus.
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C. Cell Mediated Immunity
Cytotoxic T lymphocyte (CTL) responses apparently are 
involved in decreasing the replication and dissemination of 
at least some viruses (Yap et 1978; Lin and Askonas,
1981). CTLs can be targeted against internal proteins, 
including nucleocapsid proteins, of RNA viruses (Bangham 
et al.. 1986; Bennink et ^., 1984a; Puddington et al..
1986; Townsend et al., 1984; Yewdell et al»> 1985; Hosaka 
et al.. 1988). Immunization with recombinant VACC virus 
expressing the nucleocapsid protein of Lassa fever virus 
protected guinea pigs from lethal Lassa virus challenge, 
although it did not prevent replication of the challenge 
virus (Clegg and Lloyd, 1987). Mice immunized with 
recombinant VACC virus expressing the nonstructural 89-kd 
polypeptide of murine CMV were protected from challenge with 
CMV (Jonjic et ^., 1988). Recombinant VACC virus 
expressing the nucleocapsid protein of influenza A virus, 
however, protected mice poorly compared to mice that were 
immunized with recombinant virus expressing the 
haemagglutinin (Andrew et al., 1987b). Virus-specific or 
cross-reactive CTLs were elicited by recombinant VACC 
viruses that expressed the influenza A HA or nucleocapsid 
protein, respectively (Yewdell et al., 1985; Coupar et al.. 
1987; Bennink et al., 1984a, 1986). A major component of 
the CTL response against LCM virus appeared to be specific 
for the envelope glycoprotein, and cells infected with 
recombinant VACC virus expressing this glycoprotein were
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lysed by CTLs induced by different LCM virus strains 
(Whitton et 1988b). CTL responses have been elicited
against VACC virus-vectored glycoproteins B and D of herpes 
simplex virus type 1 (Zarling et 1986; McLaughlin-
Taylor et al., 1988) and the reverse transcriptase of HIV 
(Walker et , 1988).
D. Heterologous Protein Function
Recombinant VACC viruses are particularly useful for 
the expression of polypeptides of pathogens that replicate 
poorly or not at all in cell culture and are therefore 
difficult to study. They are useful in dissecting the 
function, antigenicity, and immunogenicity of individual 
polypeptides. Genes encoding human preproenkephalin (Thomas 
et al.. 1986), the CD4 molecule of T lymphocytes (Berger 
et al.. 1988), a human melanoma 97-kd polypeptide (Estin 
et al.. 1988), firefly luciferase (Rodriguez et al., 1988), 
chloramphenicol transferase (Mackett et al., 1984; Franke 
and Hruby, 1987), neomycin resistance (Franke et al..
1985b), human clotting factor IX (de la Salle et al,f 1985), 
human factor VIII (Pavirani et ^., 1987), and the murine 
H-2k^ antigen (Coupar et. , 1986a) have been expressed 
in recombinant VACC viruses.
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CHAPTER 2
MATERIALS AND METHODS
PART 1 : CELL CULTURES AND VIRUSES
I. Cell Cultures
African green monkey (Cerconithecus aethiops) 
kidney-derived Vero cells (Yasumura and Kawakita, 1963) and 
baby Syrian hamster (Mesocricetus auratus) kidney-derived 
BHK-21 cells (MacPherson and Stoker, 1962; Stoker and 
MacPherson, 1964) were maintained in the tissue culture 
facility at the Division of Vector-Borne Viral Diseases 
(DVBVD), Centers for Disease Control (CDC), Fort Collins, 
Colorado, U.S.A., and were ordered from this facility as 
needed. African green monkey (Cercopithecus aethipgs) 
kidney-derived CV-1 cells (American Type Culture Collection 
(ATCC) No. CCL 70) and the 143B cell line (ATCC No. CRL 
8303), a TK variant of human osteosarcoma cell line 
R970-5 (Rhim et al., 1975), were obtained from the American 
Type Culture Collection (Rockville, Maryland) and maintained 
by this author. All cell lines were maintained in Eagle's 
minimal essential medium (MEM; Eagle, 1959) prepared with 
Hanks' (Hanks, 1949) or Earle's (Earle, 1943) balanced salt
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solution and fortified with extra L-glutamine (additional 
2 mM) and nonessential amino acids (additional 1 mM). Media 
contained 31 mM sodium bicarbonate, 100 units/ml penicillin 
G, 0.1 mg/ml streptomycin sulphate, and 2% (v/v) or 10% (v/v) 
heat-inactivated (56°C for 30 min) foetal bovine serum 
(mycoplasma and virus tested, Hyclone Laboratories, Logan, 
Utah) in maintenance or growth medium, respectively. Cell 
culture media were obtained from GIBCO Laboratories (Grand 
Island, New York). Vero and BHK-21 cell cultures obtained 
from the tissue culture facility at the DVBVD were grown in 
media that contained 0.001 mg/ml of amphotericin B 
(Fungizone, ER Squibb and Sons, Inc., Princeton, New 
Jersey). Cell cultures were amplified by trypsinization 
(trypsin 1:250, porcine parvovirus tested, GIBCO) of stock 
cell monolayers in the presence of disodium ethylene-diamine- 
tetraacetate (EDTA) and distribution of dispersed cells into 
fresh tissue culture vessels as described by Lennette and 
Schmidt (1969). The 143 B cell cultures were grown in MEM 
containing 0.03 mg/ml of 5-bromo-2-deoxyuridine (BUDR, SIGMA 
Chemical Co., St. Louis, Missouri).
II. Viruses
A. VEE Viruses
The passage histories of the VEE virus strains used in 
this study are shown in Table 3. All VEE virus strains were 
cloned by serial selection of isolated plaques in Vero or
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Table 3. Passage histories of Venezuelan equine 
encephalitis viruses used
Virus
Subtype
Variant
Passage^
History
Trinidad donkey (TRD) lAB GPB1V6
TC-83 lAB V4&
P676 1C SM1V7
3880 ID SM1V8
Mena II IE SM3V7
78V-3531 IF DE1SM2V5
Everglades Fe3-7c (EVE) 2 SM4V6
Mucambo BeAn 8 (MUC) 3 SM4V5BHK21-2
Pixuna BeAr 35645 (PIX) 4 SM1V6
Cabassou CaAr 508 (CAB) 5 P5SM1DE2BHK21
^GPB = guinea pig brain, V = Vero, SM = suckling mouse, 
DE = primary Pekin duck embryo, P = number of passages 
by Digoutte and Gerault (1976).
—Number of passages from commercial lot of TC-83 vaccine
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primary Pekin duck embryo cell monolayers (France et al., 
1979; Kinney et al., 1983). Primary duck embryo cell 
cultures were provided by the tissue culture facility at the 
DVBVD, and were prepared from fertile Pekin duck (Anas 
platvrhvncos domestieus) eggs (Henderson and Taylor, 1960; 
Henderson, 1961) in a manner similar to the preparation of 
primary chicken embryo cultures as described by LennetteA 
(1969). WEE (strain MacMillan) and EEE (strain NJ60) 
viruses were also used. Virus name abbreviations conform to 
those specified in the International Catalogue of Arboviruses 
(Karabatsos,1985).
VEE viruses were grown in Vero or BHK-21 cells by 
infecting confluent cell monolayers with 0.1 - 1.0 PFU/cell. 
After 70 - 90 h, when CPE was observed in 70% - 90% of the 
cells, the culture medium was centrifuged at 16,320 X g for 
30 min at 4®C in a Sorvall GSA rotor (DuPont Company, 
Wilmington, Delaware) to pellet cell debris. The 
supernatant virus suspension was made 12% (v/v) in foetal 
bovine serum and stored in small aliquots at -70®C. TC-83
virus prepared in this manner served as undiluted vaccine in 
animal studies. The TC-83 vaccine strain used in this study 
was derived from vaccine lot number 5-LD-l produced by 
Merrell National Laboratory (Philadelphia, Pennsylvania) 
and distributed by the CDC (Atlanta, Georgia).
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B. VACC Virus
Complementary DNA (cDNA) molecules encoding the 
structural proteins of VEE virus were expressed in the New 
York City Board of Health (NYBH) strain of VACC virus. The 
virus had been cloned from a vial of smallpox vaccine 
(Dryvax, Wyeth Laboratories, Marietta, Pennsylvania) by 
three serial selections of isolated plaques in CV-1 cell 
monolayers (Esposito et al., 1987). Seed stocks of VACC or 
recombinant VACC virus were grown in CV-1 cell monolayers 
using a multiplicity of infection (MOI) of 0.05 - 1.0 
PFU/cell.
Less than 20% of VACC virions are released into the
culture medium. Therefore, following development of 90% CPE
in the infected cell monolayers (approximately 78 h PI),
virus stocks were made by scraping the cells into the
culture medium using rubber policemen. The cells were
pelleted by centrifugation at 5880 X g for 20 min at 4°C in
2
a GSA rotor, resuspended (1ml for every five 150 cm 
flasks) in phosphate buffered saline (PBS, pH 7.4, 
Hemagglutination Buffer, BBL Microbiology Systems, Becton 
Dickinson, Cockeysville, Maryland) containing 10% (v/v) 
foetal bovine serum, homogenized for fifty strokes using a 
glass tissue homogenizer, and stored in 2-ml aliquots at 
-70°C.
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C. Virus Titrations
All virus titrations were performed in Vero cell 
monolayers grown in six-well, 35-mm diameter tissue culture 
plates (Costar, Cambridge, Massachusetts). Virus dilutions 
were made in BA-1 diluent (50 mM Tris-hydrochloride (HCl),pH 
7.6, 1% (w/v) bovine serum albumin, 4 mM sodium bicarbonate, 
100 units/ml penicillinG, 0.1 mg/ml streptomycin sulphate, 
0.001 mg/ml Fungizone). One-tenth ml of diluted virus 
suspension was adsorbed to each monolayer for Ih at 37®C in 
an incubator containing 5% carbon dioxide in the atmosphere. 
VEE or VACC virus-infected cell monolayers were then overlaid 
with 3 ml of 1% (w/v) Noble agar (DIFCO Laboratories,
Detroit, Michigan) or agarose (International Biotechnologies, 
Inc. (IBI), New Haven, Connecticut) in M-199 maintenance 
medium made with Earle’s salts. After incubation for two 
days at 37°C, 2 ml of 1% agar or agarose in medium containing
0.33% (w/v) neutral red vital dye (GIBCO) was added in order 
to visualize virus plaques.
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PART 2 : CLONING OF VEE VIRUS STRUCTURAL GENES
I. Purification of VEE TRD and TC-83 Viruses
Confluent monolayers of BHK-21, Vero or CV-1 cells in 
MEM medium containing 2% (v/v) foetal bovine serum were 
infected at an MOI of 0.4 - 2.0 PFU/cell. Cultures were 
incubated at 37°C until CPE was evident in 70% - 90% of the 
cells. Culture fluids were then clarified by centrifugation 
for 30 min at 16,320 X g in a GSA rotor at 4*C. Virus was 
precipitated from clarified medium by dissolving 2.2 g 
sodium chloride and 7g polyethylene glycol (PEG 8000, 
molecular weight 7000 - 9000 Carbowax powder, Fisher 
Scientific Co., Fair Lawn, New Jersey) per 100 ml of medium 
for 2h at 4®C. Virus was precipitated by centrifugation at 
16,320 X g for 30 min at 4®C, resuspended in 1 - 2 ml of TNE 
buffer (10 mM Tris-HCl, pH 8.5, 150 mM sodium chloride, 1 mM 
disodium EDTA) with the aid of a rubber policeman, and 
purified by isopycnic centrifugation at 260,000 X g for at 
least 7h in a Beckman SW41 rotor (Beckman Instruments, Inc., 
Palo Alto, California) in two separate linear density 
gradients of potassium tartrate-glycerol (30% (v/v) glycerol 
to 45% (w/v) potassium tartrate, both in TNE buffer) and 
sucrose (27% - 63% (w/v) in TNE buffer containing 1.15 M 
sodium chloride) as described by Obijeski et al. (1976). 
Purified virus was diluted in TNE buffer and pelleted 
through a 1-ml 30% (v/v) glycerol (in TNE) cushion for 3 h
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at 260,000 X g. Virus pellets were resuspended in 0.5 ml of 
TNE and stored at -70 ®C until used.
II. Purification of VEE Virus RNA
VEE TRD and TC-83 viruses were purified from 
virus-infected BHK-21 cell cultures containing 0.012 mCi/ml 
of [®H]-uridine (39.6 Ci/mmol, 1 mCi/ml, New England 
Nuclear Corp., Boston, Massachusetts) in the culture 
medium. Genomic RNA was extracted (Trent et al., 1979;
Garoff et al., 1980) from purified virions in 1 ml of TNE 
buffer by digesting viral protein with 0.1 mg of proteinase 
K (18 units/mg, IBI) for 30 min at 37°C. The digest was 
made 1% (w/v) in sterile SDS (Pierce Chemical Co., Rockford, 
Illinois) and incubated for another 15 min at 37°C. Protein 
was removed by three extractions with an equal volume of 
phenol/chloroform/isoamyl alcohol (PCI) mixture 
(phenol:chloroform:isoamyl alcohol = 25:24:1, equilibrated 
with an equal volume of TNE buffer and kept at 4°C in a dark 
bottle) that was made using redistilled, crystalline phenol 
(IBI). The phenol phase and aqueous, nucleic acid-containing 
phase were separated by low-speed (4080 X g) centrifugation 
at 4®C. Residual phenol was extracted from the aqueous 
phase with an equal volume of ether (J. T. Baker Chemical 
Company, Phillipsburg, New Jersey), and the RNA was 
precipitated for at least 14 h at -20*C by addition of 2.5 
volumes of ethanol containing 300 mM ammonium acetate and 
10 mM magnesium chloride (EtOH/OAc/Mg).
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The RNA was pelleted by centrifugation at 20,000 X g 
for 30 min using a Sorvall SA-600 rotor, rinsed with 0.2 ml 
of 80% (v/v) ethanol, resuspended in 0.2 ml of RNA gradient 
buffer (lOmM Tris-HCl, pH 7.4, 10 mM sodium chloride, 1 mM 
disodium EDTA, 0.2% (w/v) SDS), and centrifuged in a 15% - 
30% (w/v) sucrose density gradient in RNA gradient buffer at 
260,000 X g for 3.5 h at 20°C in an SW41 rotor. The 
gradient was fractionated from centrifuge tubes, which were 
punctured at the bottom, by collecting drops into sterilized 
12 X 75 mm tubes. An aliquot of each fraction was added to 
scintillation fluid (Opti-fluor, Packard Instrument Co.,
3
Inc., Downers Grove, Illinois), and the [ H]-beta 
disintegrations were determined by counting in a Packard 
Tri-Carb 4530 scintillation counter. Those fractions that 
contained the high molecular weight genomic 42S RNA were 
pooled, and the RNA was precipitated with EtOH/OAc/Mg.
Ill. Preparation of Synthetic Oligonucleotides
Synthetic oligonucleotides were constructed in our 
laboratory on a Model 380 A DNA synthesizer (Applied 
Biosystems, Inc. (ABI), Foster City, California) using 
phosphoramidite chemistry (Beaucage and Caruthers, 1981). 
Full-length oligonucleotide product was purified by 
preparative electrophoresis in 16% (w/v) acrylamide- 
bisacrylamide (19:1, IBI) gels containing 7 M urea (Pierce) 
in TBE buffer (89 mM Tris, pH 8.3, 89 mM boric acid, 2.8 mM 
disodium EDTA). A plastic-wrapped thin-layer chromatography
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plate (Redi-Plate Silica Gel GF, 20 cm x 20 cm, No. 06-601A,
Fisher Scientific Co.) was placed under the gel, and the
failure and end-product oligomers were located by shadow
casting of ultraviolet light (UV)-absorbing, DNA-containing
bands in the gel. Gel containing full length product was
excised and crushed by forcing it through a 3-ml syringe
The DNA was eluted into 250 mM ammonium acetate, 2 mM
disodium EDTA by shaking overnight at 37°C. Gel fragments
were removed by centrifugation and the eluted DNA was
adsorbed to a 5-ml column of preswollen DE-52 ion-exchange
cellulose (Whatman, Inc., Clifton, New Jersey). The column
was washed with 250 mM ammonium acetate, and DNA was eluted
with 30% (v/v) triethylammonium bicarbonate, pH 8.0,
lyophilized twice, dissolved in distilled water, and stored
at -20°C. Alternatively, oligonucleotide purification
cartridges supplied by ABI were used instead of DE-52
cellulose. Purified oligonucleotides were quantitated by
absorbance at 260 nm, assuming that one A_._ unit
260
corresponds to 0.04 mg/ml of single-stranded nucleic acid.
IV. Synthesis of Double-Stranded cDNA
A. First Strand cDNA Synthesis
Synthesis of cDNA, summarized in Fig. 2, was performed
by the procedures described by Okayama and Berg (1982),
Maniatis et al.(1982), and Gubler and Hoffman (1983). First
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Figure 2. Synthesis of double-stranded (ds) cDNA encoding 
the structural proteins of VEE TC-83 or TRD virus. 
Gradient-purified 42S genomic RNA served as template for 
first strand cDNA synthesis. Double-stranded cDNA was 
tailed with poly(dC) for cloning into poly(dG)-tailed pUC18 
plasmid.
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strand synthesis was primed with a synthetic 19-nucleotide 
long (19-mer) oligonucleotide (5’-GCATGCCAATCGCCGCGAG-3') 
that was complementary to a 19-base sequence whose 
3'-terminus was located 66 nucleotides from the 3'-end of 
VEE TRD virus genomic RNA. The sequences of the 3'-end 134 
nucleotides preceding the poly(A) tail of VEE TRD and TC-83 
virus RNAs were reported earlier by Ou et al. (1982a).
VEE TRD or TC-83 virus gradient-purified RNA (0.005 mg) 
in 0.02 ml of distilled water was denatured by heating at 
93°C for 3 min and then quick-chilled in ice water.
MethyImercurie hydroxide (Alfa products, Danvers, 
Massachusetts) was added to 60 mM, and after incubation for 
5 min at room temperature, 2-mercaptoethanol was added to 
70 mM. To this was added 0.04 ml of reverse transcriptase 
solution to give final concentrations of 50 mM Tris-HCl, 
pH 8.3, 70 mM potassium chloride, 10 mM magnesium chloride, 
30 mM 2-mercaptoethanol or 4 mM dithiothreitol (DTT), 0.7 mM 
each of dATP, dCTP, dGTP, dTTP (Pharmacia, Inc., Piscataway, 
New Jersey), 0.02 mCi alpha-[®^P]-dCTP (800 Ci/mmol,
1 mCi/ml, NEN), 0.06 mg/ml DNA oligonucleotide primer,
600 units/ml placental ribonuclease (RNase) inhibitor 
(Promega Biotech, Madison, Wisconsin), and 1500 units/ml of 
avian myeloblastosis virus reverse transcriptase (Promega). 
The reverse transcriptase reaction was incubated for 2 h at 
42°C, extracted with PCI, ether extracted, and the nucleic 
acid was precipitated at -70°C for 1 h in 2.5 volumes of 
EtOH/OAc/Mg.
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B. Second Strand cDNA Synthesis
Second strand cDNA was synthesized in a 0.1-ml volume 
containing 0.02 mCi alpha-[®^P]-dCTP (800 Ci/mmol,
1 mCi/ml, NEN), 10 mM 2-mercaptoethanol (or 2 mM DTT),
8 units Ej. coli DNA polymerase I holoenzyme (8000 units/ml, 
Bethesda Research Laboratories (BRL), Gaithersburg, 
Maryland), and 0.9 unit of RNase H (Promega) in 20 mM 
Tris-HCl, pH 7.4, 10 mM-magnesium chloride, 100 mM potassium 
chloride containing 0.25 mM of each of the four nucleoside 
triphosphates. The reaction was incubated for 1 h at 12°C,
1 h at room temperature, and then extracted with PCI. In 
this procedure the RNase H nicks the RNA strand of the 
RNA:cDNA heteroduplex, and the DNA polymerase I enzyme 
removes the RNA strand and replaces it with the second cDNA 
strand by a nick-translation mechanism.
C. Fractionation of cDNA
In order to increase cloning efficiency of high 
molecular weight cDNA molecules, the double-stranded cDNA 
was fractionated on a 2-ml Sephacryl 1000 (Pharmacia) column 
equilibrated in TNE buffer. Before loading the cDNA onto 
the column, 0.4 mg of yeast tRNA (BRL) was run through the 
column in order to block potential nonspecific nucleic acid 
binding sites. Fractions containing large cDNA molecules 
were pooled and precipitated with EtOH/OAc/Mg with or
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without addition of 0.005 mg of nuclease-free glycogen 
(Boehringer Mannheim, Indianapolis, Indiana) as carrier.
V. Cloning of VEE Virus cDNA into Plasmid pUC18
A. Plasmid pUC18
Plasmid pUC18 is a 2686-base pair (bp) derivative of 
the 4362-bp pBR322 plasmid (Bolivar et al., 1977; Sutcliffe 
et al.. 1978). The tetracycline antibiotic resistance gene 
of pBR322 has been deleted, but the ampicillin resistance 
gene and pBR322 origin of replication have been retained 
(Norrander et al., 1983). A portion of the E_,_ coli lac 
operon has been engineered into the pUC series of plasmids 
(Vieira and Messing, 1982; Messing and Vieira, 1982; Messing 
et al.. 1977). A polylinker sequence containing a multiple 
cloning site (MGS) region has been engineered into the amino 
terminus of the lac Z gene encoding beta-galactosidase 
(Fig. 3). These multiple sites permit linearization of the 
plasmid with 13 restriction enzymes (in pUG18), thereby 
permitting insertion of a variety of restriction fragments 
of foreign DNA into the plasmid.
The beta-galactosidase gene in the pUG18 plasmid is 
defective by itself, as is the gene in suitable bacterial 
hosts (for example, ^  coli TB-1, E^ . coli JMlOl). The 
inactivating mutations occur at different loci in the 
beta-galactosidase genes of pUG18 and the bacterial host. 
Thus, although the ^  coli host alone produces a defective
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Fieure 3. Multiple cloning site region (MGS) of pUG 
plasmids and M13 bacteriophage replicative form DNAs. These 
unique restriction enzyme sites permitted linearization of 
the circular, double-stranded vector to permit cloning of 
appropriately restricted cDNA fragments. The MGS of M13mpl9 
is identical to that of M13mpl8, but is inverted in the 
bacteriophage DNA backbone. The M13mplO and M13mpll 
bacteriophages used in this study lack the Sph I and Kpn I 
sites in the MGS.
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enzyme, the host-derived and pUClS-derived beta-galactosidase 
enzymes together complement (alpha complementation) each 
other to produce an active beta-galactosidase enzyme that 
can be induced by isopropyl-beta-thio-galactopyranoside 
(IPTG) and that can hydrolyze the galactose analogue 
5-bromo-4-chloro-3-indolyl-beta-galactopyranoside (BCIG or 
XGal) to produce a blue pigment (bromo-chloroindole) in 
cells that are successfully transformed. Bacterial colonies 
resulting from transformation with wild-type pUC18 are 
ampicillin resistant and are blue in colour due to the 
hydrolysis of BCIG (Fig. 4A and 4B). Bacterial colonies 
resulting from cells that are transformed with recombinant 
plasmid produce white (colourless) colonies (Fig. 4B), since 
insertion of foreign DNA (cDNA) into the MGS within the 
beta-galactosidase gene results in a defective enzyme that 
cannot be complemented by the bacterial enzyme and therefore 
cannot hydrolyze BGIG. A combination of ampicillin 
resistance and histochemistry (BGIG hydrolysis) permitted 
rapid one-step identification of bacterial colonies 
containing recombinant plasmid DNA.
B. Annealing of cDNA to pUG18
pUG18 plasmid was linearized by digestion with 
restriction endonuclease Pst I and tailed with poly-dG using 
3'-terminal deoxynucleotidyl transferase (15,000 units/ml, 
BRL) (Roychoudhury and Wu, 1980); and double-stranded cDNA 
was tailed with poly-dG. Approximately 20 nucleotide
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Fieure 4. One-step screening for ^  coli colonies, 
resulting from cells transformed with recombinant plasmids, 
on agar containing ampicillin and the histochemical 
indicators IPTG and BCIG. Only colourless colonies (B) 
containing recombinant cDNA/pUC18 DNA were studied further. 
Blue colonies resulted from growth of cells that were 
transformed by wild-type pUC18 plasmid (A and B).
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residues per tail were added by incubation of linearized 
pUClS (1.8 ug, 2 pmol of 3'-ends) or total cDNA yield with 
terminal transferase (15 units) and 0.005 mM dGTP or dCTP, 
respectively, in 0.05 ml of 50 mM potassium cacodylate, 
pH 7.5, 2 mM cobalt chloride and 0.2 mM DTT (5X buffer 
supplied by transferase manufacturer) for 10 - 15 min at 
37°C. The reaction was then PCI extracted, ether extracted, 
and precipitated twice with 2.5 volumes of EtOH/OAc/Mg with 
or without the addition of 0.005 mg glycogen as carrier to 
remove most of the free nucleotides. Tailed pUC18 vector 
(100 - 200 ng) was annealed to tailed cDNA (total yield from 
cDNA synthesis) in 0.05 ml of 20 mM Tris-HCl, pH 8.0, 0.1 mM 
disodium EDTA, 300 mM sodium acetate by heating for 2 h at 
60°C followed by slow overnight cooling to room temperature 
in the water bath (Fig. 5).
C. Preparation of Competent E. coli TB-1 Cells
E. coli K12 strain TB-1 (kindly provided by Thomas 
Baldwin of Texas A & M University), a derivative of strain 
JM 83 (Yanisch-Perron et ^ . , 1985), was transformed with 
the annealed DNA using the low pH - manganese chloride 
method described by Clark-Curtiss and Curtiss (1983).
E. coli TB-1 cultures were maintained in M9 minimal 
salt-glucose medium (41 mM dibasic sodium phosphate, 22 mM 
monobasic potassium phosphate, 9 mM sodium chloride, 19 mM 
ammonium chloride, 1 mM magnesium sulphate 0.1 mM calcium 
chloride, 11 mM glucose, 0.03 mM thiamine, filter sterilized)
—97—
Figure 5. Cloning of cDNA into the pUC18 plasmid. Plasmid 
pUC18, which contains an ampicillin antibiotic resistance 
gene (Amp^), was linearized at the Pst I site in the 
multiple cloning site region (MCS), tailed with poly(dG), 
and annealed to poly(dC)-tailed cDNA. Successful cloning of 
cDNA into the MCS inactivated the lac z gene product, 
beta-galactosidase, resulting in production of colourless 
colonies from transformed coli cells grown in the 
presence of the histochemical indicator system (IPTG and 
BCIG).
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containing 0.024 mg/ml streptomycin sulphate and 0.4 mM 
proline (Thomas Baldwin, personal communication).
TB-1 cells were made competent for DNA transformation 
by making a 1:200 dilution of an overnight culture in 100 ml 
of warm (37®C) 2X-YT broth (1.6% (w/v) tryptone, 1.0% (w/v) 
yeast extract (DIFCO) in 86 mM sodium chloride) and shaking 
at 37°C in a New Brunswick (Edison, New Jersey) controlled 
environment incubator shaker until the cell density reached 
0.2 - 0.3 absorbance at 550 nm. The cells were pelleted by 
centrifugation at 5880 X g for 10 min in a GSA rotor, 
resuspended in 100 ml of a solution containing 10 mM sodium 
chloride, 50 mM manganese chloride, 20 mM sodium acetate, 
pH 5.6, incubated for 10 min on ice, and pelleted. The cell 
pellet was resuspended in 10 ml of 75 mM calcium chloride, 
100 mM manganese chloride, 20 mM sodium acetate, pH 5.6 and 
kept on ice.
D. Transformation of E. coli TB-1 Cells
The solution containing the annealed DNA was added to 
0.6 ml of competent TB-1 cells in a 1.5-ml microcentrifuge 
tube (microtube), incubated for 40 min on ice, then heated 
for 3 min at 37®C. The transformed cells were pelleted by 
centrifugation at 66 X g for 30 sec in a microcentrifuge 
(Beckman Micro 11 centrifuge), resuspended in 0.6 ml of warm 
2X-YT broth, and incubated for 1 h at 37®C to allow the 
transformed cells time to synthesize ampicillinase. The 
gene for ampicillin resistance is carried by the pUC18
—100“
plasmid, and only those TB-1 cells that are transformed by 
pUC18 or by a recombinant cDNA-pUC18 plasmid are able to 
replicate in the presence of ampicillin. Stock IPTG 
(2% (w/v) in water, SIGMA) and BGIG (2% (w/v) in 
dimethyformamide, SIGMA) were then added to the cell 
suspension to achieve 0.03 mg of each chemical per 
yeast-tryptone agar (YTA) plate (0.5% (w/v) yeast extract, 
0.8% (w/v) tryptone, 86 mM sodium chloride, 1.5% (w/v) agar 
(Bacto-Agar, DIFCO), 0.1 mg/ml ampicillin). One-tenth ml of 
the transformed cells was spread onto each YTA plate with a 
sterile, curved glass rod, and the plates were incubated 
overnight at 37®C.
VI. Screening of Recombinant cDNA Clones
A. Strategv
Recombinant bacterial colonies were transferred to 2 ml 
of 2X-YT broth and placed in a shaker overnight at 37®C. 
Recombinant plasmid was extracted from the cells by the 
rapid boiling method of Holmes and Quigley (1981) and 
screened for relative cDNA insert size by agarose gel 
electrophoresis using wild-type pUC18 as control. Large 
recombinant plasmids were further screened by dot blot DNA 
hybridization (Wallace et al., 1981) using specific 
synthetic oligonucleotide probes. Those plasmids containing 
the relevant regions of the VEE virus genome were then 
amplified in 500-ml TB-1 cultures, extracted by the
-101-
preparative scale alkaline procedure of Birnboim and Doly 
(1979), and purified by caesium chloride density gradient 
centrifugation (Garger et al., 1983).
B. Extraction of Plasmid DNA
One ml of an overnight 2-ml 2X-YT broth (containing 
0.1 mg/ml ampicillin) culture of recombinant TB-1 cells was 
centrifuged in a 1.5-ml microtube for 2 min at 11,600 X g 
(Beckman Microfuge 11) at room temperature, and the 
supernatant was aspirated. Recombinant pUC18 plasmid was 
extracted from the cells by the boiling method of Holmes and 
Quigley (1981). The cells were resuspended in 0.5 ml of 
lysis buffer (40 mM Tris-HGl, pH 8.0, 50 mM disodium EDTA,
25 mM sucrose, 0.5% (v/v) Triton X-100) to which 0.025 ml of 
freshly dissolved lysozyme (40 mg/ml in 10 mM Tris-HCl, pH 
8.0) was added. After incubating for 30 min on ice, the 
samples were placed in a boiling water bath for 1 min and 
then centrifuged at 12,400 X g for 10 min at room 
temperature. The gelatinous pellet containing bacterial DNA 
and cell debris was removed with a sterile toothpick. A 
0.03-ml aliquot of the supernatant was transferred to a 
second tube containing 0.003 ml of TBE gel loading dye 
(5.4 M glycerol, 52 mM disodium EDTA, 1% (w/v) SDS, 0.2% 
(w/v) bromophenol blue, 0.2% (w/v) xylene cyanol FF,100 mM 
Tris-HCl, pH 8.0, 90.6 mM boric acid), and the sample was 
electrophoresed in a 1% (w/v) agarose (IBI) gel in AgarTBE 
buffer (100 mM Tris, pH 8.0, 90.6 mM boric acid, 2 mM
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disodium EDTA) for 2 - 16 h at 30 - 130 volts at room 
temperature. The remaining supernatant was frozen at -70°C.
Selected samples, based on migration relative to the 
pUClS control plasmid in the agarose gel, were thawed, 
extracted with an equal volume of PCI, extracted with ether, 
precipitated with 2.5 volumes of EtOH/OAc/Mg, and resuspended 
in 0.1 ml of TE buffer (10 mM Tris-HCl, pH 7.6, 1 mM disodium 
EDTA). This procedure provided enough DNA for initial 
screening and restriction mapping, as well as for 
preparative restriction to obtain cDNA fragments for 
subcloning into the M13 bacteriophage for sequence analysis.
C. Preparation of Hybridization Probes
Four [^^P]-labelled synthetic DNA probes (Fig. 6) 
were hybridized to the recombinant DNA samples spotted on 
nitrocellulose membranes. The 3’-end probe was the 
oligonucleotide that had been used to prime first strand 
cDNA synthesis. The capsid probe was based on amino acid 
sequence homology between the carboxyl-terminal ends of the 
nucleocapsid proteins of SIN (Strauss et al., 1984), RR 
(Dalgarno et al., 1983), and SF (Garoff et al., 1980a) 
viruses at the carboxyl-terminal end. The El and E2 
glycoprotein-specific probes were chosen to hybridize to 
cDNA encoding the amino termini of the VEE virus El and E2 
proteins, respectively. The amino termini of the El and E2 
proteins of several alphaviruses, including VEE virus, were 
determined previously by amino-terminal sequencing of
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Fieure 6. Synthetic DNA oligonucleotide probes used in 
hybridization studies to identify recombinant plasmids 
containing VEE virus-specific cDNA. The probes were used to 
detect cDNA encoding the carboxyl-terminus of the 
nucleocapsid protein (capsid probe), the amino-termini of 
the El and E2 glycoproteins (El and E2 probes), and the 
3’-end site that was used for priming of first strand cDNA 
synthesis (3’-end probe). Oligonucleotide permutations 
resulting from degeneracy of the genetic code in the reverse 
translation of short amino sequences are shown.
- 1 0 4 -
El probe (17 mer, 128 permutations)
3’-ATACTTGTACGATGATG-5’
G C G G G 
T T 
C C
E2 probe (17 mer, 128 permutations)
3'-CTCCTTAACAAATTACT-5'
T CG T G G 
A 
G
Capsid probe (17 mer, 16 permutations)
3'ATATTAACCGTAGTACC-5’
G G G G
3'-end probe (19 mer, no permutations) 
3'GAGCGCCGCTAACCGTACG-5'
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purified proteins (Bell et al., 1984). Due to the 
degeneracy of the genetic code, each of the structural 
protein probes was synthesized as a mixture of 17-mer DNA 
molecules of 16 or 128 sequence permutations (Fig. 6). One 
permutation of each 17-mer mixture was exactly complementary 
to the viral cDNA encoding the amino acid region in question.
Oligonucleotide probes synthesized on the ABI DNA 
synthesizer were 5’-end labelled according to Maniatis 
et al.(1978, 1982). Synthetic oligonucleotide (440 ng) was 
labelled with 20 units of T4 polynucleotide kinase
32(10,000 units/ml, Promega) and 0.02 mCi of gamma-[ P]-ATP 
(3000 Ci/mmol, NEN) in 0.03 ml of 50 mM Tris-HCl, pH 7.5,
15 mM magnesium chloride, 5 mM DTT, and 2 mM spermidine for 
30 min at 37°C. Free radiolabelled nucleotide was removed 
by separation on a 2-ml Sephadex G-10 column in TNE buffer 
containing 0.1% (w/v) SDS, through which 0.4 mg of yeast 
tRNA (BRL) in TNE had been eluted. An aliquot of the eluted 
radiolabelled probe was counted in scintillation fluid and 
then used directly in hybridization experiments.
D. Screening of Recombinant Plasmids bv Hybridization
Plasmids containing large inserts of VEE virus cDNA 
were extracted from bacterial cultures and screened by 
hybridization according to Maniatis et al. (1982) and 
Wallace et al. (1981). Precipitated plasmid DNA was 
rehydrated in 0.3 ml of melting buffer (30 mM Tris-HCl, 
pH 7.4, 0.2 N sodium hydroxide in 6.7X SSPE buffer (3.6 M
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sodium chloride, 200 mM monobasic sodium phosphate, pH 7.4, 
20 mM disodium EDTA)), melted by heating at 80 °C for 
10 min, neutralized with 0.08 ml of 2 M Tris-HCl, and then 
quick-chilled on ice. The melted DNA was spotted onto 
6X SSPE-soaked nitrocellulose membranes (4 inch by 5.25 inch 
BA85 0.45 um nitrocellulose sheets, Schleicher and Schuell, 
Inc., Keene, New Hampshire) using a 96-well filtration 
manifold (SRC-96 Minifold, Schleicher and Schuell). The 
membranes were air dried at room temperature for 10 min and
then baked for 2 h at 80*C.
The baked filters were soaked for 5 min in 6X SSPE
buffer and sealed in plastic bags containing 15 ml of
prehybridization solution (11.1 M formamide, 5X Denhardt’s 
solution (made from 5OX solution - 1% (w/v) ficoll (SIGMA), 
1% (w/v) polyvinylpyrrolidone (SIGMA), 1% (w/v) of bovine 
serum albumin (Fraction V, Reheis Chemical Co., Phoenix, 
Arizona)), 5X SSPE, 0.1% (w/v) SDS, and 0.1 mg/ml of 
denatured (boiled for 10 min), sheared (by forcing several 
times through a 25-gauge needle) salmon sperm DNA (Type III, 
SIGMA)) using a Dazey Seal-a-Meal heat sealer (Dazey Corp., 
Industrial Airport, Kansas). After incubation at 42°C for 
4 h, radioactive oligonucleotide probe was added 
( 1 - 5  million counts per minute (cpm) per bag) and the 
membranes were incubated for 16 - 48 h at room temperature.
The hybridization solution was discarded and the 
in
filters were washed IIX SSPE containing 0.1% (w/v) SDS at 
42®C. Membrane radioactivity was monitored using a Model 2 
survey meter (Ludlum Measurement, Inc., Sweetwater, Texas)
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until it became evident that background radioactivity had 
been eluted. The filters were air dried for 1 h at room 
temperature. Autoradiography was performed using SB-5 X-ray 
film (Eastman Kodak Co., Rochester, New York). Those 
recombinant plasmids that hybridized to the appropriate 
probes were then amplified, purified by caesium chloride 
density gradient centrifugation, and analyzed further for 
sequence determination.
VII. Amplification of Recombinant Plasmids
A. Preparative Alkaline Extraction of Plasmid DNA
After initial screening, recombinant plasmids of 
interest were extracted from 500-ml overnight E^ coli TB-1 
cultures. The pUClS plasmid replicates to a high copy 
number per cell, making addition of chloramphenicol to the 
culture medium unnecessary to achieve good plasmid yields. 
Plasmid was extracted from the cells by the method of 
Birnboim and Doly (1979). Each cell pellet resulting from 
100 ml of cell culture was resuspended in 4 ml of GTE buffer 
(50 mM glucose, 25 mM Tris-HCl, pH 8.0, 25 mM-disodium EDTA) 
in 50-ml Oak Ridge polycarbonate tubes (Nalge Co., Rochester, 
New York), and 0.8 ml of freshly prepared lysozyme solution 
(40 mg/ml in 10 mM Tris-HCl, pH 8.0) was added. After 
incubation for 30 min on ice, 9.6 ml of 1% (w/v) SDS in 
0.2 N sodium hydroxide was added. After incubation for 
5 min on ice, 7.2 ml of 3 M potassium acetate in 7 M acetic
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acid (pH 4.8 final) was added, followed by 10 min incubation 
on ice, then centrifugation for 30 min at 26,900 X g at 4®C 
in a Sorvall SA-600 rotor.
The supernatant containing plasmid DNA was vigorously 
mixed with an equal volume of PCI, centrifuged for 5 min at
4300 X g, and the aqueous phase was mixed with 0.6 volume of
2-propanol to precipitate the DNA. This mixture was 
incubated for 20 min at room temperature and then 
centrifuged at 16,320 X g for 10 min in a GSA rotor. The 
DNA pellet was dissolved in 5 ml of sterile TE buffer to 
which 0.02 ml of bovine pancreatic RNase A (50,000 units/mg, 
SIGMA) solution (10 mg/ml, in 50 mM sodium acetate, pH 5.5, 
boiled for 10 min, cooled slowly to room temperature, and 
stored in aliquots at -20®C) was added. Bacterial RNA was 
digested for 30 min at 37®C, after which time the DNA 
solution was extracted with an equal volume of PCI. The 
aqueous phase was extracted with 4 ml of ether, and the DNA 
was precipitated with 2.5 volumes of EtOH/OAc/Mg at -20®C.
The precipitated DNA was resuspended in 0.5 - 1.0 ml of 
sterile TE buffer and stored at 4®C or frozen at -20®C. DNA 
yield was quantitated by agarose gel electrophoresis of an 
aliquot and comparison of the fluorescence intensity (UV 
light visualization) of the resulting DNA bands in ethidium 
bromide-stained gels (at least 2 h in 0.5 mM ethidium 
bromide; SIGMA) with Polaroid prints of stained gels 
containing standard quantities of DNA (Fig. 7). Plasmid DNA 
was further purified by caesium chloride density gradient 
centrifugation.
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Fieure 7. Standard agarose gel electropherograms of various 
dilutions of caesium chloride-purified pUC18 that was 
quantitated spectrophotometrically by absorbance at 260 nm. 
DNA bands stained with ethidium bromide fluoresced in 
ultraviolet light. The nanogram quantities of DNA 
electrophoresed in agarose gel lanes are indicated. These 
electropherograms served as standards for estimating DNA 
yields. Uncut circular pUC18 plasmid (right gel) exists as 
several supercoiled species that migrate variably in agarose 
gels. Linearization of the plasmid by restriction with 
Pst I enzyme eliminates supercoiling, and all plasmid DNA 
migrates as a single species (left gel).
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B, Caesium Chloride Purification of Plasmid DNA
Residual bacterial DNA and bacterial high molecular 
weight RNA was removed from recombinant plasmid DNA by 
caesium chloride density gradient centrifugation (Garger 
et al.. 1983). Precipitated DNA was resuspended in 2.8 ml 
of TE buffer, pH 7.6. Caesium chloride (IBI) and ethidium 
bromide were added to 6.5 M and 3.4 mM, respectively, and 
4 ml of the resulting solution was layered under 8 ml of 
light-density caesium chloride solution (42% (w/w) in TE 
buffer) in a Beckman Quick-Seal tube. The tube was heat 
sealed and centrifuged for 16 h in a Beckman Ti 70.1 rotor 
at 230,000 X g at 20°C in a Beckman L5-50 ultracentrifuge or 
for 5 h at 400,000 X g in a Sorvall OTD 75B ultracentrifuge. 
The ethidium bromide-stained plasmid DNA band, which 
equilibrated below the less dense bacterial DNA band 
(bacterial RNA pelleted in the tube), was visualized by 
indirect UV light and removed by needle puncture at the side 
of the tube. Ethidium bromide was removed by extracting 
three times with an equal volume of sodium chloride-saturated 
2-propanol. The DNA-caesium chloride solution was diluted 
seven-fold with TE buffer and precipitated with 2.5 volumes 
of ethanol.
The DNA was resuspended in TE buffer and precipitated 
two more times to remove caesium chloride salt. Purified 
plasmid DNA was dissolved in TE buffer and stored at 4®C or 
frozen at -20°C. DNA was quantitated by absorption at 260 
nm of 0.01 ml of DNA solution diluted in 1 ml of water.
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Based on a standard curve of calf thymus DNA (Boehringer) 
versus UV light absorption, the DNA concentration was 
calculated as follows:
mg/ml DNA =0.05 mg/ml X 1.0 ml + 0.01 ml DNA X A
260
1 A260 0.01 ml DNA solution
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PART 3 : NUCLEOTIDE SEQUENCING OF VEE VIRUS cDNA
I. Restriction Enzyme Mapping of cDNA
Since the practical limit of sequencing reactions 
permitted the resolution of only 400 - 600 bases per 
reaction, recombinant plasmids containing approximately 
4000 bp of cDNA were analyzed by restriction enzyme 
mapping. This was necessary in order to determine the 
optimal subcloning strategy for sequence analysis.
Recombinant plasmid was restricted with a variety of 
enzymes, and the resulting DNA fragments were analyzed by 
electrophoresis in 1% (w/v) agarose gels. Migration 
distance (in mm) of each ethidium bromide-stained DNA band 
was compared with a standard molecular weight marker (Pst I 
- cut pUClS plasmid and Hinf I - cut pBR327 plasmid) run in 
the same gel and plotted on a semilogarithmic graph to 
determine the size (number of base pairs) of each 
restriction fragment.
Restriction enzymes were obtained from BRL, Promega,
New England Biolabs, Inc. (Beverly, Massachusetts), NEN, and 
Boehringer Mannheim. Digests of 0.0005 - 0.002 mg of DNA 
were performed in 0.03-ml reactions using 2 - 1 0  units of 
appropriate enzyme for 1 - 4 h at 37°C, except for 
restriction enzymes Tthlll I and Taq I, which were incubated 
at 60®C. The latter two enzymes are isolated from 
thermophilic bacteria. Six enzyme buffers (Table 4), each a
- 1 1 4 -
Buffer 
RENZ #1
RENZ in
RENZ in
RENZ #4
RENZ #5
RENZ #6
Table 4, Restriction enzyme buffers
Recipe Restriction Enzymes
50 mM Tris-HCl, ph 8.0 
10 mM magnesium chloride 
50 mM sodium chloride 
6 mM 2-mercaptoethanol
6 mM Tris-Hcl, pH 7.7 
6 mM magnesium chloride 
150 mM sodium chloride 
6 mM 2-mercaptoethanol
10 mM Tris-Hcl, pH 7.6 
10 mM magnesium chloride 
55 mM sodium chloride 
6 mM 2-mercaptoethanol
100 mM Tris-Hcl, pH 7.5
5 mM magnesium chloride 
50 mM sodium chloride
6 mM 2-mercaptoethanol
100 mM Tris-Hcl, pH 7.5
5 mM magnesium chloride 
50 mM sodium chloride
6 mM 2-mercaptoethanol
6 mM Tris-Hcl, pH 7.5 
6 mM magnesium chloride 
20 mM sodium chloride 
6 mM 2-mercaptoethanol
Pst I 
Sst I 
Taq I 
Hind III 
Hae III
Bam HI^ 
Xba I^ 
Sal I
Hinc II 
Sau 3AA 
Bgl Ilh 
Sph ih 
Acc I 
Tthlll I
Eco RI
Hpa II 
Sma I
Xma I 
Kpn I
^No 2-mercaptoethanol in buffer.
Ê10 mM 2-mercaptoethanol in buffer.
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compromise of related buffer conditions reported by several 
manufacturers for individual restriction enzymes, were used 
for restriction enzyme digestions.
II. Subcloning of cDNA into Bacteriophage M13
A. Bacteriophage M13
Mature filamentous M13 bacteriophage (phage) contains a 
circular, single-stranded DNA genome. The bacteriophage 
enters susceptible bacterial cells through the F pilus. 
Replication within the bacterial cell is mediated by a 
circular, double-stranded, 7200-bp replicative form (RF) 
from which positive sense, single-stranded, circular genomic 
DNA molecules are derived. The genetically engineered 
M13mpl0 and M13mpll bacteriophages (Messing and Vieira, 
1982), like the pUC18 plasmid, contain the lac operon 
elements and MGS (identical to pUClO and pUCll, which lack 
only the Sph I and Kpn I restriction sites of the pUG18 and 
pUG19 MGS) for rapid subcloning of foreign DNA and screening 
of recombinants.
B. Isolation of cDNA Fragments from Agarose Gels
Based on restriction map analyses of the cDNA clones, 
the cDNA was digested with restriction enzymes, and the 
resulting DNA fragments were electrophoresed in, and 
isolated from, agarose gels. Restriction fragments were
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separated by electrophoresis in 1.0% (w/v) agarose (GTG 
agarose, FMC Corp., Rockland, Maryland) gels in AgarTBE 
buffer in a BRL Model H3 horizontal gel electrophoresis 
apparatus and stained for 10 min in 0.5 mM ethidium 
bromide. Gel slices containing DNA bands were excised and 
crushed thoroughly with a spatula. The volume was brought 
to 0.4 ml with TE buffer in a 1.5-ml microtube, and 0.4 ml 
of phenol (equilibrated with TE buffer) was added. This 
mixture was vortexed vigorously, frozen (at -70*C) and 
thawed three times, and centrifuged for 10 min at 4®G to 
separate phases and remove agarose fragments. The aqueous 
phase was extracted with an equal volume of PGI, ether 
extracted, and EtOH/OAc/Mg-precipitated. Precipitated DNA 
was rehydrated in 0.03 ml of TE buffer, and a 0.003-ml 
aliquot was run on a 0.8% (w/v) analytical agarose gel to 
determine quantity and purity of yield. DNA isolated from 
three lanes (2 mm X 5 mm wells in a 11 cm X 14 cm, 100-ml 
gel) was generally sufficient for most purposes. This 
preparative procedure is a modification of a procedure used 
by James Wong and Bruce Roe (University of Oklahoma, 
personal communication).
G. Ligation of cDNA to M13 Phage RF DNA
Replicative form DNA was extracted from M13-infected 
overnight cultures of ^  coli JMlOl (Yanisch-Perron et al.. 
1985) cells as described for extraction of pUG18 plasmid 
DNA, except that infected JMlOl cells were washed once with
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GTE buffer in order to remove extracellular bacteriophage 
particles before proceeding with the RF extraction.
Complementary DNA was digested with restriction enzymes 
that linearize the M13 phage RF at the MGS, with enzymes 
Hpa II and Taq I, which produce DNA fragments that clone 
into the Acc I site of the MGS, and/or with enzyme Sau 3A, 
which produces fragments that clone into the Bam HI site of 
the MGS. Restriction fragments were isolated and ligated 
into appropriately cut,caesium chloride-purified M13mpl0 or 
M13mpll phage RF.
Following digestion of RF DNA, restriction enzymes were 
inactivated by heating for 10 min at 70*G. Ligase buffer 
(lOX stock: 250 mM Tris-HGl, pH 7.8, 100 mM magnesium 
chloride, 1 mM DTT, 2 mM ATP; stored as small aliquots at 
-70°G), cDNA fragment, and 1 unit of bacteriophage T4 DNA 
ligase (1000 units/ml, IBI) were added directly to the 
heat-inactivated restriction enzyme digests of RF DNA. 
Typically, 10-20 ng of linearized RF DNA was ligated to 
100-500 ng of cDNA fragment in a 0.03-ml volume for 12 - 18 
h at 4®G or 2 - 4 h at room temperature (Maniatis et al.. 
1982).
D. Transformation of E. coli JMlOl Cells
The bacterial F pilus is encoded by an episome that 
also codes for proline synthesis. Therefore, JMlOl cells 
were maintained in M9 minimal salt-glucose medium containing 
inorganic salts as sole source of nitrogen in order to
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provide pressure for maintenance of the F pilus. These 
cells readily become refractory to bacteriophage infection 
if maintained in enriched media. JMlOl cultures were grown 
in 2X-YT broth that was inoculated from minimal medium stock.
JMlOl cells were transfected with the ligated DNA by 
the method of Messing (1983). Cells were grown to 0.2 - 0.3 
AggQ in 2X-YT broth, washed sequentially with cold (4°C)
100 mM magnesium chloride and 100 mM calcium chloride, and 
then resuspended in one-tenth of the original culture volume 
in 50 mM calcium chloride. The ligation solution was added 
to 0.3 ml of competent cells, which were then incubated for 
40 min on ice. The transfected cells were heat-shocked for 
3 min at 37®C. An aliquot of 0.001 to 0.02 ml of the 
transfected cells was added to a tube containing 0.2 ml of 
lawn cells (fresh late logarithmic phase JMlOl cells in 
2X-YT broth), 2.5 ml of warm (50®C) TopAgar (1.0% (w/v) 
tryptone, 0.8% (w/v) Bacto-Agar, in 89 mM sodium chloride), 
and 0.03 ml each of IPTG and BGIG. This mixture was poured 
onto the surface of an H-agar plate (1% (w/v) tryptone, 
1.5%(w/v) Bacto-Agar in 89 mM sodium chloride).
After overnight incubation at 37®G, isolated white 
(colourless) plaques were chosen for further investigation. 
Plaques resulting from bacteriophage that lacked a cDNA 
insert were blue in colour due to the hydrolysis of BGIG by 
a functional beta-galactosidase. Plaques produced by M13 
bacteriophage, which do not lyse the bacterial host cell, 
appeared as translucent zones of reduced JMlOl growth in the 
cell lawn.
-119-
III. Screening of Recombinant M13 Phage Clones
A. Strategv
Recombinant M13 phage plaques were picked with sterile 
toothpicks and placed in 2 ml of 2X-YT broth containing 
early logarithmic phase JMlOl cells in 17 mm (internal 
diameter) by 14.5 cm tubes with metal enclosures. The 
cultures were shaken at 300 rpm at 37®C for 7 h or 
overnight. Good aeration was essential for adequate 
production of bacteriophage. The cultures were decanted 
into 1.5-ml microtubes and centrifugation 12,400 X g for 
10 min at room temperature. The supernatant media 
containing mature bacteriophage particles were tested for 
cDNA orientation by the complementation test, which 
identified bacteriophage minicultures useful for sequence 
analysis.
B. Complementation Test
cDNA fragments resulting from restriction with a single 
enzyme can be ligated into the M13 phage MGS in either of 
two orientations. Since mature M13 phage virions contain 
only one sense strand of the RF, single-stranded recombinant 
M13 phage DNA containing cDNA cloned in opposite orientations 
will contain opposite sense cDNA strands. Single-stranded 
M13 DNA containing cDNA inserts of opposite orientations 
were readily identified via the complementation test
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(C-test), which was performed according to the procedure of 
Messing (1983) as modified by Young (1984).
Briefly, 0.015 ml of reference M13 phage DNA or M13 
2X-YT broth supernatant was mixed with 0.015 ml of each of 
several other DNAs isolated from individual recombinant 
virus plaques (or with other infectious 2X-YT supernatants), 
0.0023 ml of 125 mM sodium chloride and 0.008 ml of C-test 
dye (3.0% (w/v) SDS, 0.2% (w/v) bromophenol blue, 0.2% (w/v) 
xylene cyanol FF, 25.0 mM disodium EDTA, 13.3 M deionized 
formamide, 125 mM sodium hydroxide) and incubated for 30 min 
at 55 - 65®C, then for 30 min at 37®C. Formamide (IBI, 
spectral grade) was deionized for 2 h at room temperature 
with 5% (w/v) mixed ion exchange resin (Amberlite MB-1, 
SIGMA), which was then removed by filtration. The samples 
were electrophoresed in 0.8% (w/v) HGT agarose (Seakem, FMC) 
gels in AgarTBE buffer for 1.5 - 2 h at 130 volts. If the 
cDNA strand in the reference recombinant Ml3 DNA were 
complementary to that in the test DNA, the two cDNA species 
hybridized to form a larger duplex molecule that was evident 
as a slower-migrating secondary DNA band in the agarose 
gel. If, however, the two recombinant DNAs contained cDNA 
of identical sense and orientation, no hybridization was 
evident. Sequencing reactions were performed with M13 DNAs 
containing both orientations of cDNA fragments. In some 
instances, cDNA fragments resulting from cleavage with two 
different restriction enzymes were force-cloned into both 
M13mpl0 and M13mpll RF that was cut with the two appropriate 
enzymes in order to obtain both cDNA orientations.
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IV. Nucleotide Sequencing of Recombinant M13 Phage DNA
A. Purification of the M13 Phage DNA
/
Single-stranded DNA was extracted from the bacteriophage 
particles by transferring 1 ml of the miniculture supernatant 
to a 1.5-ml microtube containing 0.2 ml of 20% (w/v) 
polyethylene glycol (PEG 8000, Fisher) in 2.5 M sodium 
chloride. After incubation for 15 min at room temperature 
the bacteriophage precipitate was collected by centrifugation 
at 12,400 X g for 5 min at room temperature. The supernatant 
was aspirated, and the tube was centrifuged briefly and 
aspirated again to remove residual fluid. The bacteriophage 
pellet was resuspended in 0.125 ml of 10 mM Tris-HGl, 
pH 7.6, ImM disodium EDTA, 200 mM sodium acetate. The M13 
phage DNA was extracted by vigorous mixing with 0.09 ml of 
phenol (equilibrated with TE buffer) at room temperature 
during a period of 20 min. Phases were separated by 
centrifugation, and the aqueous phase was extracted with 
0.5 ml of ether and precipitated with 2.5 volumes of 
ethanol. The single-stranded DNA pellet was rehydrated in 
0.06 ml of TE buffer and stored at 4°G. The concentration 
of the purified DNA solution was not measured.
B. Dideoxvnucleotide Sequencing
DNA sequencing was performed in 50-cm-long, 0.4-mm 
thick, 6% (w/v) acrylamide-bisacrylamide (19:1) gels by the
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dideoxyribonucleotide chain termination method of Sanger et 
al. (1977, 1980). A 40% (w/v) stock acrylamide-bisacrylamide 
solution was deionized for 2 h at room temperature with 
5% (w/v) mixed anion-cation exchange resin (Amberlite MB-1, 
SIGMA). The resin was removed by filtration, and the 40% 
stock was stored at 4°C. Sequencing gels contained 7 M 
urea, 0.11% (w/v) ammonium persulfate, 0.07% (v/v)
N,N,N',N'-tetramethylethylenediamine (TEMED) in SeqTBE 
buffer (134 mM Tris, pH 9.0, 420 mM boric acid, 2.8 mM 
disodium EDTA). The polyacrylamide gel solution was not 
degassed before casting the gel.
A 0.005-ml aliquot of single-stranded recombinant DNA 
was annealed with 1 - 3 ng of universal synthetic DNA primer 
(5’-GTTTTCCCAGTCACGAC-3') (Fig. 8) in 10 mM Tris-HCl, 
pH 7.6, 7 mM magnesium chloride, 60 mM sodium chloride, 1 mM 
DTT in a volume of 0.012 ml for 5 min at 55®C, followed by 
30 min at 37®C. Then 0.0015 ml (1000 units/ml) of the large 
fragment (Klenow, IBI) of E_,_ coli DNA polymerase I and 
0.02 mCi (0.002 ml) of alpha-[ -dATP (3000 Ci/mmol,
10 mCi/ml, NEN) were added, and 0.0033 ml of the resulting 
solution was aliquoted into each of four 0.5-ml microtubes. 
The appropriate dideoxynucleotide mixture (0.0025 ml) was 
added to each of the four tubes, and the polymerase reaction 
was incubated for 20 min at room temperature. Reaction 
components were added by pipetting the appropriate volume 
onto the sides of the reaction tubes which were positioned 
in a microcentrifuge. The tube caps were closed, and all 
reactions were initiated simultaneously by brief
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Figure 8. Dideoxynucleotide sequencing: Extension of the
universal M13 phage primer on a recombinant, single-stranded 
(ss) MlSmpll phage DNA template.
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centrifugation, followed by brief mixing and centrifuga­
tion. A 0.002-ml aliquot of chase mixture (0.04 mM each of 
dATP, dCTP, dGTP, and dTTP) was added, and the reactions 
were incubated for another 15 min at room temperature to 
ensure elongation of all DNA chains that were not terminated 
by the random incorporation of a dideoxynucleotide-ATP,
-CTP, -GTP, or -TTP in each reaction tube, respectively.
Sequencing reactions were terminated with the addition 
of 0.006 ml of stop dye solution (2.5 mM disodium EDTA,
120 mM sodium hydroxide, 0.2% (w/v) bromophenol blue,
0.2% (w/v) xylene cyanol FF, in deionized formamide). The 
samples were heated (with tube caps open) for 5 min at 95°C 
in a heating block, transferred to ice, and 0.002 - 0.003 ml 
of each reaction was loaded onto sequencing gels. 
Electrophoresis was performed for 4 - 24 h at limits of 
24 milliamperes per gel and 1800 volts. Heat dissipation 
was provided by fans. Following electrophoresis, gels were 
transferred to precut Whatman SMMChr filter paper (Whatman 
Lab Sales, Inc., Hillsboro, Oklahoma), dried on a Hoeffer 
Scientific Model SE 1150 slab gel dryer (Hoeffer Scientific 
Instruments, San Francisco, California) and autoradiographed 
at room temperature using Kodak SB-5 35 cm X 43 cm X-ray 
film.
Concentrations of deoxynucleotides (dNTPs) and 
dideoxynucleotides (ddNTPs) used in the dideoxynucleotide 
mixtures were; (ddATP mix) 0.015 mM ddATP, 0.08 mM each of 
dCTP, dGTP, and dTTP; (ddCTP mix) 0.015 mM ddCTP, 0.006 mM 
dCTP, 0.12 mM each of dGTP and dTTP; (ddGTP mix) 0.015 mM
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ddGTP, 0.006 mM dGTP, 0.12 mM each of dCTP and dTTP; (ddTTP 
mix) 0.045 mM ddTTP, 0.006 mM dTTP, 0.12 mM each of dCTP and 
dGTP.
These mixes and the chase mixture were made in 5 mM 
Tris-HCl, pH 7.6, 0.1 mM disodium EDTA. Dideoxynucleotide 
mixtures were adjusted empirically to determine optimal dNTP 
and ddNTP concentrations for obtaining both short and long 
sequences. A combination of short (4 h, bromophenol blue 
dye to bottom of gel) and long (8 - 24 h) sequencing gels 
routinely permitted reading of 400-600 nucleotides per 
recombinant Ml3 phage DNA in a single set of sequencing 
reactions. Deoxy- and dideoxynucleotides were obtained from 
Pharmacia.
V. Sequencing of Double-Stranded cDNA
Caesium chloride-purified recombinant pUC18 or 
agarose-purified cDNA fragment was sequenced directly by 
melting (boiling for 10 min) 0.0003 - 0.002 mg of 
double-stranded DNA in 0.02 ml of a solution consisting of 
TO mM Tris-HCl, pH 7.6, 7 mM magnesium chloride, 60 mM 
sodium chloride, and 4 - 10 ng synthetic oligonucleotide 
primer. The mixture was quick-chilled on ice, and 2 units 
(0.002 ml) Klenow enzyme, 0.04 mCi (0.004 ml) of 
alpha-[^^P]-dATP and 0.001 ml of DTT were added. A 
0.005-ml aliquot of the resulting solution was pipetted into 
each of four 0.5-ml microtubes. Dideoxynucleotide mixes 
(0.004 ml) were added and dideoxynucleotide sequencing was
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performed as described for sequencing of M13 single-stranded 
DNA, except that the reactions were incubated at 50°C 
instead of room temperature. The procedure was modified 
from that of Chen and Seeburg (1985).
VI. Primer Extension Sequencing of VEE Virus RNA
Selected regions of VEE virus genomic RNA were 
sequenced by reverse transcriptase-catalyzed extension from 
synthetic DNA primers by the dideoxynucleotide chain 
termination method essentially as described by Ou et al. 
(1981). A 20-fold molar excess of primer was hybridized to
0.002 mg of VEE virus genomic RNA for 2 min at 95®C and 
placed on ice. Two units of avian myeloblastosis reverse 
transcriptase (10,000 units/ml, Promega) and 9 units of 
placental RNase inhibitor (10,000 units/ml, Promega) were 
added to 44 mM Tris-HCl, pH 8.1, 8.3 mM magnesium chloride,
54 mM potassium chloride, 8.3 mM DTT, 0.02 mCi of
32
alpha-[ P]-dATP, 0.0037 mM of each dNTP, and 0.0016 mM of 
the appropriate ddNTP in a final volume of 0.005 ml. The 
reactions were incubated for 5 min at 20°C and then for 
30 min at 37°C. A 0.002-ml aliquot chase mixture (0.5 mM 
each dNTP) was added for 15 min at 37®C. Reactions were 
stopped and loaded onto sequencing gels as already described,
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VII. Computer Analysis
Computer analysis of sequence information was 
accomplished with the aid of a 2019-line FORTRAN 77 
(Version 5) programme (RKSEQ) written by this author.
Various programme capabilities were developed as needed.
This DNA sequencing management system was designed for batch 
operation while time-sharing on a Control Data Corporation 
Cyber Model 176 mainframe computer. Hydrophobicity plots 
were obtained by routing files containing calculated average 
hydrophobicity values to a plotting routine (EZGRAF) 
accessible on the Cyber. The major analysis options 
provided by programme RKSEQ were;
(1) Enter sequence data into the database (file 
SEQDAT).
(2) Meld or split sequences and enter result into 
SEQDAT.
(3) Edit sequence data in SEQDAT.
(4) Print annotated data from SEQDAT.
(5) Subsequence (portion of a sequence data file) 
analysis.
(6) Convert DNA sequence to RNA sequence and vice- 
versa.
(7) Convert DNA sequence to its inverse complement.
(8) Amino acid translation in all reading frames.
(9) Search for matching sequences in different data 
files and print aligned, annotated sequences, 
indicating all mismatches. This routine was
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useful for cloning and sequencing of DNA 
fragments, and included the capability to search 
all three reading frames of a normal and 
inverse-complement DNA sequence for a match with a 
file containing an amino acid sequence.
(10) Search for user-specified sequence sites or select 
restriction enzyme sites from within RKSEQ.
(11) Determine base composition.
(12) Determine codon usage for amino acid translation.
(13) Determine amino acid composition and molecular
weight.
(14) Calculate moving average hydrophobicity plots of 
amino acid sequences. User specifies amino acid 
residue lengths (windows) for the moving peptide 
segment.
(15) Identity analysis of aligned sequences.
The programme provided a variety of format options 
for output, including :
(1) No spacing between lines.
(2) Double or up to 6 spaces between lines.
(3) Print 70, 100, or 120 characters per line.
(4) Include or suppress sequence annotation.
(5) Maintain original annotation for subsequence 
analysis or treat the subsequence as an 
independent sequence.
(6) Print translated amino acid sequence aligned over 
the nucleotide sequence (RNA or DNA sense).
-130-
Late in the sequencing project, the GDC laboratory in 
Fort Collins invested in several IBM-compatible 
microcomputers. Most of programme RKSEQ was rewritten by 
this author to operate within the DOS operating system of 
the microcomputer using the F77L FORTRAN 77 compiler from 
Lahey Computer Systems, Inc. (Incline Village, Nevada). 
This 1835-line program, which was named BASEQUE, contained 
all of the algorithms of programme RKSEQ except for the 
matching sequence search, restriction enzyme site search, 
and hydrophobicity analysis. These latter functions were 
then performed using two commercial software packages, 
DNASIS and PROSIS, written for the microcomputer and 
supplied by Hitachi Software Engineering Company, Ltd.(San 
Bruno, California). One set of polypeptide hydrophobicity 
profiles and all of the secondary structure analyses 
reported here were performed using the Hitachi software.
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PART 4: RECOMBINANT VACCINIA VIRUS -
EXPRESSION OF VEE VIRUS STRUCTURAL PROTEINS
I. Construction of the Chimeric Insertion Plasmid
Plasmid pGS-62 (Esposito et , 1987), a derivative of 
the pGS-20 vector (Mackett and Smith, 1986; Mackett et al., 
1984) with a single Eco RI site downstream of the VACC 7.5K 
promoter, was used to insert VEE virus cDNA into the 
wild-type VACC virus genome. Tthlll I restriction (Fig. 9) 
of recombinant pUC18 plasmid pTC-5, which contained VEE cDNA 
encoding the entire structural polyprotein precursor, 
released the cDNA so that the start codon for translation of 
the complete structural genes of VEE virus could be ligated 
(using Eco RI linkers) into pGS-62 immediately downstream of 
the vaccinia 7.5K early-late promoter and mRNA start site 
and between flanking sequences from the VACC TK gene 
(Fig. 10). The VEE virus-specific cDNAs contained in 
recombinant pUC18 plasmids pTRD-1 and pTRD-20 were excised 
and inserted into pGS-62 in essentially identical fashion.
Restricted recombinant pUC18 plasmid was made 
blunt-ended by filling in 5'-overhang sequences, which 
resulted from restriction enzyme cutting, with Klenow enzyme 
and dNTPs. Commercial (Boehringer) double-stranded Eco RI 
linker (5'-GGAATTCC-3', 200 ng) was ligated to the blunt 
ends. Ligase was inactivated by heating for 10 min at 70*C,
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Figure 9. Location of the Tthlll I restriction enzyme site 
in VEE TRD and TC-83 virus cDNA clones. Cut positions are 
indicated by vertical arrows. Only the positive, mRNA sense 
strand of the cDNA is shown. The Tthlll I site was 
instrumental in the subcloning of the VEE virus cDNA into 
the insertion vector, pGS-62.
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Figure 10. Construction of the chimeric insertion vector, 
pTC-5A. cDNA encoding the structural proteins of VEE TC-83 
virus was removed from the recombinant pTC-5 plasmid by 
combined Tthlll I and Eco RI restriction. The cDNA was 
cloned, using Eco RI linkers, into the Eco RI site of the 
7000-bp pGS-62 insertion plasmid just downstream of the VACC 
virus 7.5K promoter and between arms of the VACC virus 
thymidine kinase (TK) gene.
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and ligation-ready Eco RI sites were generated at both ends 
of the cDNA by Eco RI digestion, followed by preparative GTG 
agarose gel electrophoresis to remove excess Eco RI linker.
The cDNA fragment was ligated into pGS-62 that had been 
linearized with Eco RI, and coli TB-1 cells were 
transformed with the resulting chimeric insertion plasmid. 
Although the pGS-62 plasmid encodes ampicillin resistance, 
it does not contain the beta-galactosidase marker system.
In order to reduce the number of background colonies due to 
self-ligation of vector ends, 0.001 mg of Eco Rl-cut pGS-62 
plasmid was treated with 19 units of calf intestinal 
phosphatase (19,000 units/ml, Boehringer) in 50 mM Tris-HCl, 
pH 9.3, 10 mM magnesium chloride, 1 mM zinc chloride for 
30 min at 37®C. The phosphatased DNA was extracted with PCI 
and ether, and then precipitated with EtOH/OAc/Mg. Ligation 
requires 5'-phosphate and 3'-hydroxyl groups. Without the 
5'-phosphate groups the vector is unable to ligate to 
itself, yet the cDNA 5'-phosphate moieties permit ligation 
of cDNA to the vector molecule.
The VEE-specific mRNA transcript in recombinant 
virus-infected cells should initiate translation at the AUG 
start codon of the VEE structural polyprotein and terminate 
at the UGA stop codon located at the end of the cDNA 
encoding glycoprotein El (Fig. 10).
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II. Insertion of VEE Virus Genes into VACC Virus
A. Transfection of VACC Virus-Infected Cells
Production of recombinant VACC viruses has been
reviewed by Mackett et al. (1982, 1984). Caesium
chloride-purified recombinant pGS-62 plasmid (0.005 mg) was
gently mixed with 0.001 mg of purified VACC virus DNA and
0.014 mg of carrier calf thymus DNA in 1 ml of Hepes-buffered
saline, pH 7.05, containing 125 mM calcium chloride. This
mixture was incubated for 30 min at room temperature and
then poured onto a PBS-rinsed CV-1 cell monolayer in a 
225-cra flask. The monolayer had been infected 1.5 h 
earlier with 0.05 PFU of VACC virus per cell. The calcium 
phosphate-precipitated DNA was allowed to adsorb for 30 rain 
at room temperature. Nine ml of MEM was then added, and the 
flasks were incubated at 37°C. The culture medium was 
replaced with fresh medium after 3.5 h.
B. Screening for Recombinant VACC Viruses
After 24 - 36 h incubation the cells were harvested,
freeze-thawed three times, and titrated on TK” 143 B cells
in the presence of 0.03 mg/ml BUDR. Virus plaques were
amplified in 24-well cultures of 143 B cells, which were
then lysed by freeze-thawing, spotted onto nitrocellulose
membranes, and screened for the presence of VEE virus genes
32by hybridization using nick-translated, [ P]-labelled VEE
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virus-specific cDNA as probe. Nick translation was
performed as described in the nick translation kit supplied
by NEN. A duplicate spotted nitrocellulose filter was
screened for expression of VEE virus antigen by incubating
the membrane with a 1:150 dilution of VEE TC-83
virus-specific mouse hyperimmune ascitic fluid, followed by 
125[ I]-labelled sheep anti-mouse whole antibody (Amersham;
10 mCi/mg, 0.1 mCi/ml) in 5% (w/v) dry milk (Carnation 
Company, Los Angelos, California) in PBS containing 
0.01% (v/v) anti-foam A (SIGMA) and 0.0001% (w/v) 
merthiolate. VEE TC-83 virus-specific ascitic fluid was 
obtained from the Arbovirus Reference Branch, DVBVD. 
Recombinant viruses from positive plaques were 
plaque-purified three times in 143 B cells in the presence 
of BUDR and once in CV-1 cells without BUDR.
Ill. Partial Purification of VACC Virus
VACC and recombinant viruses were adsorbed (0.05 - 1.0 
PFU/cell) to freshly confluent monolayers of CV-1 cells for 
Ih at 37®C. The cell monolayers were then overlaid with 
35 ml of MEM containing 2% (v/v) foetal bovine serum, and 
incubation was continued until CPE was evident in 90% of the 
cells (approximately 78 h PI). Cells that remained attached 
to the vessel wall were dislodged by scraping with a rubber 
policeman. Cells were pelleted by centrifugation for 20 min 
at 5880 X g at 4®C in a GSA rotor, and then were swollen in 
2 ml/flask of swelling buffer (10 mM Tris-HCl, pH 9.0,
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10 mM sodium chloride, 1.5 mM magnesium chloride) for 1 h on 
ice. The swollen cells were sheared for 50 strokes using a 
40-ml glass ball Dounce and then centrifuged for
10 min at 163 X g in a GSA rotor to pellet the released cell 
nuclei. The nuclear pellet was sheared again in one-tenth 
of the original volume of swelling buffer, centrifuged, and 
the pooled supernatant fractions were centrifuged a second 
time.
The enucleated cell lysate was made 0.15% (w/v) in 
trypsin (trypsin 1:250, porcine parvovirus tested, GIBCO) 
(Ichihashi and Oie, 1982; Ichihashi et al., 1982), incubated 
for 30 min at 37®C, homogenized for 70 strokes using a 40-ml 
glass tissue homogenizer, and then sonicated at 55 watts for 
three 30-sec bursts at 30-sec intervals on ice (Joklik, 
1962). The homogenate was immediately layered onto 12 ml of 
40% (w/w) sucrose (in 10 mM Tris-HCl, pH 9.0, 1 mM disodium 
EDTA), under which 0.2 ml of glycerol was layered. After 
centrifugation for 80 min at 34,000 X g at 4®C in a Beckman 
SW27 rotor, all fluid, including the cell membrane debris 
that remained at the sample-sucrose interface, was aspirated 
from the tube. The virus, which pelleted as an annular ring 
surrounding the 0.2-ml glycerol pad, was resuspended in a 
minimal volume of 10 mM Tris, pH 9.0, 1 mM disodium EDTA, 
incubated overnight at 4®C, freeze-thawed three times to 
disrupt virus aggregates, and stored in aliquots at -70°C. 
Three 0.02-ml aliquots of each partially-purified virus 
preparation were titrated in Vero cells. This purification 
procedure closely followed that of Esposito et al. (1981).
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I
The partially purified virus served as vaccine in mouse 
immunization studies.
IV. Analvsis of Recombinant Virus Genome Structure
A. Purification of Recombinant Virus DNA
DNA was isolated from partially purified VACC or 
recombinant VACC virus as described by Esposito et al. 
(1981). Pelleted virions were resuspended in 10 ml of 10 mM 
Tris-HCl, pH 8.0, 1 mM disodium EDTA. To this was added 
0.5 ml of 20% (v/v) Triton X-100 and 0.025 ml of 
2-mercaptoethanol (Ichihashi, 1981). After incubation for 
10 min on ice, the mixture was centrifuged for 1 h at 
28,000 X g in an SW41 rotor to pellet the released virus 
cores. Core particles were resuspended in 10 mM TE buffer, 
pH 8.0, 4% (w/v) N-laurlysarcosine (SIGMA), 630 mM 
2-mercaptoethanol, and 1.2 mg/ml of proteinase K 
(Boehringer). After incubation for 30 min on ice, 1.5 ml of 
54% (w/v) sucrose, 0.5 ml of 20% (w/v) sarcosine, 0.03 ml of 
2-mercaptoethanol, 0.08 ml of proteinase K (25 mg/ml), and
0.01 ml of 10% (w/v) SDS were added. This mixture was 
incubated for 2 h at 55®C, then extracted once with phenol, 
twice with PCI, and once with ether. The extracted nucleic 
acid was precipitated with EtOH/OAc/Mg.
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B. Restriction Enzvme Analvsis
Digestion of the 186,000-bp VACC virus genomic DNA with 
the Hind III produces 15 fragments that can be separated on 
agarose gels (Esposito and Knight, 1985). The VACC virus TK 
gene is located in the approximately 5000-bp Hind III J 
fragment. Since the VEE virus cDNA contained no internal 
Hind III sites, insertion of the approximately 4000-bp cDNA 
fragment should decrease the gel migration rate of the 
recombinant virus Hind III J (Fig. 11). DNA was digested 
for several hours with the appropriate restriction enzyme 
and then electrophoresed in a 0.6% (w/v) GTG agarose gel in 
AgarTBE buffer at 30 volts for 10 - 16 h. The gel was 
stained in ethidium bromide, and the DNA was blotted onto 
nitrocellulose for hybridization analysis.
C. Southern Blotting and Hybridization
Localization of VEE virus cDNA in the recombinant virus 
genome was accomplished by the transfer method of Southern 
(1985) as described by Maniatis et al. (1982). DNA in the 
agarose gel was denatured by soaking the gels in 300 ml of a 
solution of 1.5 M sodium chloride and 0.5 M sodium 
hydroxide for 1 h at room temperature, followed by soaking 
in 300 ml of 1 M Tris-HCl, pH 8.0, in 1.5 M sodium chloride 
for 1 h at room temperature. The gel was placed on a 
Whatman 3MMChr filter paper wick in contact with lOX SSPE 
buffer. A presoaked (in 6X SSPE) nitrocellulose membrane
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Figure 11. Cloning of VEE virus cDNA into the Hind III J 
region of the VACC virus genome. A linear map showing the 
fifteen restriction fragments resulting from Hind III enzyme 
digestion of VACC virus DNA is shown (top of figure). The 
VEE virus cDNA was inserted into the thymidine kinase (TK) 
gene located in the Hind III J region by homologous 
recombination, which was mediated by the TK arms of the 
chimeric pTC-5A insertion plasmid. Insertion of the VEE 
virus cDNA and the VACC 7.5K promoter into the J fragment 
should decrease the migration rate of this fragment in 
agarose gels. Map distance in kilobase pairs is shown.
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was layered onto the gel, and a stack of paper towels was
placed on top of the nitrocellulose membrane under a 500-g
weight. After allowing the transfer to proceed for 18 h,
the nitrocellulose membrane was air dried and baked for 2 h
32
at 80®C. Hybridization using [ P]-labelled, nick- 
translated VEE virus cDNA fragments as probes was performed 
as already described.
V. Detection of VEE Virus Structural Proteins
A. Immunoblots
Polypeptides resolved by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) were transferred to nitrocellulose 
by the method of Towbin et al. (1979) at 60 volts for 4h in 
transfer buffer (50 mM Tris base, 380 mM glycine, 20% (v/v) 
methanol) using a Transphor electrophoresis unit (Hoeffer). 
Free nitrocellulose binding sites were blocked with 3% (w/v) 
bovine serum albumin (Fraction V, Reheis Chemical Co.) in 
10 mM Tris-HCl, pH 7.4, 150 mM sodium chloride for 4 h at 
room temperature. The filter was rinsed with 0.05% (v/v)
Tween 20 (polyoxyethylene-sorbitan monolaurate, SIGMA) in 
PBS and placed in a sealed plastic bag containing a 1:200 
dilution of anti-TC-83 virus mouse hyperimmune ascitic fluid 
in 15 ml of PBS/Tween. The filter was incubated on a 
rotating platform for 4 h at room temperature, washed with 
PBS/Tween, incubated for 1 h with a 1:500 dilution of 
alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson
-145.
Immuno Research Labs, Inc., Avondale, Pennsylvania) in 15 ml 
of PBS/Tween, rinsed three times with PBS/Tween, and rinsed 
briefly with distilled water. The immunoblot was developed 
by adding substrate (1 ml of 5-bromo-4-chloro-3-indolyl 
phosphate, 1 ml of nitro blue tétrazolium) and 6 ml of 0.1 M 
Tris-HCl, pH 9.5, from a kit supplied by Kirkegaard & Perry 
Laboratories, Inc. (Gaithersburg, Maryland) for 4 min. The 
reaction was stopped by washing the filter in water.
B. Radioimmune Precipitation
Expression of VEE virus structural proteins was
detected by radioimmune precipitation (RIP) analysis of 
35[ S]-methionine-labelled lysates of CV-1 cell infected
with recombinant virus. Monolayers of CV-1 cells grown in 
2
25 cm flasks were infected with 20 PFU/cell of VACC, 
recombinant, or wild type VEE virus. At 18 h postinfection 
the culture medium was replaced with MEM lacking methionine. 
After 1 h of incubation at 37®C, the medium was replaced 
with 2 ml of the same medium containing 0.1 mCi of 
[^^S]-methionine (NEN; 1110 Ci/mmol, ImCi/ml), and the 
cultures were incubated further for 6 h at 37°C. Lysates 
were prepared by washing the cells with cold PBS and then 
adding per monolayer 0.7 ml of RIPA buffer (1% (w/v) sodium 
desoxycholate, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 50 mM 
Tris-HCl, pH 7.4, 1% (v/v) aprotinin (SIGMA)) on ice. Cell 
lysates were forced several times through a 25-gauge needle 
to sheer DNA and then stored at -70°C until used.
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RIP experiments were performed by incubating 0.2 ml of 
cell lysate with 2 mg of protein A Sepharose CL-4B 
(Pharmacia), 0.1 mg of affinity chromatography purified BSA 
(Pierce Chemical Company), and 0.1 ml of a 1:150 dilution of 
anti-TC-83 virus mouse hyperimmune ascitic fluid for 2 h at 
room temperature. Protein A Sepharose was washed three 
times with RIPA buffer, concentrated by centrifugation, and 
boiled for 2.5 min in loading buffer (2.5% (w/v) SDS, 1.1 N 
glycerol, 700 mM 2-mercaptoethanol, 0.002% (w/v) bromophenol 
blue). Discontinuous SDS-PAGE was performed as described by 
France et al. (1979). The lower, 9-cm high (1.5-mm thick) 
resolving gel contained 0.1% (w/v) SDS, 2.5 M urea,
10% (w/v) acrylaraide-N,N’-diallyltartardiamide (DATD, 19:1, 
Bio-Rad Laboratories, Richmond, California), 0.05% (v/v) 
TEMED, 0.02% (w/v) ammonium persulfate in 375 mM Tris-HCl, 
pH 8.9. The 3-cm high upper stacking gel contained
0.1% (w/v) SDS, 2.5 M urea, 5% (w/v) acrylamide-DATD,
0.05% (w/v) TEMED, 0.04% (w/v) ammonium persulfate in 125 mM 
Tris-HCl, pH 6.7. The 40% (w/v) stock acrylamide-DATD 
solution was deionized and filtered as described for 
sequencing gels. Gel solution was degassed under vacuum 
before casting.
Electrophoresis was performed in electrophoresis buffer 
containing 380 mM glycine, 50 mM Tris and 0.1% (w/v) SDS for 
3.5 - 4 h at 20 millamperes per gel with a maximum of 
130 volts. Following electrophoresis the gel was soaked for
0.5 h in 25% (v/v) methanol and 9% (v/v) acetic acid in
3
water, then for 1 h in EN HANCE autoradiograph
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enhancer (NEN), 1 h in water, and 10 min in 100 mM 
glycerol. Autoradiography was performed using Kodak SB-5 
X-ray film.
C. Immunofluorescence Analvsis
Indirect immunofluorescence assays for VEE virus
protein expression were performed with CV-1 cells (grown in
4-chamber or 8-chamber Lab-Tek tissue culture slides. Miles
Laboratories, Inc., Naperville, Illinois) infected with
virus at an MOI of 10 or 20 PFU/cell. At 24 h PI, cell
monolayers were rinsed twice with PBS and air-dried with or
without prior acetone fixation. Cells were fixed by soaking
slides in cold (-20°C) acetone for 10 min, followed by air
drying. Detection of VEE virus glycoprotein epitopes in VEE
or recombinant virus-infected CV-1 cells was determined
using acetone-fixed spot slides of PBS-washed cells that
2were scraped from 25 cm flasks. Binding of virus 
specific antibody was detected using a 1:20 dilution of 
fluorescein-isothiocyanate-conjugated goat anti-mouse IgG 
(SIGMA) in PBS containing 0.00005% (w/v) Evans blue dye. 
Photography was performed with a Zeiss III RS microscope, 
Zeiss M35 camera and Zeiss MC63 autoexposure system using 
Eastman Kodak Ektachrome 160 tungsten 35 mm film.
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PART 5: RECOMBINANT VACCINIA VIRUS -
IMMUNIZATION AND PROTECTION OF MICE
I. Mice
Outbred general purpose white male Swiss NIH mice 
maintained at the CDC facility in Fort Collins, Colorado and 
inbred male C3H/HeSnJ (Charles River Laboratories,
Wilmington, Massachusetts) and female A/J (Jackson 
Laboratory, Bar Harbor, Maine) mouse strains were used in 
this study. Animals were fed TEKLAD LM-485 mouse/rat diet 
(Harlan Sprague Dawley, Inc., Madison, Wisconsin).
II. Immunization and Challenge of Mice
Five-week-old mice were immunized with TC-83 virus by
i.p. injection of 0.2 ml of PBS containing 10,000 PFU of
5 8virus. Mice were immunized with 10 - 10 PFU of VACC
or recombinant virus by intradermal (i.d.) tail scarification 
with 0.02 ml of virus suspension in PBS. Mice that were 
immunized i.d. were first anaesthetized with methoxyfluorane 
(Metofane, Pittman-Moore, Inc., Washington Crossing, New 
Jersey). The dorsal, anterior one-third portion of the tail 
was scarified with the edge of an 18-gauge needle. Virus 
suspension was spread over the wound and further gentle 
scarification was performed. No bleeding occurred.
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Mice were challenged 19 - 21 days postimmunization by
i.p. injection of 0.2 ml of virulent VEE virus in PBS or by 
intranasal (i.n.) inoculation of 0.005 ml of virulent virus 
in lightly anaesthetized animals. Fifty percent median 
lethal dose titrations of VEE virus strains administered
i.p. (IPLD^q ) or i.n. (INLD^q ) routes were determined in 
8-week-old Swiss NIH or A/J mice by the method of Reed and 
Muench (1938).
III. Serologv
A. ELISA
Enzyme-linked immunosorbent assays (ELISA) were 
performed as described by Voiler (1976). Gradient-
purified TC-83 virus protein was measured by the dye-binding 
spectrophotometric method of Bradford (1976) using a Bio-Rad 
protein assay kit. TC-83 virus protein (0.002 mg) in 0.1 ml 
of coating buffer (1 M sodium carbonate-bicarbonate, pH 9.6) 
was dropped into wells of 96-well flat-bottomed plates 
(Dynatech, Inc., Kensington, Maryland) and incubated 
overnight at 4®C. The plates were rinsed three times with 
PBS/Tween 20, and serial two-fold serum dilutions were made 
in the plates using a multichannel pipette (Titertek).
After incubation for 2 h at room temperature, the wells were 
rinsed three times with PBS/Tween, and 0.05 ml of alkaline- 
phosphatase-conjugated goat anti-mouse IgG (1:500 dilution, 
Jackson Immuno Research Labs) in PBS/Tween was added to each
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well for 1 h at room temperature. Four mg of freshly 
dissolved SIGMA 104 phosphate substrate tablets in 0.1 ml of 
PBS/Tween was added to each well. The reaction was stopped 
by the addition of 0.05 ml of 3 M sodium hydroxide after 
10 - 20 min when the yellow colour of positive controls had 
developed sufficiently. Optical densities were measured at 
405 nm in a Titertek Multiscan ELISA reader (Flow 
Laboratories, Inglewood, California).
B. HI Assay
Surface proteins of many viruses specifically bind and 
agglutinate mammalian or avian erythrocytes. Virus 
haemagglutination (HA), first reported by Hirst (1941) for 
influenza virus, is the basis for the HA test. The 
haemagglutination-inhibiion (HI) test is used to measure 
antibody. HA and HI tests were performed essentially as 
described by Clarke and Casals (1958) and as adapted for 
microtitre plates as described by Lennette and Schmidt 
(1969). Borate saline (50 mM boric acid, 120 mM sodium 
chloride, pH 9.0 with sodium hydroxide) containing 
0.4% (w/v) bovine serum albumin was used as diluent (BABS). 
Male goose (Anser cinereus) erythrocytes (Colorado Serum 
Co.), suspended in dextrose-gelatin-veronal buffer 
(0.058% (w/v) veronal (barbital), 0.038% (w/v) sodium 
barbital, 0.06% (w/v) gelatin, 0.14 mM calcium chloride,
0.49 mM magnesium chloride, 1.45 M sodium chloride, 55.6 mM 
D-glucose, pH 7.4), were standardized so that a 1:40
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dilution of the cell suspension had an optical density of
0.45 at 490 nm. For the test, the standardized cells 
suspension was diluted 1:24 (0.75 in virus-
adjusting-diluent (VAD), a buffer made with monobasic 
(150 mM sodium chloride, 200 mM monobasic sodium phosphate, 
pH 5.75) and dibasic (150 mM sodium chloride, 200 mM dibasic 
sodium phosphate, pH 7.0) sodium phosphate solutions mixed 
in predetermined proportions to produce the desired final pH 
after addition to an equal volume of BABS, pH 9.0. Optimum 
pH for HA was determined by making a two-fold dilution 
series of purified VEE virus in BABS and adding an equal 
volume of a 1:24 dilution of cells in VAD. The antigen 
dilution containing 8 HA units per 0.05 ml was obtained by a 
2^-fold dilution of the stock antigen, where n equals the 
number of wells, beyond the fourth well (1:16 antigen 
dilution), showing complete agglutination of the 
erythrocytes.
In order to remove lipid inhibitors of HA that are 
normally present in sera, ascitic fluids and sera were 
diluted 1:10 in PBS and extracted twice with 6 volumes of 
chilled (-20°C) acetone (Clarke and Casals, 1958). The 
precipitated protein was air-dried and rehydrated in borate 
saline, pH 9.0. Concentrated goose cells (0.05 ml) were 
added to the acetone-extracted fluids for 20 min at 4°C to 
absorb nonspecific agglutinins. The cells were removed by 
centrifugation.
HI tests were performed in 96-well Microtiter plates 
(Dynatech) by making serial two-fold dilutions of serum.
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starting with a 1:10 dilution. Four units of VEE virus 
antigen in 0.025 ml of BABS was added to each well 
containing 0.025 ml of diluted antibody, and the plates were 
incubated for 2 h at room temperature. A 0.05-ml aliquot of 
a 1:24 dilution of standardized erythrocytes in VAD of the 
appropriate pH was added to each well. The HI antibody 
titer was read at the highest dilution that resulted in 
complete inhibition of HA by the antigen, as indicated by 
settling of a compact, well-defined cell ’’button” at the 
bottom of the well.
C. Nt Assav
Neutralization (Nt) tests were performed in six-well 
plates of Vero cells by the serum-dilution plaque-reduction 
method described by Calisher et (1973) and Hunt and 
Calisher (1979). Sera were heat-inactivated for 30 min at 
56®C, and serial two-fold dilutions were made in BA-1 
diluent in 96-well plates (tissue culture serocluster with 
U-bottom; Costar). Virus stocks were diluted in BA-1 
diluent to 60 - 90 PFU/0.1 ml, and 0.1 ml of the diluted 
virus as added to each well containing 0.1 ml of diluted 
antibody. The plates were incubated for 14 - 18 h at 4°C. 
One-tenth ml from each well was transferred to a Vero cell 
monolayer, adsorption of virus was performed for Ih at 37®C, 
and the cell sheets were overlaid with agar as described for 
virus titrations. The endpoint was read as the final 
dilution of antibody that inhibited 70% or greater of the
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PFU added to the test, as indicated by a concurrent control 
titration of the virus suspension used in the test.
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CHAPTER 3
RESULTS
PART 1 : CLONING OF VEE VIRUS cDNA
I. Purification of VEE Virus RNA
VEE virus genomic RNA extracted from gradient-purified 
TRD and TC-83 viruses was centrifuged through 15% - 30% 
sucrose gradients. The gradient elution profile of
3
[ H]-uridine-labelled TRD viral RNA is shown in Fig. 12. 
TC-83 RNA showed a similar profile (data not shown). 
Fractions 4 - 9  were pooled and used as template for first 
strand cDNA synthesis.
II. cDNA Synthesis
Short cDNA molecules are cloned with much greater 
efficiency than are large molecules. Therefore, without 
prior size fractionation of the cDNA, many recombinant 
bacteria must be screened to find clones of useful size. To 
increase the cloning efficiency of high molecular weight 
cDNA molecules, double-stranded cDNA was fractionated on 
Sephacryl S-1000 columns (Fig. 13). Successful cDNA
-155-
3
Figure 12. Elution profile of [ H]-uridine-labelled VEE 
TRD virus 42S genomic RNA fractionated in a 15% - 30% 
sucrose gradient.
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Flgure 13. Sephacryl S-1000 column elution profile of 
32
[ P]-labelled, double-stranded cDNA synthesized by the 
RNase H - DNA polymerase I method. | The peaks at 
fractions 10 and 17 contain large molecular weight 
cDNA and free nucleotides, respectively.
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syntheses resulted in column elution profiles that contained 
a well-defined shoulder preceding the free nucleotide peak. 
Those fractions (fractions 9 and 10 in Fig. 13) which 
contained large molecular weight cDNA were pooled for 
cloning into pUC18.
III, Screening of cDNA Clones Bv Size
E. coli TB-1 cells were transformed with Pst I-cut, 
poly(dG)-tailed pUClS plasmid that was annealed to 
poly(dC)-tailed cDNA. Colourless recombinant colonies were 
grown, and plasmids were extracted from the cells by the 
rapid boiling method. Recombinant plasmids were 
electrophoresed in agarose gels in order compare their 
relative mobility, which is a function of cDNA insert size. 
One such electropherogram is shown in Fig, 14, One 
recombinant plasmid, labelled pTRD-1 in Fig, 14, was chosen 
for further investigation, and eventually sequenced,
IV, Screening of cDNA Clones bv Hybridization
Large recombinant plasmids resulting from the cloning
of VEE TRD or TC-83 cDNA were extracted from TB-1 cells and
spotted onto nitrocellulose membranes, which were then
probed by hybridization in order to identify those plasmids
that contained relevant cDNA copies of the VEE virus 26S
32RNA, The membranes were tested with the [ P]-labelled 
probes shown in Fig, 6, The hybridization results for
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Figure 14. Screening of recombinant plasmids for size in 
agarose gels. Electropherogram showing the migration of 
uncut recombinant plasmids versus wild-type pUC18 plasmid. 
DNA bands were stained with ethidium bromide. The diffuse 
bands at the bottom of the gel were due to bacterial RNA.
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recombinant plasmids containing TRD virus-specific cDNA are 
shown in Fig. 15. The pTRD-1 recombinant plasmid, which was 
spotted at coordinate position a2 (Fig. 15) on each of four 
nitrocellulose membranes, hybridized to the capsid 
(Fig. ISA), E2 amino-terminal (Fig. 15B), El amino-terminal 
(Fig. ISC), and 3'-end (Fig. ISD) probes. These results 
indicated that the pTRD-1 recombinant plasmid contained cDNA 
encoding the carboxyl terminus of the capsid protein and all 
of glycoproteins E2 and El of VEE TRD virus. Similar results 
were obtained for the recombinant plasmid pTC-S, which 
contained VEE TC-83 virus-specific cDNA (data not shown).
163-
Figure 15. Screening of recombinant plasmids by
hybridization. Hybridization of VEE TRD virus-specific
recombinant plasmid DNA spotted onto nitrocellulose 
32membranes using [ P]-labelled probes complementary in 
sequence to cDNA encoding the carboxyl-terminus of the 
capsid protein (A), the amino-terminus of the E2 (B) or El 
(C) glycoprotein, or the 3'-end site (D) used in the priming 
of first strand cDNA synthesis.
Hybridization anomalies, 
such as occurs with sample a9 (which appears 
to hybridize with probes used in panels A, C, 
and D, but not B) probably result from false 
positive reactions (a9 in panel A) due to 
probe binding at more than a single locus.
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PART 2 : NUCLEOTIDE SEQUENCING OF VEE VIRUS cDNA
I. Restriction Mapping of the cDNA Clones
pTRD-1 cDNA was mapped for restriction enzyme sites by
digesting recombinant plasmid with one or more enzymes and
analyzing the resulting restriction fragments by agarose gel
electrophoresis. The electropherograms shown in Fig. 16A
ion
and 16B provided information for construct' of an accurate 
restriction map of Pst I, Sst I, Bgl II, Xma I, and Hinc II 
sites in the pTRD-1 cDNA (Fig. 16, schematic diagram at 
bottom). The pTC-5 cDNA clone was not mapped thoroughly, 
since preliminary restriction mapping indicated that it 
contained essentially the same cDNA region that was 
contained in the pTRD-1 clone. Specifically, Pst I 
digestion of pTC-5 cDNA resulted in four cDNA restriction 
fragments, three of which were identical in size to the 
three smallest Pst I fragments of the pTRD-1 cDNA 
(Fig. 16). The largest Pst I fragment of pTC-5 was slightly 
larger than the largest Pst I fragment of pTRD-1. This 
suggested that both cDNA molecules contained the same 3’-end 
(positive, mRNA sense strand) and that cDNA synthesis that 
was primed from this point (3’-end primer) resulted in a 
larger cDNA clone in pTC-5 than in pTRD-1. This hypothesis 
was proven correct after both cDNAs were sequenced, and it 
was shown that both cDNAs contained the 3'-end priming site
—167—
Figure 16. Preliminary restriction enzyme mapping of VEE 
virus-specific cDNA cloned into recombinant plasmid pTRD-1. 
Analysis of the DNA fragments resulting from differential 
enzyme cuts (A, B) permitted construction of a restriction 
map of the pTRD-1 cDNA (schematic drawing at bottom). The 
termini of the recombinant plasmid after enzyme digestion 
are indicated (bases of solid triangles). Pst I restriction 
removed all cDNA from pTRD-1 and regenerated linearized 
wild-type pUC18 plasmid. The molecular weight marker 
consisted of linearized pUC18 (2686 bp) and Hinf 
I-restricted pBR327 (1631, 517, 452, 298, 221, and 154 bp). 
The two lanes next to the marker lane in (B) show 
preliminary results of the testing of a new marker.
? = unknown DNA fragment.
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that was used for first strand cDNA synthesis and that the 
pTC-5 cDNA was slightly longer than that of pTRD-1.
II. Subcloning of the cDNA into M13 Phage
Based on the results of restriction enzyme mapping, 
overlapping cDNA fragments of pTRD-1 and pTC-5 cDNAs were 
subcloned into M13mplO or M13mpll phage RF DNA for 
dideoxynucleotide sequencing. Recombinant plasmid was 
digested with restriction enzymes, and the resulting 
fragments were separated in,and isolated from, agarose 
gels. An analytical agarose gel electropherogram 
demonstrating the purity, quantity, and correct 
electrophoretic mobility of purified pTC-5 cDNA fragments 
resulting from restriction with enzymes Eco RI + Hind III 
(simultaneous digestion with both enzymes), Pst I, and Bgl 
II is shown in Fig. 17. Digestion of recombinant plasmid 
with Pst I or simultaneous digestion with two MCS-specific 
enzymes (Eco RI + Hindlll) cleaved the entire cDNA insert 
from the pUC18 vector. Neither the pTRD-1 nor the pTC-5 
cDNA contained any internal Eco RI or Hindlll sites 
(Fig. 17).
Purified cDNA fragments Were ligated into appropriately 
cut M13mpl0 or M13mpll phage RF double-stranded DNA. E. 
coli JMlOl cells were transfected with the ligated DNA, and 
bacteriophage from isolated plaques in JMlOl cell lawns were 
amplified. Individual cDNA fragments possessing identical 
restriction sites at both termini ligated into single-cut RF
—169—
Figure 17. Electropherogram demonstrating the purity and 
quantity of pTC-5 cDNA restriction fragments separated by, 
and extracted from, preparative agarose gels. RP = 
restricted recombinant plasmid. FI - F4 = aliquots of 
purified fragments (FI being the largest). FV = pUC18 
vector DNA containing portion of cDNA that was not excised 
from the vector by enzyme digestion. Marker = Hinf I-cut 
pBR327 (154 - 1631 bp), Pst I-cut pUC18 (2686 bp), and 
Eco Rl-cut pTC-5 (6728 bp). Combined Eco RI + Hind III , or 
Pst I, digestion cleaved the entire cDNA from pUC 18 and 
regenerated authentic wild-type, linearized plasmid that 
comigrated with the pUC18 band in the marker.
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in either of two orientations. Recombinant M13 phage 
single-stranded DNA containing cDNA inserts of opposite 
orientation (lanes marked '+') were readily determined using 
the complementation test (Fig. 18). Recombinant M13 phage 
DNAs containing opposite orientations of a given cDNA 
fragment were sequenced to determine the nucleotide sequence 
of both ends of the cDNA fragment. Complementary DNA 
nucleotide sequences obtained from recombinant M13 phage 
containing opposite orientations of a cDNA fragment are also 
of opposite strand sense.
Ill. Dideoxynucleotide Sequencing of the cDNAs
A combination of restriction mapping and sequencing 
results indicated that the pTRD-1 and pTC-5 cDNA molecules, 
which contained poly(dC-dG) tails of 12 - 21 bp length, were 
cloned into the Pst I site of pUC 18 in opposite 
orientations (Fig. 19). Both strands of the pTRD-1 and 
pTC-5 cDNA clones were sequenced in their entirety according 
to the strategies diagrammed in Figs. 20 and 21, 
respectively. All restriction enzyme junctions were 
confirmed by sequencing recombinant clones containing cDNA 
sequences that spanned the junctions. VEE virus-specific 
synthetic DNA primers were used to obtain the second strand 
sequence in two areas of the largest Pst I fragment of 
pTRD-1 (Fig. 20) and in one area of the largest Pst I 
fragment of pTC-5 (Fig. 21). Examples of typical short (4-h
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Figure 18. Complementation test (C-test) used to determine 
the orientation of cDNA fragments in single-stranded, 
recombinant bacteriophage M13 DNA. R = reference 
bacteriophage DNA. Positive ('+') and negative ('-') 
hybridization reactions of test bacteriophage DNAs with the 
reference DNA are indicated. Bacteriophage-containing 2X-YT 
broth was directly tested in all reactions shown except for 
the two lanes marked 'DNA Extract* in which extracted, 
sequencing-quality reference DNA was tested against a known 
positive DNA of the same purity, wt = wild-type M13mpl9 DNA.
-173-
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Figure 19. Orientation of pTRD-1 and pTC-5 cDNAs in the MGS 
of pUGlS. Poly (dG)-tailed TRD and TG-83 virus cDNAs were 
cloned into the poly(dG)-tailed Pst I site of the MGS of 
pUGlS. The cDNA strands corresponding to the mRNA sense 
strands of VEE TRD and TG-83 virus RNAs are indicated by 
solid arrows pointing in the 5* - 3* direction. Gloning of 
the tailed cDNA into the Pst I site of the MGS regenerated 
the Pst I restriction site at both termini of the cDNA.
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Orientation of pTRD-1 and pTC-5 cDNAs in pUC18
[
----------Multiple Cloning Site of pUC18-
Eco RI Hind III
-ÇTGCAG-
-GACGTC-
Pst I
 I
pTRD-1
5 * CTGCAGGGGGGGGGGGGGGGGGGGGGC ## CCCCCCCCCCCCÇTGCAG 3 *
3’ GAGGTCCCCCCCCCCCCCCCCCCCCCC-----  GGGGGGGGGGGGGACGli 5’
13 pTC-5 17
-CCCCCCCCCCCCCCCCCTGCAG 3'
■gggggggggggggggg6acgtc 5'
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Fleure 20. Subcloning strategy for sequencing the pTRD-1 
cDNA clone. Solid arrows indicate the extent (number of bp) 
of sequencing of individual cDNA restriction fragments that 
were subcloned into M13 phage replicative form DNA. The 
mRNA sense strand sequence is indicated by arrows pointing 
to the right. Two synthetic oligonucleotide primers 
(Primer) were used to obtain the second-strand sequence in 
two regions of the recombinant M13 bacteriophage DNA library 
that were inaccessible to sequencing. Kilobase pairs are 
indicated at the bottom. A schematic diagram of the 26S 
mRNA and the encoded structural proteins is shown for 
reference.
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Flgure 21. Subcloning strategy for sequencing the pTC-5 
cDNA clone (see legend for Figure 20).
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electrophoresis) and long (16-h electrophoresis) sequencing 
gels for three recombinant M13 phage DNAs are shown in 
Fig. 22.
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Flgure 22. Typical short (4-h) and long (16-h) sequencing 
electropherograms for three recombinant M13 phage DNAs.
Start positions for cDNA sequences (following the 
appropriate restriction enzyme site in the MGS) are 
indicated for the three clones by arrowheads. In the long 
gel; short DNA chains below the 'Overlap' point in the short 
gel were electrophoresed out of the gel, resulting in better 
resolution of long dideoxynucleotide (A,C,G,T)-terminated 
chains.
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PART 3 : SEQUENCE OF THE pTRD-1 cDNA
I. Complete Nucleotide Sequence of the 26S RNA
The complete annotated nucleotide and deduced 
translated amino acid sequences of the 26S RNA region of the 
VEE TRD virus genomic RNA are shown in Fig. 23. Excluding 
the poly(dC) tails used in cloning the cDNA, the pTRD-1 cDNA 
clone contained 3852 bp. The putative 5'-end of the 26S RNA 
occurred at the sixth nucleotide position from the 5'-end of 
the TRD-specific cDNA clone. The five nucleotides preceding 
the 26S RNA start position were excluded from Fig. 23. The 
pTRD-1 cDNA clone contained all of the nucleotide sequence 
encoding for the structural polyprotein precursor molecule 
and the first 55 nucleotides of the 3'-end noncoding region 
of the TRD RNA genome. The 3'-18 nucleotides of pTRD-1 were 
complementary to the 19-base synthetic oligonucleotide 
primer that was used to prime first strand cDNA synthesis 
(solid dots in Fig. 23). The 3'-end of cDNA clone pTRD-1 
occurred at 26S RNA nucleotide position 3847 (solid triangle 
in Fig. 23).
The remaining 66 nucleotides of the 3'-end noncoding 
region immediately preceding the poly(A) tail were 
determined by dideoxynucleotide sequencing of one end of 
heat denatured double-stranded recombinant plasmid pTRD-20. 
Complementary DNA cloned into pTRD-20 was synthesized using 
synthetic oligo(dT) 25-mer as first strand primer. Pst I
— 1 8 4 —
Figure 23. Nucleotide and deduced amino acid sequences of 
the VEE TRD virus 26S RNA and the translated polyprotein 
precursor. The small solid dots (base positions 3830 - 
3848) indicate sequence complementary to the 3'-end primer 
used in cDNA synthesis. The solid triangle indicates the 
3’-end of the pTRD-1 cDNA clone. The five 5’-end bases of
pTRD-1 that preceded the 26S RNA start have been excluded
from this figure. The 3'-terminal 66 bases of the 26S RNA 
were obtained from clone pTRD-20. Amino-termini of capsid, 
E3, E2, 6K, and El proteins are marked. Solid stars 
indicate potential Asn-linked glycosylation sites. Solid 
lines are drawn above probable transmembrane domains of El 
and E2. Nucleotide sequence differences between cDNA clones 
pTRD-1 and pTC-5 are underscored ('+' or '-'). Those 
differences marked ('+') were confirmed by RNA sequencing, 
those marked ('-') were not. Single letter amino acid 
abbreviations: A=Ala, C=Cys, D=Asp, E=Glu, F=Phe, G=Gly,
H=His, I=Ile, K=Lys, L=Leu, M=Met, N=Asn, P=Pro, Q=Gln,
R=Arg, S=Ser, T=Thr, V=Val, W=Trp, Y=Tyr.
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restriction analysis of this large cDNA clone indicated that 
pTRD-20 also encoded all of the VEE TRD virus structural 
proteins. The slightly larger size of the third largest,
3'-end Pst I cDNA fragment of pTRD-20, relative to the 
analogous fragment of pTRD-1 (Figs. 16 and 20) suggested 
that the pTRD-20 cDNA resulted from the cloning of cDNA that 
was primed from within the poly(A) tail of the TRD virus 
genomic RNA by the oligo(dT) primer and that it contained 
the entire 3'-end noncoding region of the RNA. This was 
confirmed by sequence analysis.
II. Base Composition and Codon Usage
The base composition of the translated portion of the 
VEE TRD virus 26S RNA was 28% A, 21% U, 25% G, and 26% C. 
Codon usage in this translated region was nonrandom 
(Table 5) and was similar to the codon usage reported for 
SIN, SF, RR, and EEE viruses (Rice and Strauss, 1981; Garoff 
et al.. 1980a, 1980b; Dalgarno ^  al., 1983; Chang and 
Trent, 1987, respectively). Codon usage in the translated 
region encoding the polyprotein precursor of the structural 
proteins was random for amino acids Phe, lie. Pro, Tyr, His, 
Gin, Lys, and Glu (Table 5). Usage was not random for Leu,Cys 
Val, Ser, Thr, Ala, Asn, Asp, Arg, and Gly. It has been 
suggested that this codon frequency distribution permits 
efficient translation of viral-encoded proteins in both 
vertebrate and invertebrate host cells (Rice and Strauss,
1981; Dalgarno et al., 1983).
-187-
Table 5. Codon usage in the translated region of VEE 
virus, strain TRD, 26S subgenoraic RNA
Phe UUU 20A Ser UCU 11 Tyr UAU 31 Cys UGU 11
UUC 23 UCC 18 UAC 22 UGC 32
Leu UUA 8 UCA 21 Ocher UAA 0 Opal UGA lb
UUG 14 UCG 9 Amber UAG 0 Trp UGG 17
Leu CUU 11 Pro ecu 24 His CAU 17 Arg CGU 1
cue 10 CCC 15 CAC 23 CGC 12
CUA 12 CCA 28 Gin CAA 22 CGA 1
CUG 31 CCG 24 CAG 26 CGG 7
lie AUU 17 Thr ACU 21 Asn AAU 18 Ser AGU 3
AUC 21 ACC 37 AAC 31 AGC 14
AUA 14 ACA 30 Lys AAA 40 Arg AGA 17
Met AUG 28 ACG 11 AAG 46 AGG 14
Val GUU 17 Ala GCU 17 Asp GAU 21 Gly GGU 11
GUC 23 GCC 39 GAC 22 GGC 20
GUA 8 GCA 34 Glu GAA 27 GGA 30
GUG 44 GCG 18 GAG 35 GGG 25
^Number of times codon is used.
^The translated polyprotein precursor is terminated by an 
opal codon.
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III. Deduced Amino Acid Sequences
A. Amino Acid Composition
Starting at the AUG initiation codon of the VEE virus 
capsid protein and structural polyprotein precursor, a 
single open reading frame extended for 3762 nucleotides 
until terminated by an opal stop codon (UGA) at the 3’-end 
of the gene encoding glycoprotein El. Computerized 
translation of the other reading frames resulted in 
termination codons that occurred at intervals of 79 
nucleotides or fewer, except for one open frame of 109 
nucleotides. The amino acid compositions of the translated 
proteins of VEE TRD virus are shown in Table 6.
B. Hydropathic Analvsis of VEE TRD Virus Proteins
Hydropathic profiles of VEE TRD virus capsid, E3, E2, 
6K, and El proteins were obtained by the method of Kyte and 
Doolittle (1982) for identification of transmembrane domains 
of integral proteins (Fig. 24). Solid circles in the 
hydropathic profiles indicate sites of potential 
asparagine-linked glycosylation (Asn - X - Ser or Thr, where 
X = any amino acid). Hydrophobic and hydrophilic regions of 
these proteins are indicated by positive and negative 
hydropathic indices, respectively.
The polypeptide region between capsid amino acid 
positions 51 - 117 was highly hydrophilic. The E3
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Table 6. Deduced amino acid compositions of the structural 
proteins translated from the 26S mRNA of VEE virus, 
strain TRD
Amino
Number of residues (percentage composition!
Acid Capsid E3 12 6K El
Ala A)a 19 6.9) 6 10.2) 32(7.6) 7 12.7) 44 10.0
Val V) 18 6.5) 5 8.5) 30(7.1) 6 10.9) 33 7.5
Leu L) 12 4.4) 7 11.9) 34(8.0) 9 16.4) 24 5.4
H e I) 5 1.8) 1 1.7) 16(3.8) 3 5.5) 27 6.1
Pro P) 25 9.1) 6 10.2) 30(7.1) 2 3.6) 28 6.3
Phe F) 10 3.6) 1 1.7) 13(3.1) 2 3.6) 17 3.8
Trp W) 4 1.5) 0 0.0) 5(1.2) 3 5.5) 5 1.1
Met M) 12 4.4) 2 3.4) 7(1.7) 2 3.6) 5 1.1
Gly G) 26 9.5) 2 3.4) 27(6.4) 2 3.6) 29 6.6
Ser S) 9 3.3) 2 3.4) 33(7.8) 1 1.8) 31 7.0
Thr T) 13 4.7) 4 6.8) 33(7.8) 3 5.5) 46 10.4
Cys C) 2 0.7) 4 6.8) 18(4.3) 3 5.5) 16 3.6
Tyr Y) 10 3.6) 2 3.4) 18(4.3) 0 0.0) 23 5.2
Asn N) 15 5.5) 3 5.1) 11(2.6) 3 5.5) 17 3.8
Gin Q) 16 5.8) 1 1.7) 12(2.8) 3 5.5) 16 3.6
Asp D) 10 3.6) 3 5.1) 13(3.1) 1 1.8) 16 3.6
Glu E) 13 4.7) 3 5.1) 24(5.7) 2 3.6) 20 4.5
Lys K) 37 13.5) 3 5.1) 23(5.4) 0 0.0) 23 5.2
Arg R) 15 5.5) 4 6.8) 23(5.4) 2 3.6) 8 1.8
His H) 4 1.5) 0 0.0) 21(5.0) 1 1.8) 14 3.2
^Standard three-letter (single-letter) abbreviation for 
amino acid
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Figure 24. Hydropathic profiles of the structural proteins 
of VEE TRD virus. Plots are moving average hydrophobicity 
indices (Kyte and Doolittle, 1982) of 9-residue amino acid 
segments. Positive hydropathic indices indicate hydrophobic 
amino acid residues. Solid dots indicate potential sites of 
Asn-linked glycosylation.
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polypeptide possessed a hydrophobic amino terminus which may 
serve as a signal sequence for insertion of the pE2 
polypeptide precursor into the endoplasmic reticulum during 
translation (Garoff et al., 1978). A broad hydrophilic 
domain was evident between E2 amino acid positions 209 - 
244, while two major hydrophobic domains occurred at the 
carboxyl-terminus of E2. The first hydrophobic domain 
(amino acids 363 - 390) satisfied the criterion determined 
by Kyte and Doolittle (1982) for identification of 
transmembrane domains of membrane-associated polypeptides. 
This criterion requires the presence of a peptide segment of 
at least 19 consecutive residues, whose average hydropathic 
index is (+1.6) or greater.
TRD virus 6K position 17 - 55 satisfied the criterion 
of Kyte and Doolittle (1982) for transmembrane domains of 
integral membrane proteins, indicating that this polypeptide 
serves as a signal peptide for insertion of El into the 
membrane. The El glycoprotein had a 33-residue 
transmembrane anchor between amino acid positions 405 - 437.
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PART 4: COMPARISON OF pTRD-1 AND pTC-5 cDNAs
I. Nucleotide Sequences
A. Sequence of the dTC-5 cDNA
The pTC-5 clone was slightly larger than pTRD-1. The 
pTC-5 cDNA, excluding tails, was 4013 bp long. Although the 
pTC-5 clone terminated at the same 3'-end point as pTRD-1, 
it contained 161 bp preceding the putative beginning of the 
26S RNA of TC-83 virus. Sequencing of double-stranded 
recombinant plasmid pTC-8, obtained by cloning 
oligo(dT)-primed TC-83 virus-specific cDNA (approximately 
800 bp in length), provided the 3’-terminal sequence of 
TC-83 26S RNA.
B. Comparison of Nucleotide Sequences
The overall organization of the cDNA copy of TC-83 
virus 26S RNA was identical to that of the pTRD-1 clone. 
Analysis of pTRD-1 and pTC-5 indicated that the nucleotide 
sequences of these cDNAs differed at thirteen positions. 
Seven nucleotide differences were detected in the gene 
encoding glycoprotein E2, four in El, one in the 6K protein, 
and one in the short noncoding region preceding the 26S RNA 
start site. | The single U nucleotide deletion
(detected in cDNA clones pTG-8 and pTRD-20) in 
the 3'-noncodihg region of TC-83 virus 
confirmed the data of Ou et al. (1982a).
-194-
Reverse transcriptase errors that occur during first 
strand cDNA synthesis or cloning of a minor variant from 
purified molecules of 42S genomic RNA molecules may 
introduce false mutations into cDNA clones. Therefore, to 
verify the differences detected between the pTRD-1 and pTC-5 
cDNAs, primer extension sequencing of both TRD and TC-83 
viral genomic RNAs was performed. Seven synthetic DNA 
primers (arrows in Fig. 25) were used to sequence the RNAs 
across the loci where the cDNA differences occurred 
(vertical lines along the TRD-l/TC-5 axis in Fig. 25).
Four of the cDNA differences, those marked with an 'X' 
in Fig. 25, were unconfirmed by RNA sequencing. Primer 
extension sequencing of 42S RNAs indicated that a G residue 
was present in both viruses at 26S RNA nucleotide positions 
-2 (second base preceding the start site for transcription 
of the 26S mRNA), 1657, and 2370. The A residues at these 
positions in pTRD-1 were, therefore, in error. Nucleotide 
position 2822 was a C in both viral RNAs, indicating that a 
T residue at this position in pTC-5 was in error. The 
question mark in Fig. 25 indicates a cDNA difference at 
nucleotide position 3366 that could not be evaluated by 
sequencing on RNA templates due to band compression in the 
sequencing gels. Partial sequencing of two other cDNA 
clones, pTRD-7 and pTC-17 containing TRD and TC-83 
virus-specific cDNA molecules, respectively, indicated that 
an A residue was present at nucleotide position 3366 in both 
viruses. The G residue in pTC-5 at this position was 
probably in error. The nucleotide and deduced amino acid
-195-
Fieure 25. Primer extension sequencing of regions of VEE 
TRD and TC-83 virus 42S RNAs to verify sequence differences 
between cDNAs cloned into recombinant pTRD-1 and pTC-5 
plasmids. Vertical lines indicate nucleotide differences 
between cDNA clones pTC-5 and pTRD-1. cDNA clone 
differences that were not confirmed by RNA sequencing are 
denoted 'X'. The nucleotide difference that could not be 
evaluated by RNA sequencing ('?') was resolved by examining 
an independent cDNA clone.
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sequences of pTRD-1 and pTC-5 cDNAs were modified according 
to the corrections provided by primer extension sequencing 
of RNA (Fig. 23).
Sequence analysis of pTRD-20 and pTC-8 cDNAs confirmed 
the difference between TRD and TC-83 viruses at 268 RNA 
nucleotide position 3874 in the 3'-noncoding region that was 
reported by Ou et (1982a). TRD virus contained six U 
residues at this position, whereas TC-83 virus had only 
five. The 3'-end noncoding regions of TRD and TC-83 virus 
genomic RNAs were 121 and 120 nucleotides long, respectively.
II. Deduced Amino Acid Sequences
A. Summary of Point Mutations
The nucleotide and deduced amino acid sequence 
differences between VEE TRD and TC-83 viruses in the 26S RNA 
region, corrected for cDNA errors as indicated by RNA 
sequencing, are summarized in Table 7. The most numerous 
nucleotide differences were clustered in the gene encoding 
the E2 glycoprotein. Five of the six differences resulted 
in non-conservative amino acid changes in the E2 protein.
The charge of E2 should be altered as a result of the 
substitution of amino acids Asn, Arg, and Asp at amino 
positions 7, 120, 192, in the E2 protein of TC-83 virus, 
respectively. These positions were identified as Lys, Thr, 
and Val in the TRD virus E2 glycoprotein, respectively.
These three substitutions make the E2 glycoprotein of the
—198-
Table 7. Nucleotide and deduced amino acid sequence 
differences between the 26S RNA regions of 
VEE TRD and TC-83 viruses
Position
Nucleotide Amino Acid
Nucleotide 
TRD TC-83
Amino Acid 
Change 
TRD TC-83
1053
1285
1391
1607
1866
1919
E2-7
E2-85
E2-120
E2-192
E2-278
E2-296
U
U
G
A
C
U
Lys Asn 
His Tyr 
Thr Arg 
Val Asp 
None 
Thr H e
2947
3099
El-161
El-211
Leu H e  
None
3874 3'-Noncoding UU U Noncoding
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TC-83 vaccine virus slightly less basic than that of its 
virulent TRD parent. The sixth mutation at E2 amino acid 
position 278 was silent, resulting in no amino acid 
substitution. Neither of the nucleotide differences between 
the El genes resulted in a predictable an alteration in the 
chemical nature of the El protein. One mutation was silent, 
while the other resulted in the substitution of H e  for 
Leu. These two hydrophobic amino acid residues differ only 
by a single methylene group.
B. Potential Sites of Glvcosvlation
Both TRD and TC-83 virus E2 glycoproteins possessed 
three sites of potential glycosylation at Asn residues 
located at E2 positions 212, 291, and 318 (Figs. 24 and 
26). Mecham and Trent (1982) demonstrated three 
carbohydrate-containing tryptic peptide fragments in 
purified TRD E2 glycoprotein, indicating that the three 
sites are indeed glycosylated. The first two sites were 
located in hydrophilic regions of the E2 molecule, while the 
third was present in a relatively nonpolar portion of the 
molecule near the carboxyl terminus (Fig. 24). A single 
glycosylation site was present at amino acid position 134 in 
the sequence of the El proteins of these viruses.
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G. Hydropathic Effects of Amino Acid Mutations
The positions of the five deduced amino acid 
differences between the E2 glycoproteins of TRD and TC-83 
viruses are indicated on a hydropathic profile of the TC-83 
E2 protein (Fig. 26). Four of the mutations occurred in 
hydrophilic domains, while one occurred in a hydrophobic 
domain. The Lys - Asn (TRD virus - TC-83 virus) and His - 
Tyr mutations at E2 positions 7 and 85, respectively, did 
not alter the hydropathic profile of the TRD parent E2 
glycoprotein (Fig. 24). However, the Thr - Arg and 
especially the Val - Asp mutations at positions 120 and 192, 
respectively, resulted in decreased hydrophobicity in the 
TC-83 E2 protein around these positions, whereas the Thr - 
H e  mutation at E2 - 296 increased hydrophobicity relative 
to TRD virus E2.
The Leu - H e  mutation at TC-83 virus position El - 161 did 
not alter the hydropathic profile of the TRD parent El 
glycoprotein (Figs. 24 and 26). Sites of glycosylation are 
indicated in Fig. 26.
D. Conformational Effects of Amino Acid Mutations
The mutations in the E2 glycoprotein of TC-83 virus 
(Table 7), which potentially are involved in attenuation 
from the virulent TRD parent virus phenotype, resulted in 
changes in predicted secondary structure (Chou and Fasman, 
1978; Rose, 1978). These changes (solid triangles) are
—201—
Figure 26. Hydropathic profiles of the El and E2 
glycoproteins of VEE TC-83 virus. Solid dots indicate 
potential glycosylation sites. VEE TRD-to-TC-83 virus amino 
acid mutations (single letter amino acid code) are indicated 
for each mutation position ('X' on the hydropathic curve). 
Positive hydropathic indices indicate hydrophobic amino acid 
residues, whereas negative values indicate hydrophilic 
residues.
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illustrated diagraimnatically in Fig. 27. The Lys - Asn (TRD 
to TC-83) mutation at position E2 - 7 changed the predicted 
character of amino acids E2 - 9 to E2 - 11 from helical to 
beta-sheet conformation. The His - Tyr mutation at E2 - 85 
reversed the helical or sheet attributes of amino acids E2 - 
84 and E2 - 85 and changed E2 positions 87 and 89 from coil 
to turn or sheet conformation, respectively. The Thr - Arg 
mutation at E2 - 120 resulted in a sheet-to-helix switch for 
positions 119 - 121. The Val - Asp mutation at E2 - 190 
resulted in a turn-to-coil shift at position 190 and 
sheet-to-turn shift at 191 - 192. In between the latter two 
sites of mutation, sheet-to-helix switches occurred at 
positions 148 - 149 and 151 - 154. No change in predicted 
secondary structure occurred as a result of the Thr - lie 
mutation at position E2 - 296 (small solid triangle in 
Fig. 27).
The Leu - lie mutation at TC-83 virus position El - 161 
did not alter the predicted secondary structure of the El 
glycoprotein of the TRD parent virus (diagram not shown).
-204-
Figure 27. Schematic diagram of predicted secondary 
structure alterations in the TC-83 virus E2 protein.
Mutation positions are indicated by solid triangles. The 
amino acid phenotypes of TRD and TC-83 viruses are indicated 
at each mutation that alters the predicted secondary 
structure of the glycoprotein. The Thr to lie mutation at 
position 296 (small solid triangle) did not change the 
predicted structure of TRD virus E2. Secondary structure 
predictions were accomplished by the methods of Chou and 
Fasman (1978) and Rose (1978) using the PROSIS computer 
programme.
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PART 5; COMPARISON OF VEE VIRUS WITH OTHER ALPHAVIRUSES
I. Nucleotide Sequence
A. 3’-Noncoding Region
The 121-nucleotide 3’-noncoding region of VEE TRD virus 
genomic RNA was considerably shorter than that of SIN (318 
nucleotides), WEE (300), SF (264), RR (524), and EEE (363) 
viruses (Rice and Strauss, 1981; Ou et , 1982a; Garoff 
et al.. 1980b; Dalgarno et al., 1983; Chang and Trent,
1987 , respectively). The function of repeated nucleotide 
sequences found in the 3’-end noncoding regions of 
alphaviruses remains to be determined (Ou et al.,1982a).
The 3’-terminal 19 bases that immediately precede the 
poly(A) tail are highly conserved, indicating an essential 
function for this region in the replication of alphaviruses 
(Fig. 28).
B. 26S Junction Region
The intracellular 26S mRNA species of alphaviruses is 
identical in sequence to the 3’-one-third portion of the 42S 
genomic RNA. The 26S RNA junction is that region where the 
genes encoding the nonstructural proteins of the virus end 
and those encoding the structural proteins begin. The 26S 
RNA junction regions for SIN, SF, RR, and Middelburg (MID)
-207-
Flgure 28. Comparison of the 3'-end noncoding regions of 
VEE TRD, VEE TC-83, and several other alphaviruses 
(Ou et al., 1982a; Chang and Trent, 1987). Solid dots 
indicate nucleotide sequence identity with TRD virus.
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viruses reported by Ou et al, (1982b) as well as that of EEE 
virus (Chang and Trent, 1987) are compared to the 26S 
junction of VEE (TRD and TC-83) virus in Fig. 29. This 
region was present in the pTC-5 cDNA clone. Although only 
five nucleotides preceding the 26S RNA start site were 
present in the pTRD-1 clone (underlined nucleotides in 
Fig. 29), RNA sequencing of an independent clone (pTRD-26) 
provided the junction sequence of TRD virus and 
demonstrated, along with primer extension RNA sequencing, 
that the pTRD-1 clone contained an error (substitution of 
an A) at the second base position preceding the 26S RNA 
start position. The 5'-position of the VEE 26S RNA was 
deduced by homology comparison with the alphavirus junction 
regions reported by Ou et (1982b), who sequenced the 
5'-termini of isolated intracellular 26S mRNA molecules 
directly.
The top portion of Fig. 29 shows the nucleotide 
sequences at the 3'-ends of the nsP4 genes. Translation of 
the nsP4 polypeptide ends at termination codons (overlined 
nucleotide triplets in Fig. 29) lying within the 26S RNA 
regions of SIN, SF, RR, and MID viruses. An ochre (UAA) or 
opal (UGA) termination codon occurred before the putative 
26S RNA start position in VEE or EEE virus, respectively, 
indicating that the nsP4 protein of VEE and EEE viruses may 
be slightly shorter (by three or more amino acid residues) 
than the nsP4 polypeptides of the other alphaviruses. The 
deduced amino acid sequence at the carboxyl terminus of VEE 
nsP4 is indicated above the nucleotide sequence.
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Fleure 29. Comparison of the 26S RNA junction regions of 
VEE TRD virus and several other alphaviruses. Data for SIN, 
SF, RR, and MID viruses were obtained from Ou et al. (1982), 
that for EEE virus from Chang and Trent (1987). Top: 
nucleotide sequences encoding the carboxyl-terminus of 
nonstructural polypeptide nsP4 (VEE virus amino acid 
sequence shown above VEE virus nucleotide sequence). Solid 
dots represent nucleotide identity with the VEE virus 
nucleotide sequence. Solid bars indicate termination 
codons. The underlined portion of the VEE virus sequence 
corresponds to the 5'-end terminus of the pTRD-1 cDNA 
clone. Bottom: nucleotide length of the noncoding region
from the beginning of the 26S RNA to the Met initiation 
codon of the translated structural polyprotein precursor.
-211-
L P G A P I T L Y G  ^  P K 
VEE CUGAGAGGGGCCCCUAUAACUCUCUACGGCUAACCUGA
SIN
SF
RR
MID
A.C.......AAAUA.AGCA..........UGGU...A.
U # # # # # #.AC.UGU....CAC.........GGU...A.
...C.U..AC..AUCG..CAC.........GGU...A.
..A.....AC..GU...UGAC.........GGU...A«
EEE A.A. .UCA.
VEE
SIN
SF
RR
MID
EEE
^ 2 6  S
W T T T 
AUGGACUACGACAUAG
..U.GUGCGUUA?
• • À •
• * A #
. .A.
30 Nucleotides
r
AUG
Capsid
49 Nucleotides
-► AUG
51 Nucleotides
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Nucleotide sequence identity between VEE virus and the 
other viruses is indicated by solid dots in the latter 
sequences (Fig. 29). A highly conserved region of 21 
nucleotides (first two bases of the 26S RNA region and the 
preceding 19 bases) was evident in the SIN, SF, RR, and MID 
virus sequences (Ou et ^., 1982b). VEE and EEE viruses 
differed from the other alphaviruses in this conserved 
region in the substitution of a stop codon in place of the 
GGU codon (coding for Gly) present in the other viruses. 
Recently, Takkinen (1986) reported the presence of a G 
residue at position (-1) relative to the beginning of the SF 
virus 26S RNA. This contrasts with the A residue at this 
position reported by Ou et (1982b) for other 
alphaviruses and which also occurs in VEE and EEE viruses 
(Fig. 29). The reason for this discrepancy is unknown.
The number of noncoding nucleotides between the 5'-end 
of the 26S RNA and the first AUG of the translated 
polyprotein precursor varies between 48 and 58 for SIN, SF, 
RR, MID and EEE viruses, but was only 30 for VEE virus 
(bottom portion of Fig. 29). The amino termini of 
alphavirus capsid proteins are blocked (Bell et ^., 1978; 
Boege et ^., 1980), thus preventing their resolution by 
direct Edman degradation protein sequencing. However, the 
amino acid compositions of the amino-terminal tryptic 
peptides of SIN and SF virus capsid proteins have been 
determined, permitting identification of the amino-terminal 
residue (Boege et ^., 1980).
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Although the VEE virus sequence possessed an AUG codon 
beginning at 26S RNA nucleotide position 49 (Fig. 23), which 
corresponds closely to the capsid start of the other 
alphaviruses (Fig. 29), an in-frame AUG codon also was 
present beginning at nucleotide position 31. The latter 
codon occurred within the sequence CAAGAUGU and most closely 
resembled the consensus sequence CAXXAUGG (where X = any 
nucleotide) for initiation codons in eukaryotic mRNAs 
(Kozak, 1981). The AUG codon which initiates translation in 
eukaryotic mRNAs is usually that which appears first in the 
open reading frame (Kozak, 1983). The structural proteins 
of VEE virus are translated in reading frame one relative to 
the 26S start position. Although an AUG codon occurred at 
the putative 5’-end of the VEE 26S RNA, an amber stop codon 
was present at nucleotide positions 19 - 21 in reading frame 
one. In addition, AUG codons occurring at or very close to 
the 5'-end of eukaryotic mRNAs are thought to be inefficient 
initiators of translation (Kozak, 1983). The Met codon at 
nucleotide positions 31 - 33 was chosen as the initiation 
coding for translation of the structural polyprotein 
precursor (Fig. 23).
II. Protein Composition. Size, and Hvdropathicitv
The amino acid compositions of the deduced sequences 
, of the translated proteins of VEE TRD virus (Table 6) 
were similar to the compositions of the cognate structural 
proteins of SIN (Strauss et aJL., 1984), SF (Garoff et al..
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1980a, 1980b), RR (Dalgarno et 1983), and EEE (Chang
and Trent, 1987) viruses (data not shown).
The analogous proteins of these five alphaviruses were 
of approximately the same amino acid length and deduced, 
nonglycosylated molecular weight (Table 8). The molecular 
weights of the nonglycosylated alphavirus capsid, E2, and El 
structural proteins averaged 29,880 (+/- 880, standard 
deviation); 46,810 (+/- 200); and 47,696 (+/- 426) daltons, 
respectively.
The net charge of alphavirus envelope proteins El and 
E2 varied from (-5) (VEE TRD virus) to (+2) (SF virus) for 
El, and (0) (SF virus) to (+13) (EEE virus) for E2 
(Table 8). The capsid proteins were highly basic, with 
charges of (+22) (EEE virus) to(+29) (VEE virus). The small 
polypeptides (nonglycosylated forms) E3 and 6K averaged 7099 
(+/- 386) (59 - 60 amino acids in length) and 6369 (+/- 179) 
(55 - 60 amino acids) daltons, respectively. The latter two 
polypeptides possessed no charge or a weak (+1) to (+2) 
positive charge (data not shown). The structural 
polyprotein precursors averaged 137,783 (+/- 655) daltons.
The hydropathic profile of the structural polyprotein 
precursor of VEE TRD virus was aligned with those of EEE, 
SIN, SF, and RR viruses (Fig. 30). Potential glycosylation 
sites for the polyproteins are indicated by solid circles. 
The similarities among the profiles were striking, and 
indicated that the gross chemical makeup of the structural 
proteins of these viruses is similar.
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Table 8 Comparisons of molecular weights (MW), net charges, 
and lengths of the deduced amino acid sequences of 
alphavirus structural proteins.
Virus Protein MWA Charge^ AAsA
TRD C 30,938 +29 275
EEE C 28,736 +22 259
SIN C 29,354 +27 264
SF C 29,861 +28 267
RR C 30,509 +28 270
TRD c 1-iioâ +22 110
EEE C 1-95 +17 95
SIN C 1-98 +24 98
SF C 1-103 +23 103
RR C 1-106 +23 106
TRD E2 46,950 + 9 423
EEE E2 46,915 +13 420
SIN E2 46,914 + 9 423
SF E2 46,806 0 422
RR E2 46,465 + 2 422
TRD El 47,904 - 5 442
EEE El 48,352 0 441
SIN El 47,368 - 4 439
SF El 47,437 + 2 438
RR El 47,420 - 3 438
TRD 26Se 138,383 +33 1254
EEE 26S 137,542 +35 1239
SIN 26S 136,758 +31 1245
SF 26S 138,010 +30 1253
RR 26S 138,224 +29 1254
^Deduced, nonglycosylated molecular weight (daltons)
^Net charge = number of Lys and Arg residues minus the 
number of Asp and Glu residues
^Number of deduced amino acids in protein
^Amino-terminal, hydrophilic region of the capsid protein.
^Entire structural polyprotein precursor translated from 
the 26S mRNA.
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Figure 30. Comparison of the hydropathic profiles of the 
structural protein precursors of VEE (TRD), EEE, SIN, SF, 
and RR viruses. The moving peptide segment used to 
determine the average hydropathic indices was 9 residues in 
length. Hydrophilic residues are indicated by negative 
hydropathic indices. Polyprotein cleavage sites are 
indicated by arrows. Solid dots indicate potential 
Asn-linked glycosylation sites.
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III. Computer Analysis of Amino Acid Sequence Identities 
A, Conservation of Amino Acid Residues
The aligned amino acid sequences of the structural 
polyprotein precursors of five alphaviruses are shown in 
Fig. 31. Deletions ('-' in Fig. 31) were inserted into the 
sequences to optimize the identity alignments. Potential 
glycosylation sites are indicated by substitution of solid 
circles for appropriate Asn residues.
The degree of conservation of each amino acid in the 
polyproteins is shown in Table 9. The amino- terminal 110 
amino acids of the VEE virus capsid protein were excluded 
from this comparison since this region showed little 
sequence identity with the analogous regions of the other 
alphaviruses (Fig. 31). However, SF and RR viruses, both of 
which are members of the SF virus alphavirus serological 
complex, shared substantial identity in this region of the 
capsid protein. Cys, Trp, Gly, and Pro residues were highly 
conserved in the structural polyprotein precursors of the 
five viruses. At least three of the four heterologous 
alphaviruses shared 91%, 75%, 72%, and 70% identity of each 
of these amino acids, respectively, with amino acid 
positions in the VEE TRD virus structural polyprotein 
precursor (Table 9). Tyr (61%) and Phe (51%) were also 
conserved to a large extent.
Certain amino acid substitutions, which result in the 
exchange of one amino acid by another residue of similar but
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Fieure 31. Alignment of the deduced amino acid sequences of 
the translated regions of the 26S RNAs of VEE (TRD), EEE 
(Chang and Trent , 1987), SIN (Strauss et al., 1984), SF 
(Garoff et ^., 1980a, 1980b), and RR (Dalgarno et al..
1983) viruses. Deletions ('-') have been introduced to 
optimize identity alignment. Solid dots indicate amino acid 
identity with the sequence of VEE TRD virus. Potential 
Asn-llnked glycosylation sites are indicated by substitution 
of solid circles for the appropriate Asn residues. Solid 
lines indicate probable transmembrane domains of the VEE 
virus El and E2 envelope glycoproteins.
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Table 9. Amino acid conservation between the structural 
polyprotein precursors, excluding the 
amino-terminal 110 residues of the capsid 
protein, of VEE TRD virus and the 
sequence-aligned polyproteins of EEE, SIN,
SF, and RR viruses
Total Conserved Percentage
mino Acid Residues Residues^ Conservation^
Ala (A)b 100 35 35
Val (V) 90 26 29
Leu (L) 83 31 37
H e  (I) 52 12 23
Pro (?) 74 52 79
Phe (F) 37 19 51
Trp (W) 16 12 75
Met (M) 22 7 32
Gly (G) 78 56 72
Ser (S) 73 22 30
Thr (T) 94 27 29
Cys (C) 43 39 91
Tyr (Y) 51 31 61
Asn (N) 42 15 36
Gin (Q) 38 8 21
Asp (D) 45 21 47
Glu (E) 59 17 29
Lys (K) 66 20 30
Arg (R) 45 21 47
His (H) 40 15 38
^VEE virus residue position shared by at least three 
other viruses (Fig. 31)
^(Conserved residues/total residues) x 100
^Three-letter (single-letter) designation for amino acid.
- 2 2 2 -
not identical biochemical character, are considered to be 
conservative changes. Conservative amino acid changes 
presumably cause minimal perturbation of protein character. 
Consideration of conservative amino acid substitutions in 
the calculation of percent amino acid conservation among the 
structural polyprotein precursors increased percentage 
conservation by up to 10% for Lys - Arg and Ser - Thr 
substitutions, and 8% - 9% for Leu - lie and Asp - Glu 
substitutions, respectively (Table 10). Perusal of computer 
printouts of highlighted, aligned conservative amino acid 
pairs, and the degree of enhancement in percentage 
conservation when considering the actual level of 
substitution between members of conservative amino acid 
pairs (Table 10), indicated that members of conservative 
amino acid pairs were not freely interchangeable.
The amino acid positions of Cys residues and Pro and 
Gly residues are highlighted in Figs. 32 and 33, 
respectively. The high level of conservation of these three 
residues in the structural proteins of alphaviruses is 
clearly evident.
Percentage identity comparisons among the capsid 
proteins and structural polyproteins of VEE (TRD), SIN, SF, 
and RR viruses are summarized in Table 11, while comparisons 
among the El and E2 glycoproteins are summarized in 
Table 12. SF and RR virus proteins were clearly the most 
closely related, with identities of at least 75% between 
their capsid, El, E2, and entire polyproteins. The VEE 
virus proteins were most closely related by sequence
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Figure 32. Highlighting of Cys residues in the aligned, 
deduced amino acid sequences of the structural polyprotein 
precursors of five alphaviruses. Solid dots indicate 
non-Cys residues. Deletions ('-*) were introduced to 
optimize alignment. Solid lines indicate transmembrane 
domains.
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Flgure 33. Highlighting of Pro and Gly residues in the 
aligned, deduced amino acid sequences of the structural 
polyprotein precursors of five alphaviruses. Solid dots 
represent non-Pro, non-Gly residues. Deletions have
been introduced to optimize alignment. Solid lines indicate 
transmembrane domains.
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Table 11. Percentage amino acid identities between 
alphavirus capsid proteins (lower left) 
and structural polyprotein precursors 
(upper right)
TRD EEE SIN RR
TRD _a 56 47 45 46
EEE 62b - 48 47 46
SIN 43 47 - 47 48
SF 45 48 58 - 75
RR 44 46 54 80
^Diagonal of identity
^Percentage identity between TRD and EEE virus capsid 
proteins. Value based on the identity alignment presented 
in Fig. 31. Only those amino acid positions for which 
there existed a corresponding amino acid in the compared 
virus were included in the analysis.
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Table 12, Percentage amino acid identities between 
alphavirus El (lower left) and E2 (upper 
right) envelope glycoproteins
TRD EEE SIN RR
TRD _a 48 42 38 40
EEE 5sb - 43 38 39
SIN 51 51 — 41 42
SF 51 55 49 - 79
RR 53 52 51 79
^Diagonal of identity
^Percentage identity between TRD and EEE El 
glycoproteins. Value based on the identity alignment 
presented in Fig. 31. Only those amino acid positions 
for which there existed a corresponding amino acid in the 
compared virus were included in the analysis.
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conservation to those of EEE virus, showing 62%, 58%, 48%, 
and 56% identity with EEE virus capsid, El, E2, and 
polyproteins, respectively. Alphavirus El proteins showed 
more extensive sequence conservation than did the E2 
proteins (Table 12).
The nucleotide sequences of the translated regions of 
the 26S RNAs of these five viruses were also aligned for 
comparisons of identity. The alignment of codons 
corresponded exactly with the alignment of the encoded amino 
acids presented in Fig. 31. Paired comparison of the 
aligned nucleotide sequences showed increases of (+3) to 
(+13) percentage identities (data not shown) relative to the 
percentage identity values between amino acid sequences 
(Tables 11 and 12).
B. Capsid Proteins
The capsid region between amino acid positions 51 and 
117 was highly hydrophilic (Figs. 24 and 30) and exhibited a 
large positive charge (Table 8) due to the concentration of 
basic residues in this region. This region contained 22 of 
the 37 Lys residues and 4 of the 15 Arg residues, but only 3 
of the 23 Asp or Glu residues, present in the capsid protein 
of VEE virus. The clustering of Arg, Lys and Pro residues 
(Fig. 33) in the amino terminal portion of the capsid 
proteins of SF, SIN, and RR viruses was noted previously 
(Garoff et ^ . , 1980a; Rice and Strauss, 1981; Dalgarno 
et al.. 1983). Essentially no amino acid conservation was
—231-
observed in this region of the capsid proteins of VEE, SIN, 
and SF viruses. The carboxyl terminal 165 amino acids of 
the capsid proteins of these viruses, on the other hand, 
showed significant conservation (60% or greater) of sequence 
(Fig. 31). Secondary structure predications, based on the 
methods of Chou and Fasman (1978) and Rose (1978), were 
calculated using the DNASIS programme, and sequences 
consisting of single letter code conformational attributes of 
each amino acid residue were compared using programme 
BASEQUE (Fig. 34A).
Predicted beta-turns, highlighted in Fig. 34B, clearly 
were concentrated in the highly hydrophilic and charged 
region of the capsid protein between residues 51 - 117. All
five alphavirus capsid proteins also possessed a strong
beta-turn about 50 residues from the carboxy1-terminus. EEE
virus had an extra turn at positions 177 - 181.
C. E3 and E2 Proteins
The single potential Asn-linked glycosylation site at 
VEE virus E3 amino acid position 11 is conserved in EEE,
SIN, SF, and RR virus E3 polypeptides (Figs. 30 and 31). SF 
and RR E3 proteins possess a second potential glycosylation 
site at position 60. Only one of the two sites is 
glycosylated in the E3 protein of SF virus (Garoff et al.. 
1980b).
The VEE virus E2 protein was 423 amino acids long with 
a deduced nonglycosylated molecular weight of 46,899
-232-
Figure 34. Alignment of predicted secondary structure 
attributes of the deduced amino acid sequences of alphavirus 
capsid proteins. Calculations were based on the methods of 
Chou and Fasman (1978) and Rose (1978), using the PROSIS 
computer programme. (A) Identity comparisons of the 
conformational attributes of the amino acid sequences.
Solid dots indicate identity to TRD virus. (B) High­
lighting of the residues that contribute to beta-tums.
Solid dots indicate positions of non-beta-tum attributes.
H = alpha helix, C = random coil, S = beta-pleated sheet,
T = beta-tum attribute.
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daltons. The deduced amino-terminal 37 amino acids of E2 
agreed with the amino-terminal sequence of purified VEE TRD 
virus E2 glycoprotein obtained by direct protein sequence 
analysis Bell et al., 1984). E2 amino acid position 29 was 
identified as Thr by Bell et (1984), and the amino acid 
at position 30 was unidentified. Our results showed Ser and 
Pro at these two positions, respectively.
There was little conservation of amino acid sequence 
among the membrane-spanning segments of VEE, SIN, SF, and RR 
virus E2 proteins (Fig. 31), indicating that conservation of 
functional amino acid hydrophobicity rather than actual 
sequence is important in the membrane domains of these 
envelope glycoproteins. VEE and EEE virus E2 sequences 
shared 11 of the 28 amino acid residues in this region.
The second hydrophobic domain (positions 396 - 418) of 
VEE virus E2 did not satisfy the transmembrane criterion of 
Kyte and Doolittle (1982). The E2 envelope proteins of the 
alphaviruses were conserved in this domain (Fig. 31). Rice 
and Strauss (1981) suggested that conserved amino acids, 
particularly Cys residues, may be important in the 
interaction between nucleocapsid and the envelope 
glycoproteins during the budding process. The second 
hydrophobic domain of VEE virus E2 differed from those in 
the E2 proteins of SIN, SF, and RR viruses in the presence 
of two charged Arg residues at positions 401 and 407 
(Fig. 31). EEE virus also possessed a charged residue (Lys) 
at position 401. Approximately 33 amino acid residues of
-235-
the carboxyl end of the VEE virus E2 protein probably extend 
beyond the cytosol surface of the lipid bilayer.
Chou-Fasman-Rose secondary structure predictions for 
the E2 proteins of VEE TRD and TG-83 viruses and EEE, SIN, 
SF, and RR viruses are shown in Fig. 35A. Predicted 
beta-turns are highlighted in Fig. 35B. EEE virus had 
strong predicted beta-turns at E2 positions 115 - 118, 244 - 
248, and 338 - 344. SF virus possessed a strong turn at E2 
positions 183- 186 that aligned with a beta-turn in SIN 
virus E2. SIN virus E2 also had a strong beta-turn at 
positions 190 - 195. RR virus E2 had a single beta-turn at 
positions 77 - 81. The E2 proteins of VEE strains TRD and 
TC-83 as well as that of SIN virus possessed no predicted 
beta-turns.
D. 6K and El Proteins
VEE virus 6K amino acids 17 - 55 probably serve as a 
signal peptide for insertion of El into the endoplasmic 
reticulum. The deduced amino sequence of the VEE virus El 
protein was 442 residues in length with a nonglycosylated 
molecular weight of 47,881 daltons. The 54 amino terminal 
residues of El shown in Fig. 23 coincided with the amino 
terminal sequence of the VEE virus El glycoprotein reported 
by Bell ejb (1984) except for a Val residue at position 
424, which was reported as a questionable Pro, and a Cys at 
El - 49 that was previously unidentified. Amino acids Cys, 
Pro, Thr, and Ser are difficult to identify in liquid
-236-
Figure 35. Alignment of predicted secondary structure 
attributes of the deduced amino acid sequences of alphavirus 
E2 proteins. Solid dots indicate positions of identity with 
VEE TRD virus in (A) and non-beta-tum residues in (B).
T = turn, C = coil, S = sheet, H = helix.
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chroma tographic analysis of amino-terminal Edman degradation 
products (J. R. Bell; personal communication). Only a few 
amino acid residues appeared to extend beyond the membrane 
on the nucleocapsid (or cytosol) surface of the lipid 
envelope.
Alphavirus El secondary structure predictions are shown 
in Fig. 36. The El proteins of VEE and EEE viruses 
possessed no predicted beta-turns. SIN virus El had 
predicted beta-turns at positions 98 - 101, 245 - 249, and 
323 - 326. The second predicted beta-turn of SIN virus El 
aligned with the fourth beta-turn of RR virus, which also
had three other beta-tums at positions 70 - 74, 194 - 198,
and 223 - 226. The single predicted beta-turn of SF virus
El aligned with the second beta-turn of RR virus El.
Although VEE virus El possessed no beta-turns as strictly 
defined (four consecutive residues of the turn attribute), 
it did contain doublets and triplets of consecutive amino 
acids that are commonly found in beta-turns, and these 
residues were aligned with all of the aforementioned 
beta-turns of the other alphaviruses. This did not appear 
to be the case for the VEE virus E2 protein (Fig. 35).
E . Cleavage Sites in the Structural Polvprotein Precursors
Amino acid sequences surrounding putative cleavage 
sites in the structural polyprotein precursors of the 
alphaviruses showed considerable conservation (Fig. 37).
The carboxyl-termini of the E2 and 6K polypeptides were rich
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Figure 36. Alignment of predicted secondary structure 
attributes of the deduced amino acid sequences of alphavirus 
El proteins. Solid dots indicate positions of identity with 
VEE TRD virus in (A) and non-beta-turn residues in (B).
T = turn, C = coil, S =sheet, H = helix.
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Figure 37. Conservation of amino acids surrounding 
proteolytic cleavage sites in the structural polyprotein 
precursors of five alphaviruses. Solid dots indicate 
intervening sequences between the indicated amino- and 
carboxyl-terminal amino acids of each polypeptide.
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in Ala residues, indicating perhaps that proteolytic 
cleavages at these sites are mediated by the same enzyme or 
by enzymes of similar specificities. Conservation of basic 
charged amino acid residues at the carboxyl-termini of 
alphavirus E3 polypeptides is probably necessary for 
cleavage by a different enzyme. The amino acid sequences 
surrounding the capsid-E3 cleavage indicate a third 
specificity for enzymatic cleavage.
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PART 6 : RECOMBINANT VACCINIA VIRUS
EXPRESSION OF VEE VIRUS STRUCTURAL PROTEINS
I, Construction of the Chimeric Insertion Plasmid
The chimeric insertion plasmid containing cDNA encoding 
the VEE virus structural genes was constructed as shown in 
Fig. 10. Ligation of VEE virus cDNA into the Eco RI site of 
the pGS-62 insertion plasmid resulted in cloning of the VEE 
virus genes in either appropriate or reverse orientation 
relative to the vaccinia virus 7.5K promoter. The presence 
of Pst I sites in both VEE cDNA and in pGS-62 (Fig. 38A) 
permitted rapid identification of recombinant plasmids 
containing VEE virus cDNA inserts of appropriate 
orientation. Recombinant insertion plasmids restricted with 
Pst I consisted of two populations. Recombinant plasmids 
with VEE virus genes in the correct orientation ('+’ in 
Fig. 38B) contained a 2020-bp PstI fragment (large arrow in 
Fig. 38B). Plasmids that contained VEE virus genes in the 
wrong orientation ('-', in Fig. 38B) had a Pst I fragment of 
6040 bp. This large fragment consisted of the 4350-bp Pst I 
fragment of pGS-62 and the largest Pst I fragment of the VEE 
virus cDNA.
Recombinant plasmids were amplified in E_,_ coli 
cultures, extracted, and ceasium chloride-purified. A more
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Fieure 38. Identification of recombinant pGS-62 plasmids 
containing VEE TC-83 virus cDNA cloned in the appropriate 
orientation relative to the VACC 7.5K promoter. Pst I 
digestion of recombinant plasmids (B) demonstrated those 
recombinants containing the 2020-bp fragment (large arrow), 
diagnostic of the correct orientation ('+'). A schematic 
Pst I map of the appropriate recombinant plasmid is shown 
in (A). Pst I digests of recombinant plasmids containing 
VEE virus cDNA in the incorrect orientation are also 
indicated ('-').
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thorough analysis of the pTC-5A chimeric plasmid showed 
restriction fragments of appropriate sizes after restriction 
with Pst I, Eco RI and Bam HI (Fig. 39). Eco RI or Pst I 
digestion excised the VEE virus cDNA in its entirety from 
the recombinant pUClS and pGS-62 plasmids. The largest Pst 
I fragment (1690-bp) of the VEE virus cDNA resulting from 
Pst I-digested pTC-5A plasmid contained an additional 330 
bp, which was derived from the 7.5K-proximal Pst I - Eco RI 
fragment of the pGS-62 plasmid.
II. Insertion of VEE Virus Genes into VACC Virus
CV-1 cells infected with the Wyeth strain of VACC virus 
were transfected with chimeric pGS-62 plasmid pTC-5A, 
pTRD-lA, or pTRD-20A. These chimeras contained the cDNA 
encoding all of the structural proteins of VEE TC-83 or TRD 
virus. The pTRD-20 cDNA clone, unlike pTC-5 and pTRD-1, was 
not sequenced and was obtained by priming first strand cDNA 
synthesis with oligo(dT) 25-mer.
VACC virus plaques resulting from titration of
freeze-thawed transfected 143 B cells were amplified in
24-well cultures of these cells, and portions of the
resulting cell lysates were spotted onto nitrocellulose
32membranes. One membrane was probed with [ P]-labelled 
pTC-5 cDNA (Fig. 40). Although the positive pTC-5 plasmid 
control DNA resulted in overexposure of the autoradiogram, 
the probe appeared to hybridize to nucleic acid in a number 
of spots. Arrows in Fig. 40 indicate the spots from
— 2 4 8 —
Figure 39. Restriction enzyme analysis of the pTC-5A 
chimeric insertion plasmid. Recombinant plasmids containing 
TC-83 virus cDNA, which was subcloned into pGS62 or pUClS 
after restriction with Tthlll I and ligation to Eco RI 
linkers, are indicated by solid circles.
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Flgure 40. Screening for VEE virus cDNA in recombinant VACC
32virus genomic DNA by hybridization of [ P]-labelled VEE 
virus cDNA probe to recombinant VACC virus-infected 143 B 
cell lysates. Lysates were spotted onto nitrocellulose. 
Arrows indicate recombinant viruses that were selected for 
vaccine use in this study.
TC-5A
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positive, cDNA-containing recombinant viruses that were used
in this study, A duplicate filter was incubated with
anti-TC-83 antibody (mouse hyperimmune ascitic fluid) and
125detected indirectly with [ I]-labelled goat anti-mouse 
antibody (Fig. 41). Numerous cell lysates, which were 
derived from different virus plaques, appeared to contain 
VEE virus-specific antigens. The arrows in Fig. 41 indicate 
the same recombinant VACC virus spots that were highlighted 
in the nucleic acid analysis (Fig. 40).
Recombinant VACC/TC-5A, VACC/TRD-IA, and VACC/TRD-20A 
viruses were plaque-purified in 143 B and CV-1 cells and 
grown for further study in CV-1 cells. To avoid 
quickly-sedimenting virus aggregates, which might have 
contained wild-type VACC virus, the final plaque 
purification of recombinant virus was performed by titration 
in CV-1 cells of clarified (5880 X g for 20 min in a GSA 
rotor) medium from recombinant virus-infected 143 B cell 
cultures.
DNA was extracted from plaque-purified recombinant VACC 
viruses containing cDNA specific for VEE or St. Louis
encephalitis (SLE) virus and hybridized to VEE or SLE
32
virus-specific [ P]-labelled cDNA (Fig. 42). The 
plaque-purified recombinant viruses still contained the 
heterologous cDNA inserts. The VACC/SLE virus served as a 
recombinant vaccinia virus negative control, and its 
construction using SLE virus-specific cDNA (Trent et al.. 
1986) is not a topic of this dissertation.
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Fieure 41. Immunoblot screening for VEE virus antigens in
recombinant VACC virus-infected 143 B cell lysates, which
were spotted onto nitrocellulose and probed with 
125[ I]-labelled goat anti-mouse antibody. The primary
antibody was anti-TC-83 virus mouse hyperimmune ascitic 
fluid. Arrows indicate positive recombinants that were 
selected for vaccine use in th is  study.
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Figure 42. Hybridization analysis of DNAs extracted from
CV-1 cells infected with plaque-purified recombinant VACC
viruses and spotted onto duplicate nitrocellulose
32membranes. Membranes were probed with [ P]-labelled VEE 
(top panel of figure) or St. Louis encephalitis (SLE) 
(bottom panel) virus-specific cDNA. Recombinant VACC 
viruses containing SLE virus genes served as negative 
recombinant VACC virus controls. Spots labelled TC5,
TRDl, and TRD20 contained DNA isolated from cells infected 
with recombinant VACC/TC-5A, VACC/TRD-IA, and VACC/TRD-20A 
viruses, respectively. These three
recombinant viruses were selected for use as 
recombinant vaccines in this study (see also 
Figs. 40 and 41). Four other positive 
VACC/TRD viruses (rows A and B in top panel) 
and three positive VACC/SLE viruses (rows 
(B and C in bottom panel) were not used 
further in this study.
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III. Partial Purification of VACC Virus
To determine the optimum time for harvesting VACC or 
recombinant VACC virus from infected CV-1 cells, a growth 
curve of VACC/TC-5A virus was performed in duplicate in 
cells infected at an MOI of 0.05 PFU/cell (Fig. 43). Virus 
present in freeze-thawed cells and in the cell culture 
medium was titrated in Vero cell monolayers. The average 
virus titre in harvested cell lysates peaked at about 75 h 
postinfection. At this time 90% of the cells in the culture 
were rounded and aggregated in grape-like clusters, but only 
a small proportion of the cells were actually detached and 
floating in the culture medium. Only about 10% of the 
infectious virus was released into the culture medium 
(Fig. 43). In this study, VACC viruses were harvested from 
infected cells and culture media were discarded.
VACC and recombinant VACC viruses used in this study 
were partially purified from enucleated CV-1 cell lysates by 
pelleting the virions through 40% sucrose. In one 
experiment 13%, 86% and 0.1% of the total VACC/TC-5A virus 
PFU present in the CV-1 cell lysate was recovered in the cell 
culture medium, enucleated cell lysate, and nuclear , 
fraction, respectively. After centrifugation of the 
enucleated cell lysate through sucrose, 39% and 16% of the 
virus PFU originally present in the enucleated lysate were 
recovered in the virus pellet and cell membrane fractions, 
respectively. Thus, only 55% of the virus PFU present in 
the enucleated lysate were recovered after centrifugation
-258-
Figure 43. Growth curve of recombinant VACC/TC-5A virus in 
CV-1 cells. Cell monolayers grown in 75-cm tissue culture 
vessels were infected with 0.05 PFU/cell. Virus present in 
freeze-thawed cells and in the culture medium of duplicate 
virus-infected cell cultures at each time point was titrated 
in monolayers of Vero cells. All data points are average 
titres measured for two virus-infected cell cultures.
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through sucrose. The low recovery of PFU presumably was due 
to the discarding of virus-laden membranes between the virus 
pellet and the sample-sucrose interface and the aggregation 
of concentrated virus in the VACC/TC-5A virus pellet.
IV. Recombinant VACC Virus Genome Structure
Three recombinant VACC viruses were produced:
VACC/TC-5A virus expressing the genes encoding the
structural proteins of VEE TC-83 virus, and two VACC/TRD
virus recombinants, VACC/TRD-IA and VACC/TRD-20A viruses,
expressing the structural genes of VEE TRD virus. To
confirm insertion of VEE virus cDNA into the VACC virus TK
locus. Hind III fragments of DNA purified from wild-type or
recombinant VACC virus were separated in agarose gels
(Fig. 44A) and blotted onto nitrocellulose for hybridization 
32
analysis using [ P]-labelled VACC virus DNA or VEE 
virus-specific cDNA probes (Fig. 44B and 44C, 
respectively). DNA bands resulting from Hind III 
restriction(Fig. 44A)showed that the approximately 5000-bp 
Hind III J fragment (Figure 11) of VACC virus (lower arrows 
in Fig. 44) was not present in recombinant virus DNA (TC-5A, 
TRD-IA, and TRD-20A), which showed instead the appearance of 
a new fragment of about 9000 bp (upper arrows) - the 
predicted size of the Hind III J fragment containing the 
approximately 4000-bp VEE virus cDNA fragment plus the 7.5K 
promoter sequence from the chimeric plasmid. The wild-type 
J fragment was not detected in the recombinant virus genome
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Fieure 44. Hind III restriction analysis of the genomic 
DNAs of VACC and recombinant VACC (TC-5A, TRD-IA, TRD-20A) 
viruses. DNA bands from duplicate ethidium bromide-stained 
agarose gels (A) were blotted onto nitrocellulose and probed 
with [^^P]-labelled VACC virus DNA (B) or VEE virus- 
specific cDNA (C). Lower arrows indicate the position of 
the Hind III J fragment of wild-type VACC virus DNA. Upper 
arrows indicate altered migration of the J fragment due to 
insertion of VEE virus cDNA. The 11,930 molecular weight 
marker (MW) band is linearized chimeric pTC-5A plasmid.
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by hybridization with radiolabelled VACC virus DNA probe 
(Fig. 44B), indicating that the recombinant viruses were 
essentially pure populations. Radiolabelled VEE virus cDNA 
probe hybridized to the 9000-bp fragment of the recombinant 
VACC virus DNAs (Fig. 44C).
In a separate experiment, restriction of genomic DNA 
with Eco RI resulted in excision of the VEE virus cDNA 
fragment from recombinant VACC/TC-5A virus DNA. Comparison 
of the migration of this Eco RI cDNA fragment with cDNA 
excised from recombinant pUClS plasmid and from the pTC-5A 
chimeric insertion plasmid indicated that the VEE 
virus-specific cDNA fragment in the recombinant virus genome 
was of the appropriate size to encode the structural 
polyprotein precursor mRNA of TC-83 virus (data not shown).
V. Expression of VEE Virus Structural Proteins
A. Immunoblots
Immunoblots of VACC/TC-5A, VACC/TRD-IA, and 
VACC/TRD-20A virus-infected CV-1 cell lysates clearly showed 
a polypeptide band that comigrated with the capsid protein 
band in VEE TC-83 and TRD virus-infected cell lysates and in 
dissociated purified virus (Fig. 45). Lysates of cells 
infected with the three recombinant viruses also contained 
polypeptides that comigrated with the El and E2 envelope 
glycoprotein bands present in cells infected with wild-type 
VEE virus or in purified VEE virus. There was no evidence
—264—
Figure 45. Immunoblot analysis of VEE virus structural 
polypeptides in lysates (equal volumes in all lanes) of CV-1 
cells infected with recombinant VACC/TC-5A, VACC/TRD-IA, or 
VACC/TRD-20A virus or with VEE TC-83 or TRD virus. Proteins 
of purified VEE TC-83 and TRD viruses are shown in the lanes 
at the right. Cell lysates were harvested 18 h 
postinfection. C = capsid protein, El and E2 = envelope 
glycoproteins.
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of El, E2, or capsid polypeptide in lysates of uninfected or
VACC virus-infected cells. The E2 polypeptide band in the
VACC/TRD-IA lysate was more pronounced than in the
VACC/TC-5A or VACC/TRD-20A virus-infected cell lysates.
This apparent differential expression of E2 in the three
recombinant lysates was confirmed in a second immunoblot of
independent CV-1 cell lysates (data not shown). Equal
volumes of all cell lysates were tested in Fig. 45. The VEE
virus-specific polypeptide band intensities in the various 
appeared to
lysatesAindicate that expression levels of VEE virus 
proteins in recombinant VACC virus-infected cells were 
several fold lower than in VEE virus-infected cells
(visual estimate).
B. Radioimmune Precipitation
Native cell protein synthesis is rapidly shut down
following infection with an alphavirus. As shown in
Fig. 46A, 24 h following infection of CV-1 cells with TC-83
35virus in the presence of [ S]-methionine, TC-83 
virus-specific capsid (C), El, E2, and pE2 (intracellular 
precursor of E2) proteins were the predominant proteins 
produced in the infected cells. VACC and recombinant VACC 
virus-infected cells also showed reduced levels of native 
cell proteins, but produced many VACC virus-specific 
polypeptides (Fig. 46A). VEE virus polypeptides were 
obscured by comigrating VACC polypeptides.
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35Figure 46. Autoradiographs of [ S]-labelled polypeptides 
in CV-1 cell lysates 24 h postinfection. (A) Direct PAGE 
analysis of lysates. (B) Radioimmune precipitates from cell 
lysates. (C) Radioimmune precipitates from cell lysates 
following preincubation of the lysates with protein 
A-Sepharose, but without antibody. The protein A-Sepharose 
was removed by centrifugation and then treated as in (B). 
Aliquots of the same cell lysates were tested in (A), (B), 
and (C). . In (C) the volume of the TC-83 and TRD 
virus-infected cell lysates loaded onto the gel was 
one-seventh that of the other lysates. C = capsid, El and 
E2 = envelope glycoproteins, pE2 = intracellular precursor 
of E2. In (C), TC-83 Virus -  pu r if ied  virus, m arker .
—2 68—
snjjA 68-01 
GUI 33A I 
88-01 33A 
voz-cai/oovA
Vl-GWl/OOVA
V9-01/00VA I 
OOVA
pepe^ujun I
CM
UJ CM T- 
Q. LU UJ 
t ▼ ▼
I
88-01 33A I 
VGZ-Cai/OOVA I 
VL-GWl/OOVA I 
VS-Ol/OOVA I
OOVA I I 
pepepiun
CM
lu CM r-
auj LU O
T T ▼ T
t
4» #4# 
'#» #41 
'#• #4!
88-01 33A I
vo2-aai/oovA |
Vl-Gdl/OOVA 0  
V9-01/OOVA ^  
OOVA 0  
pajoepiun
UJ CM 1-auj UJ
-269-
Standard radioimmune precipitation (RIP) analysis was 
performed using the same lysates (Fig, 46B). Although many 
of the background polypeptide bands were eliminated by this 
procedure, the VEE El and E2 were still obscured. The VEE 
virus capsid polypeptide, however, showed somewhat better 
resolution.
The RIP analysis was repeated with the same lysates, 
but with modification. Lysates were preincubated for 2 h 
with protein A-Sepharose but without anti-TC-83 antibody.
The protein A-Sepharose was removed by centrifugation, and 
RIP testing of the supernatant was performed as in the 
previous RIP experiment using fresh protein A-Sepharose and 
anti-TC-83 antibody. This procedure removed much of the 
polypeptide background and also resulted in loss of most of 
the VEE capsid protein, since this polypeptide band was 
absent or nearly absent in the lysates of both recombinant 
VACC and wild-type VEE virus-infected cells (Fig. 46C). 
Although a VACC-specific polypeptide doublet (VACC lane) 
comigrated with E2, the diffuse pE2 and E2 polypeptide bands 
that were apparently evident in the recombinant VACC and VEE 
virus infected-cell lysates were absent from lysates of 
uninfected or VACC virus-infected cells. The pE2 
polypeptide band, which was obscured by background in the 
immunoblot (Fig.45), was clear in Fig. 46C.
Although the precipitated El polypeptide present in the
VEE TRD virus-infected cell lysate comigrated with the El
band of the purified TC-83 virus control, the El 
polypeptides of the three recombinant and TC-83
-270-
virus-infected cell lysates migrated somewhat slower 
(Fig, 46C). The reason for this gel anomaly is unknown.
The El polypeptides of recombinant VACC and VEE 
virus-infected cell lysates clearly comigrated with 
authentic El of purified VEE virus in the immunoblot shown 
in Fig. 45. The minor band that migrated just below El in 
the recombinant VACC and VEE virus-infected cell lysates has 
not been identified (Fig. 46C). The large molecular weight 
protein present in the electropherogram of the VEE TRD 
virus-infected cell lysate (Fig. 46C) may be aggregated E2 
protein. A similar polypeptide band, which occurred in an 
immunoblot of purified TC-83 virus, reacted with monoclonal 
anti-E2, but not monoclonal anti-El, antibody (data not 
shown here).
It was concluded from immunoblot and RIP analyses that
authentic VEE virus capsid, pE2, and El polypeptides were
synthesized and processed in CV-1 cells infected with
recombinant VACC/TC-5A, VACC/TRD-IA, or VACC/TRD-20A virus.
The polypeptide bands seen in Fig. 46C resulted from
electrophoresis of equal volumes of uninfected, VACC, or
recombinant VACC virus-infected cells lysates. The volume
was reduced seven fold for VEE TC-83 and TRD virus-infected
cell lysates. The polypeptide band intensities in the RIP
appeared to
analysis, as in the immunoblot,A indicate that the level of 
VEE virus polypeptide expression in recombinant 
virus-infected cells was s e v e ra l  fold lower than in
VEE virus-infected cells (visual estimate).
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C. Immunofluorescence Analysis
Expression of VEE virus proteins in recombinant 
virus-infected cells was demonstrated further by indirect 
immunofluorescence analysis (IFA) using anti-TC-83 virus 
mouse hyperimmune ascitic fluid (Fig. 47). VEE virus 
antigens were detected in acetone-fixed VEE TC-83 (Fig. 47b) 
or recombinant VACC/TC-5A (Fig. 47c) virus-infected CV-1 
cells and in unfixed TC-83 (Fig. 47e) or VACC/TC-5A 
(Fig. 47f) virus-infected cells. VEE virus antigens were 
not present in uninfected CV-1 cells (Fig. 47a and 47d). 
Although intense fluorescence often occurred in 
acetone-fixed; recombinant virus-infected cells (Fig. 47c), 
surface expression of VEE virus antigens, as indicated by 
IFA of unfixed cells, was apparently lower in recombinant 
virus-infected cells (Fig. 47f) than in cells infected with 
TC-83 virus (Fig. 47e). Time course IFA analyses showed 
that both VACC/TC-5A or VACC/TRD-IA virus-infected CV-1 
cells expressed VEE virus antigen in fixed cells by 4 h PI. 
VEE TRD and VACC/TRD-IA virus-infected cells appeared to 
fluoresce to the same extent as TC-83 and VACC/TC-5A 
virus-infected cells, respectively, between 2 - 24 h PI 
(data not shown).
VI. Expression of VEE Virus Glycoprotein Eoitopes
Antiserum prepared against VACC virus reacted only with 
VACC and recombinant VACC virus-infected cells by IFA.
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Flgiire 47. Indirect immunofluorescence analysis of the 
expression of VEE virus antigens, using anti-TC-83 virus 
mouse hyperimmune ascitic fluid (1:200 dilution), in 
acetone-fixed (a - c) or unfixed (d - f) CV-1 cell 
monolayers 24 h after infection with TC-83 virus (b, e) or 
recombinant VACC/TC-5A virus (c, f). Uninfected cell 
controls are shown (a, d). All photographs are identical 
exposures. 500X.
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Polyvalent anti-TC-83 virus ascitic fluid reacted with cells 
infected with VEE virus or VACC recombinant virus 
(Table 13). The availability of well characterized 
monoclonal antibodies identifying epitopes in the El and E2 
envelope glycoproteins of VEE virus (Roehrig et al., 1982; 
Roehrig and Mathews, 1985) permitted the investigation of 
the expression of VEE virus-specific antigenic determinants 
in some detail (Table 13). The TC-83 virus-derived 
monoclonal antibody 2A4B-12, which defines the E2^ epitope 
of VEE virus and which has no HI or Nt activity, was 
unavailable for this study. Information concerning the 
seven monoclonal antibodies used in this analysis was 
reviewed in the Literature Review section of this 
dissertation.
The anti-E2 monoclonal antibodies shown in Table 13 
generally reacted similarly with cells infected with VEE or 
recombinant VACC virus. In particular, antibody 5B4D-6 
(epitope E2^), which was shown to be specific for TC-83 
virus by ELISA (Roehrig et al., 1982; Roehrig and Mathews, 
1985), also reacted more strongly with recombinant 
VACC/TC-5A virus-infected cells than with VACC/TRD-IA 
virus-infected cells. Monoclonal antibodies 1A4A-1 (E2^), 
1A4D-1 (E2^) and 1A3A-9 (E2®) showed positive FA 
reactivities with cells infected with VACC/TC-5A, 
VACC/TRD-IA, TC-83 or TRD virus. Although antibody 1A3A-5 
(E2^) reacted poorly (VACC/TC-5A virus-infected cells) or 
not at all (VACC/TRD-IA virus-infected cells) with 
recombinant virus-infected cells, a pattern of TC-83 antigen
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Table 13. Indirect inanmofluorescence of acetone-fixed CV-1 cells 24 h 
postinfection
Virus
Antibody^ Specificity
Unin­
fected VACC
VACC/
TC-5A
VACC/
TRD-IA TC-83 TRD
Mouse serum Vaccinia - 3b 3 3 - -
MHIAF VEE TC-83 - - 3 3 4 4
5B4D-6 E2* TC-83 - - 3 1 4 1
1A4A-1 E2C PTF-39 - - 3 3 4 4
1A6C-3 E2*^  EVE - - - 2 2 2
1A3A-5 E2= P676 - - 2 - 4 2
1A4D-1 E2^ TRD - - 3 3 4 4
1A3A-9 E28 PTF-39 - - 3 3 4 4
1A3B-7 E2^ PTF-39 - - 3 1 4 4
3B2D-5 El» TC-83 - - - - 3 3
3B2A-9 Elb TC-83 - - 3 3 3 3
5B6A-6 Eic TC-83 - - - - 3 1
3A5B-1 Eld TC-83 - - 3 3 4 4
^Alphanumeric designations are anti-VEE virus monoclonal antibodies
(mouse ascitic fluids). Epitope specificity and virus used to elicit 
monoclonal antibody are shown. MHIAF = mouse hyperimmune ascitic fluid. 
All antibody preparations (Roehrig et al., 1982; Roehrig and Mathews, 
1985) were tested at 1:300 dilution.
^Relative fluorescence as determined by two observers in at least two 
experiments. - = negative; 4 = maximum.
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specificity similar to that seen with VEE virus-infected 
cells was observed. Antibody 1A6C-3 (E2^), which reacted 
poorly with cells expressing TC-83, TRD or VACC/TRD-IA virus 
antigens, failed to react with VACC/TC-5A virus-infected 
cells. The 1A3B-7 (E2^) antibody failed to react well 
with VACC/TRD-IA recombinant-infected cells, but reacted 
strongly with cells infected with VACC/TC-5A, TC-83, or TRD 
virus.
Of the four El glycoprotein epitopes identified for VEE 
virus (Roehrig et al., 1982), only the El^ and El^ 
epitopes were detected in recombinant VACC/TC-5A or 
VACC/TRD-IA virus-infected cells (Table 13). Although the 
El^ and El^ epitopes were detected in VEE TC-83 and TRD 
virus-infected, acetone-fixed cells, these two epitopes were 
not evident by IFA of recombinant VACC/TC-5A or VACC/TRD-IA 
virus-infected cells under identical conditions.
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PART 7; RECOMBINANT VACCINIA VIRUS -
IMMUNIZATION AND PROTECTION OF MICE
I, Titration of VEE Viruses in Adult Mice
Immunization studies were performed in 5-week-old mice
that were challenged with virulent VEE virus 19 - 21 days
postimmunization. To determine standard challenge doses of
VEE virus strains, 50% median i.p. (IPLD^q ) and intranasal
(INLD^q) lethal dose titrations were performed in
8-week-old outbred Swiss NIH mice or inbred A/J mice
(Table 14). IPLD^q titrations were performed for six VEE
subtype 1 variants and one strain of each of the other four
VEE virus subtypes (Table 14). One IPLD^q unit
corresponded to 0.6, 110, and 0.1 PFU of VEE TRD (subtype
lAB), P676 (1C), and 3880 (ID) viruses, respectively, in
Swiss NIH mice. EVE virus (subtype 2) killed Swiss NIH mice
nonuniformly in three separate experiments so that a
reliable IPLD__ was not determined for this virus. Mena DÜ
II (IE) virus was fatal for outbred mice only at high doses
(1.4 X 10^ PFU per IPLD^q ), while 78V-3531 (IF),
MUC (3A), PIX (4), and CAB (5) viruses were not lethal at
8doses of at least 10 PFU.
The IPLDgQ for VEE TRD virus in 8-week-old A/J mice
was 0.15 PFU. INLD endpoints of 33 and 105 TRD virusDU
PFU were obtained in 8-week-old A/J and Swiss NIH mice.
- 2 7 8 -
Table 14. Titrations of VEE viruses
Swiss NIH and A/J
in 8-week-old 
mice
Virus
Antigenic
Subtype IPLD50 ^
TRD lAB 0.60; 0.15^
P676 1C 110
3880 ID 0.10
Mena II IE 1.4 X 10^
78V-3531 IF -d
Everglades Fe 3-7c 2
Mucambo BeAn 8 3A -
Pixuna BeAr 35645 4 -
Cabassou CaAr 508 5
INLD50 &
105; 33^
^Median intraperitoneal lethal dose of virus (PFU).
^Median intranasal lethal dose of virus (PFU).
^Median lethal dose of virus for female A/J mice. 
All other values were determined for male Swiss 
NIH mice.
^Virus not lethal at dose of 10^ PFU or greater.
^Virus killed mice nonuniformly, so that a reliable 
IPLD50 was not determined.
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respectively. titrations were not performed in C3H
mice.
II. Immunological Responses in Mice
A. Antibody Responses Detected bv HI and ELISA
4
A/J mice were immunized i.p. with 10 PFU of TC-83 
virus or i.d. with 10^ PFU of VACC virus, or with 10^,
10^, or 10^ PFU of recombinant VACC/TC-5A virus.
Animals were bled 3 weeks after immunization for antibody 
determinations. Mice that survived virulent TRD virus 
challenge were bled again 2 weeks after challenge. As shown 
in Table 15, only mice that received TC-83 or VACC/TC-5A 
vaccine were protected from i.p. TRD virus challenge. VACC 
virus-immunized and PBS control mice did not survive TRD 
virus challenge.
Antibody titres are expressed in Table 15 as the 
logarithm (base 10) of the reciprocal geometric mean titre 
(GMT). Actual reciprocal geometric mean titres are used in 
this text. Mice that received 10^ or 10^ PFU of 
VACC/TC-5A virus developed reciprocal geometric mean HI and 
ELISA titres of 27 or 44 and 1076 or 1600, respectively. 
Animals given 10^ PFU of VACC/TC-5A virus, however, 
developed no measurable (three mice) or much reduced (five 
mice) HI (15 GMT) or ELISA (230 GMT) antibody levels. The 
development of recombinant VACC virus-induced tail blister, 
antibody response, and survival after TRD virus challenge.
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were dose related in the animals immunized with VACC/TC-5A 
virus.
The attenuated TC-83 virus elicited higher reciprocal 
mean HI and ELISA GMTs of 293 and at least 102,400, 
respectively. Postchallenge antibody rises suggested a dose- 
related boost in VACC/TC-5A virus-immunized animals that was 
much greater than that shown in the TC-83 mouse group 
(Table 15). These dose-related boosts in antibody titre 
suggested that greater replication of the challenge virus 
occurred in those mice which received the VACC/TC-5A vaccine 
than those immunized with TC-83 virus.
B. Antibodv Responses Detected bv NT
Prechallenge Nt antibody titres in individual animals 
receiving various doses of recombinant vaccine are shown in 
Table 16. Mice immunized with VACC/TC-5A virus developed 
dose related Nt antibody responses (less than 1:10 to 1:5120 
titres) that were generally much lower in comparison to Nt 
antibody levels (at least 1:10,240) in TC-83 virus-immunized 
mice. Three mice immunized with 10^ PFU of VACC/TC-5A 
virus and one immunized with 10^ PFU developed no Nt 
(Table 16), HI, or ELISA antibodies (data not shown). These 
mice succumbed to TRD virus challenge. A fifth mouse, given 
a 10^ dose, developed no detectable Nt or HI antibody but 
did have an ELISA titre of 1:200 and did survive TRD virus 
challenge. None of the VACC virus-immunized or PBS control 
mice developed anti-TRD Nt antibody.
- 2 8 2 -
Table 16, VEE virus neutralizing antibody 
titres in A/J mice 3 weeks after 
immunization with VACC/TC-5A virus
Vaccine dose (PFU)
10? 106 105
2,560A 160 10
640 <iok 10
320 80 <iob
640 <10 <10^
5,120 320 20
80 320 160
80 20 <10^
20 320 20
^Reciprocal of highest antiserum dilution 
that inhibited 70% or more of the VEE TRD 
virus (60 PFU) used in the test.
^Mouse died after challenge with 
100 IPLD50 of VEE TRD virus.
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A/J mice immunized with 10^ PFU of VACC/TC-5A virus 
were bled 18, 33, and 86 days after immunization to 
determine the short-term duration of immunity against VEE 
virus. Nt antibody titres indicated that antibody levels 
induced by VACC/TC-5A virus were stable for at least 3 
months (Table 17).
Nt antibody titres were determined for both Swiss NIH 
and C3H mice that received 10^ PFU of VACC/TC-5A virus 
i.d. (Fig. 48). The recombinant VACC/TC-5A vaccine appeared 
to elicit a somewhat weaker response in outbred Swiss NIH 
mice than in inbred C3H (Fig. 48) or A/J mice (Table 16). 
VACC/TC-5A virus-induced tail blisters appeared to be of 
reduced severity in Swiss NIH mice relative to the blisters 
in A/J and C3H mice.
III. Cross-Protection Studies
A. Cross-Nt Assays
Five individual, high-titre mouse antisera raised 
against TC-83 or VACC/TC-5A virus were pooled and tested for 
their ability to neutralize different antigenic subtypes of 
VEE virus (Table 18). The Nt cross-reactivities of 
anti-TC-83 and anti-VACC/TC-5A virus sera were very 
similar. Both sera neutralized epizootic VEE viruses lAB 
and 1C (P676) efficiently. Subtype ID (3880), IE (Mena II), 
and 2 (EVE) viruses were neutralized at higher antibody 
concentrations. Anti-VACC/TC-5A virus serum cross-reactive
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Table 17. Duration of neutralizing antibodies 
in individual A/J mice immunized 
intradermally with 10^ PFU 
of recombinant VACC/TC-5A virus
Mouse
Davs Dostimmunization
18 33 86
1 320â 2,560 1,280
2 640 160 320
3 2,560 640 320
4 640 2,560 2,560
5 5,120 5,120 10,240
6 20 80 40
^Reciprocal of highest antiserum dilution 
that inhibited 70% or more of VEE TRD virus 
(60 to 80 PFU) used in neutralization test.
-285-
Figure 48. Distribution of individual anti-TRD virus Nt 
antibody titres (70% endpoint) in outbred Swiss NIH mice 
(N=48) and inbred C3H mice (N=94).
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Table 18. Neutralization cross-reactivities of sera 
pooled from A/J mice immunized with VEE 
TC-83 or recombinant VACC/TC-5A virus.
Virus
Pooled mouse 
VACC/TC-5A
serum
TC-83
VACC 80^ <10
VACC/TC-5A 160 <10
TRD (lAB)fe 1,280 120,480
P676 (1C) 320 >640
3880 (ID) 10 160
Mena II (IE) 10 80
EVE (2) 40 320
PIX (4) <10 <10
WEE <10 <10
^Reciprocal of highest antiserum dilution that 
inhibited 70% or more of the VEE TRD virus 
(60-90 PFU) used in the neutralization test.
^VEE subtype.
— 2 8 8 —
Nt titres were always less than those of the anti-TC-83 
virus serum; neither antiserum neutralized the distantly 
related VEE subtype 4 (PIX) virus or WEE virus.
B. Cross-Challenge Experiments
Nt tests with anti-VACC/TC-5A virus serum indicated
that the recombinant vaccine should protect mice against
challenge with subtype lA - D and subtype 2 VEE viruses. To
evaluate this hypothesis, C3H and Swiss NIH mice were
immunized with TC-83 or recombinant virus and challenged
with virulent VEE virus (Table 19). Both TC-83 and
VACC/TC-5A vaccine viruses protected mice against at least
6 X 10^ PFU (10^ IPLDgQ in Swiss NIH mice) of TRD 
3 4
virus and 10 and 10 PFU of 3880 and P676 viruses, 
respectively. Protection of immunized Swiss NIH mice 
against fatal EVE virus challenge was ambiguous because only 
three of eight PBS control animals died. However, all of 
the C3H PBS control mice succumbed to EVE virus challenge, 
and C3H mice were clearly protected from challenge with EVE 
virus by immunization with either vaccine. High challenge 
doses of P676 and TRD viruses caused one or two fatalities, 
respectively, in recombinant virus-immunized, but none in 
TC-83 virus-immunized Swiss NIH mice (Table 19).
Two groups of six A/J mice were immunized with 
VACC/TRD-IA or VACC/TRD-20A virus and subsequently 
challenged with 100 IPLD^^ of TRD virus. All six animals 
in each group survived TRD virus challenge (data not shown).
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Table 19. VACC/TC-5A and TC-83 vaccine efficacy in 
protecting C3H or Swiss NIH mice from 
intraperitoneal challenge with four VEE 
virus strains
Challenge
Survival^
Dose
(PFU)
VACC/TC-5A TC-83
Virus C3H Swiss C3H Swiss
TRD (1AB)& 6 X loi 6/6^ 6/6 6/6 6/6
6 X 102 6/6 6/6 6/6 6/6
6 X 103 6/6 5/6 6/6 6/6
6 X 105 6/6 5/6 6/6 6/6
P676 (1C) 1.1 X io4 6/6 6/6 6/6 6/6
1.1 X 106 6/6 5/6 6/6 6/6
3880 (ID) 1 X loi 6/6 6/6 6/6 6/6
1 X 103 6/6 6/6 6/6 6/6
EVE (2) 1 X 108 8/8 8/8 8/8 8/8
^All mice in 17 PBS control groups (nine virus challenge doses, 
two mouse strains) succumbed to virus challenge. Only three of 
eight PBS control Swiss NIH mice died after EVE virus challenge,
feVEE subtype.
^Number of survivors/total.
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IV. Immunoblot Analysis of Mouse Immune Sera
SDS-dissociated proteins of purified VEE TC-83 virus 
were subjected to PAGE and then blotted onto 
nitrocellulose. The nitrocellulose sheet was cut into 
strips to permit analysis of mouse immune sera for the 
presence of antibodies specific for the VEE virus structural 
proteins (Fig. 49). Amido black-stained TC-83 virus 
proteins served as control protein markers (Fig. 49, 
lane A). Anti-SLE virus mouse hyperimmune ascitic fluid 
resulted in very low background reactivity with the TC-83 
virus proteins (lane 1). Mouse serum pools (1:150 dilution) 
from groups of six Swiss NIH, C3H, and A/J mice immunized
1.d. with 10^ PFU of VACC/TC-5A virus are shown in lanes
2, 3, and 4 respectively. Serum from TC-83 virus-immunized 
A/J mice is shown in lane 5. Lanes 6, 7, 8, and 9 show the 
reactivities of anti-TC-83 and anti-TRD virus mouse 
hyperimmune ascitic fluids and VEE virus-specific monoclonal 
antibodies 1A4A-1 (defining the E2^ epitope) and 3B2A-9 
(El^), respectively. Anti-TC-83 virus A/J serum (lane 5) 
and anti-TC-83 and anti-TRD virus hyperimmune ascitic fluids 
(lanes 6 and 7, respectively) reacted well with the pE2, E2, 
El, and capsid (C) proteins of TC-83 virus. Serum from 
VACC/TC-5A virus-immunized Swiss NIH, C3H, and A/J mice 
(lanes 2 - 4 ,  respectively) reacted predominantly with the 
E2 glycoprotein of TC-83 virus in this test. However, all 
of the immune fluids tested (except anti-El monoclonal 
antibody) reacted better with E2 than with El in the
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Fieure 49. Immunoblot analysis of immune mouse fluids. 
Proteins of purified TC-83 virus were separated by SDS-PAGE 
and blotted onto nitrocellulose. Nitrocellulose strips were 
tested with pooled immune serum from VACC/TC-5A 
virus-immunized Swiss NIH, C3H, and A/J mice (lanes 2, 3, 
and 4, respectively); TC-83 virus-immunized A/J mice 
(lane 5); anti-TC-83 and anti-TRD mouse hyperimmune ascitic 
fluids (lanes 6 and 7, respectively); and VEE virus-specific 
anti-E2^ (1A4A-1) and anti-El^ (3B2A-9) monoclonal 
antibodies (Roehrig et al., 1982) (lanes 8 and 9, 
respectively). Amido black-stained TC-83 virus proteins and 
control anti-St. Louis encephalitis virus immune ascitic 
fluid are shown in lanes A and 1, respectively. All immune 
fluids were tested at 1:150 dilution. Anti-TC-83 and 
anti-TRD mouse hyperimmune ascitic fluids were obtained from 
the Arbovirus Reference Branch, DVBVD, CDC, Fort Collins, 
Colorado.
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immunoblot. VEE-specific monoclonal antibodies 1A4A-1
c b(E2 epitope) and 3B2A-9 (El ) did show some reactivity
with the capsid protein in this test. A high molecular
weight polypeptide band that was barely visible in the amido
black stained lane (lane A) was present in all of the test
serum lanes except for the anti-El monoclonal antibody.
This band may be due to aggregated E2 protein.
V. Protection against Intranasal TRD Virus Challenge
To determine the potential level of protection against 
aerosol infection afforded by immunization with recombinant 
VACC/TC-5A virus, mice were immunized with the recombinant 
virus and challenged i.n. with virulent TRD virus 
(100 INLD^q ). The VACC/TC-5A vaccine protected mice 
against i.p. TRD virus challenge but not against i.n. 
challenge, whereas the TC-83 vaccine protected mice from 
challenge virus given by either route (Table 20). However, 
five of the 20 TC-83 virus-immunized A/J mice succumbed to 
i.n. TRD virus challenge. The six VACC/TC-5A 
virus-immunized C3H mice that survived i.n. TRD virus 
challenge all became ill and lost weight after challenge, 
but showed no signs of the paralysis that was typical in PBS 
control animal challenged with TRD virus. The six A/J 
survivors recovered very slowly and were still not normal 3 
weeks postchallenge.
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Table 20, Summary of survival of VACC/TC-5A or TC-83
virus immunized mice challenged intraperitoneally 
or intranasally with virulent VEE TRD virus
Intraperitoneal Intranasal
Challenge^ Challenge^
Mouse
strain VACC/TC-5A TC-83 VAAC/TC-5A TC-83
A/J 42/42^ 8/8 6/24 16/16
C3H 30/30 30/30 0/30 15/20
Swiss NIH 22/24 24/24 1/30 18/18
^Challenge dose = 15 PFU to 6 X 10^ PFU of TRD virus.
^Challenge dose = 3300 (A/J) or 10,500 (C3H and Swiss NIH) 
PFU of TRD virus.
^Survivors/Total
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VI. Intranasal Challenge of Passively Immunized Mice
Six A/J mice were given 0.03 mg of protein A-purified, 
anti-VEE virus E2 monoclonal antibody (3B4C-4, Roehrig 
et al.. 1982) by injection into the tail vein. This 
antibody neutralizes TRD virus to high titre (Roehrig 
et al.. 1982). Twenty-four h after receiving the antibody, 
two mice were bled for antibody determinations, and all six 
mice were challenged i.n. with 3300 PFU (100 INLD^^) of 
TRD virus. Despite Nt antibody titres of at least 1:1280 in 
the two mice tested, the TRD virus challenge was lethal for 
all six mice.
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CHAPTER 4
DISCUSSION
I. Goals
Cloning and sequencing of the genes encoding the 
structural proteins of VEE virus were undertaken to 
(1) identify the organization of genes in the 26S RNA region 
of the VEE virus genome, (2) determine the deduced amino 
acid sequences of the structural polypeptides translated 
from the VEE virus 26S mRNA, thus providing an essential 
data base for future investigations into the locations of 
epitopes that have important functions in antigenicity, host 
immunity, and cell infection processes, (3) provide 
molecular insights into the antigenic variation and 
virulence of VEE virus, and (4) obtain cloned cDNA 
containing VEE virus structural protein genes that can be 
subcloned into expression systems for the development of 
immunogens and diagnostic reagents.
II. Nucleotide Sequence of VEE Virus 26S RNA
The organization of the 26S RNA region of the VEE TRD 
virus 42S RNA genome conformed to the gene organization 
reported for the 26S RNAs of SIN, SF, RR, and EEE viruses
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(Rice and Strauss, 1981; Garoff et 1980a, 1980b;
Dalgamo et al., 1983; Chang and Trent, 1987; 
respectively). Both 5’- and 3'-tenninal noncoding regions 
of the VEE virus 26S RNA were shorter than the analogous 
regions of other alphaviruses (Ou et al., 1982a, 1982b). In 
particular, the 3'-noncoding region of VEE virus 
(121 nucleotides in TRD virus) was much shorter than that of 
other alphaviruses (264 - 524 nucleotides) (Fig. 28). The 
variability in length of the alphavirus 3'-noncoding region 
suggests a lack of critical function of a large portion of 
this region, at least in some viruses. Naturally arising 
defective interfering (DI) RNAs of SIN virus all contain at 
least 50 nucleotides preceding the poly(A) tract (Strauss 
and Strauss, 1986), indicating that the extreme 3'-terminal 
nucleotides are necessary for virus replication. Indeed, 
the 3'-terminal 19 nucleotides are conserved with high 
fidelity in all alphaviruses investigated to date, and these 
nucleotides probably constitute a replicase recognition site 
(Ou et ^ . , 1981). Work with complete cDNA copies of SIN DI 
genomes has shown that nucleotide deletions from 66 through 
20 nucleotides from the 3'-terminus do not inactivate the 
biological activity of the DI transcript, but deletions 
extending into the 3'-terminal 19-nucleotide conserved 
region do result in inactivation (Levis et al., 1986). This 
information supports the contention that this conserved 
region plays a critical role in alphavirus replication.
VEE TRD and TC-83 viruses, as well as EEE virus, 
differed from other alphaviruses in the highly conserved
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21-nucleotide sequence located in the 26S junction region of 
the 42S RNA genome (Fig. 29). This conserved sequence is 
postulated to be a promoter which controls transcription of 
the 26S mRNA from the negative-sense, intracellular 42S 
genomic RNA (Ou et al., 1982b). Both VEE and EEE (Chang and 
Trent, 1987) viruses contain a termination codon in this 
region, and VEE virus has a G nucleotide substitution for 
the A residue at 26S position (-2) in the other alphaviruses 
studied. The significance of these differences in this 
otherwise highly conserved site needs to be determined, but 
the differences may reflect altered specificities of 
transcriptase enzymes or permitted permutations in the 
recognition site of a transcriptase. Presumably, the 
full-length cDNA construct of SIN virus (Rice et ^., 1987) 
will be utilized to define the functional role of this site 
and the effects of various permutations in the conserved 
sequence.
The genes encoding the structural proteins occur in the 
26S mRNA in the order 5'-capsid-E3-E2-6K-El-3'. Clearly, 
the VEE 268 RNA possesses coding capacity for only two 
envelope glycoproteins. Although the AUG codon that 
initiates translation of the VEE capsid protein was chosen 
in conformity with the initiators of other alphavirus capsid 
proteins and with consensus sequence contexts established 
for eukaryotic mRNA initiators (Kozak, 1981, 1983), the 
amino-termini of the El and E2 envelope glycoproteins were 
identified precisely via available amino-terminal sequence 
information obtained by direct Edman degradation sequencing
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of purified VEE El and E2 glycoproteins (Bell et al..
1984). The structural polyprotein precursor cleavage order 
of the El and E2 glycoproteins was determined by pulse-chase 
studies in virus-infected cells for VEE lAB virus (France 
et al., 1979) and VEE subtype 1C, ID, IE, 2, 3, and 4 
viruses (Kinney et al., 1983).
III. Deduced Amino Acid Sequences
Codon usage in the 26S mRNAs of alphaviruses is 
nonrandom for some amino acids (Table 5; Dalgamo et al.. 
1983). Nonrandom codon usage has also been reported for 
flaviviruses (Trent et al., 1987; Deubel et ^., 1987). 
Preferential usage of certain codons is not understood, but 
may be due to the necessity of arthropod-borne viruses to 
replicate efficiently in both arthropod and vertebrate hosts 
(Rice and Strauss, 1981; Dalgamo et ^., 1983).
The structural proteins of alphaviruses are derived 
through proteolytic cleavage of the structural polyprotein 
precursor that is translated from the subgenomic 26S mRNA. 
Conservation of amino acid sequences surrounding these 
cleavage sites (Fig. 37) indicates at least three protease 
specificities: (i) cleavage at the carboxyl-terminus 
(TPE— E-W, where - = variable amino acid) of the capsid 
protein appears to be mediated by an autoprotease activity 
of the capsid protein itself (Aliperti and Schlesinger,
1978; Hahn et al.. 1985)., (ii) the carboxyl-tripeptide 
(A-A) of the E2 and 6K polypeptides may be a substrate for
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signalase in the lumen of the endoplasmic reticulum (Garoff 
et al.. 1980b; Rice and Strauss, 1981), (iii) the cleavage 
site between E3 and E2 occurs following basic residues at 
the carboxyl-terminus of E3. Cleavage after basic amino 
acid pairs may occur in the Golgi vesicles in a manner 
similar to the processing of secreted proteins such as 
proalbumin and parathyroid prohormone (Garoff et al., 1980b; 
Rice and Strauss, 1981).
The VEE virus capsid, El, and E2 proteins have deduced 
molecular weights of 30.9 kd, 47.9 kd, and 47.0 kd, 
respectively, and are similar in size to the cognate 
proteins of other alphaviruses (Table 8). Variation in 
apparent molecular weights of alphavirus El and E2 envelope 
glycoproteins by SDS-PAGE analysis is therefore probably due 
in large part to variability in glycosylation. VEE TRD 
virus E2 glycoprotein is glycosylated at three sites 
(Fig. 31; Mecham and Trent, 1982b), whereas other 
alphaviruses possess two glycosylation sites in E2.
Variable glycosylation may account for the different 
molecular weights (51 kd - 57 kd) observed for the E2 
glycoproteins of various VEE subtype viruses (France et al., 
1979; Kinney et al., 1983; Wiebe and Scherer, 1979, 1980). 
VEE GAB virus (subtype 5) contains the smallest (51 kd) E2 
protein of the agents in the VEE virus complex. The CAB 
virus E2 glycoprotein comigrates with El in polyacrylamide 
gels, but both proteins are readily separated by isoelectric 
focusing (Kinney et al., 1983).
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Similarities in hydropathic profiles (Fig. 30) and 
conservation of Cys, Pro, and Gly residues in alphavirus 
structural polyprotein precursors (Figs. 32 and 33) suggest 
that the secondary structures of the analogous proteins may 
be similar and that antigenic and functional variation 
occurs in polypeptide microenvironments within constraints 
imposed by this structure. Cys residues, in particular, are 
highly conserved. All of the Cys residues in the 
ectodomains (external to the lipid bilayer) of the El and E2 
glycoproteins of VEE TRD virus are conserved at identical 
positions (after alignment to optimize identity) in the 
cognate proteins of EEE, SIN, SF, and RR viruses. 
Conservation of Cys residues is not complete in the 
carboxyl, cytosol domain of the envelope glycoproteins of 
these viruses. Variations in this domain probably do not 
affect the secondary structure of that portion of the 
protein located external to the lipid envelope of the 
virus. Complete conservation of Cys residues also occurs in 
the envelope and NSl proteins of SLE, West Nile, Murray 
Valley encephalitis, yellow fever, and dengue type 2 
flaviviruses (Trent et al., 1987). Since Cys residues are 
involved in covalent disulfide bridges, complete 
conservation of these residues suggests that the overall 
three-dimensional surface structures of the respective El 
and E2 envelope proteins are similar.
Conservation of Pro and Gly residues, which have a high 
probability of residing in conformational bends within the 
polypeptide backbone (based on statistical analysis of more
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than 400 turns in proteins of known conformation, Chou and 
Fasman, 1978), also implies structural similarities among 
alphavirus proteins. The hydrophilic, highly basic region 
of the alphavirus capsid proteins (VEE virus capsid 
positions 50 - 110) contains many predicted polypeptide 
turns (Fig. 34B). Although little conservation of the amino 
acid sequence occurs among alphavirus capsid proteins in 
this region, amino acid substitutions in this domain, like 
transmembrane domains of the envelope glycoproteins, appear 
to maintain a common functional role. That role appears to 
involve close interaction with the phosphate backbone of the 
RNA genome in intact nucleocapsids (Garoff et al., 1980a).
Although alphavirus envelope glycoproteins El and E2 
appear to function as a dimer (Bracha and Schlesinger, 1976; 
Jones et al., 1977), certain biological activities have been 
ascribed to individual proteins. An uncharged, highly 
conserveddomain of approximately 25 amino acid residues in 
the El protein of alphaviruses (VEE virus El positions 
78 - 102, Fig. 31) may play a role in fusion of the viral 
envelope with cellular membranes (Garoff et al., 1980b). 
Although the SIN virus El elicits HI antibodies (Dalrymple 
et al.. 1976) and low level Nt antibodies (Schmaljohn 
et al., 1982; Chanas et al., 1982), the alphavirus E2 
glycoprotein contains the major Nt epitope (Dalrymple 
et al.. 1976; France et al., 1979; Roehrig et al.; 1982). 
Purified El proteins of several VEE virus strains failed to 
elicit HI antibodies (France et al., 1979), while purified 
E2 elicits both Nt and HI antibodies (France et al., 1979;
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Kinney et al., 1983). The critical Nt epitope of VEE virus 
is defined by anti-E2 monoclonal antibody that also has high 
HI activity (Roehrig ejb al., 1982). The HA site in intact 
VEE virus virions may represent a native conformation that 
is not recognized by antibodies raised against purified VEE 
virus El glycoprotein. If the VEE virus HA does indeed 
reside on El, then perhaps the HA and E2 Nt site are closely 
juxtaposed in the virion spike, and Nt antibodies inhibit HA 
through stearic hindrance or induction of altered protein 
conformation. Similar mechanisms may also explain low level 
Nt activities of anti-El sera. Adsorption of VEE viruses to 
cells in vitro is blocked by those antibodies that possess 
Nt and/or HI activities (Roehrig et al., 1988). The 
biological activities attributed to VEE virus E2 
glycoprotein, and the occurrence of greater sequence 
variation among alphavirus E2 proteins relative to El 
(Table 12 and Fig. 31), suggest that the E2 protein may be 
more directly involved in virus-host recognition phenomena, 
and that E2 is more directly affected by selection pressures 
of host immunity or host or tissue specificities.
The amount of useful information that can be gleaned by 
comparing sequence information for distantly related viruses 
of different alphavirus serological complexes (VEE, WEE, SF, 
and EEE virus complexes) rapidly diminishes after the first 
few sequences have been obtained. Regions of sequence 
identity or variation can provide guidelines for research 
into the biological significance of various protein 
domains. Research efforts should now be directed at
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specific protein domains of VEE virus proteins. The VEE 
virus sequences reported here provide a data base for the 
construction of synthetic peptides, which may be analyzed 
for antigenicity, immunogenicity, and involvement in helper 
or cytotoxic T cell function. The nucleotide sequence of 
VEE TRD virus provides information for the synthesis of 
oligonucleotide primers, which can be used to obtain rapid 
primer extension sequence data from purified genomic RNAs of 
related VEE virus strains. These related strains may be of 
natural origin or may be derived by in vitro mutagenesis via 
monoclonal antibody selection of variants in virus 
populations or via site-directed mutagenesis of a full- 
length cDNA clone from which infectious 42S genomic RNA can 
be transcribed.
Sequence comparison of the 263 RNA regions of related 
VEE subtype 1C, ID, and 2 viruses, whose structural proteins 
are closely related to those of VEE lAB virus by tryptic 
peptide mapping (Kinney and Trent, 1982), should identify 
fewer, and therefore more significant and perhaps more 
readily interpretable, amino acid changes than were found by 
sequence comparison of viruses from different alphavirus 
complexes. Nucleotide sequence analysis of both natural 
field strains (Raymond e^ al., 1986, Both et al,, 1983) and 
monoclonal antibody-derived variants (Gerhard et al,, 1981) 
of influenza A virus defined even conformational epitopes of 
the haemagglutinin that were confirmed by crystallographic 
resolution of the three dimensional structure of the 
haemagglutinin (Wilson et ^., 1981).
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The fortuitous presence of a bromelain cleavage site in 
the stalk of the haemagglutinin permitted the crystal­
lization of this integral membrane protein trimer (Wilson et 
al.. 1981). Nucleotide sequence information for VEE virus 
may provide the means to engineer a secretable form of the 
envelope E1-E2 dimer or perhaps to engineer appropriate 
cleavage sites in external domains of the dimer to permit 
purification and concentration of lipid-free spike protein 
for crystallization.
IV. Comparison of VEE TRD and TC-83 26S Virus RNAs
Sequencing of cDNA clones indicated that epizootic VEE
TRD virus and its vaccine derivative, strain TC-83, differed
at 14 nucleotide positions in the 26S RNA. Only 9 of these
differences were confirmed by primer extension RNA
sequencing. Therefore, 5 differences in the cDNAs were due
to cloning of a minor variant in the RNA population or the
occurrence of cloning artifacts, such as reverse
transcriptase errors during first strand cDNA synthesis.
Genomes of RNA viruses are highly mutable due to lack of
editing functions in the RNA polymerase (Holland et ,
-31984). Nucleotide misincorporation frequencies of 10 to 
-44 X 10 have been calculated in regions of vesicular 
stomatitis virus (Steinhauer and Holland, 1986) and RNA 
bacteriophage QB (Domingo et al., 1978). Thus, it was 
important to verify sequence differences in the cloned cDNAs
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of pTRD-1 and pTC-5 by primer extension sequencing of the 
genomic RNAs of both TRD and TC-83 viruses (Fig. 25).
Mecham and Trent (1982b) reported that the E2 
glycoproteins of VEE TRD and TC-83 virus differed in the 
extent of their glycosylation. Trypsin digestion of
3
purified [ H]-glucosamine-labelled glycoproteins resulted 
in 3 and 2 tryptic peptide peaks for the E2 proteins of TRD 
and TC-83 viruses, respectively. In the present study, the 
deduced amino acid sequence of the TC-83 virus E2 revealed 
that its second glycosylation site occurs in a tryptic 
peptide fragment whose composition (NPTYLITR) differs from 
the cognate tryptic peptide of TRD virus E2 (NPTYLTTR). The 
substitution of lie for Thr in this peptide alters the total 
hydropathic index (Kyte and Doolittle, 1982) from (-9.2)
(TRD virus) to (-4.0) (TC-83 virus). The increased 
hydrophobicity of the TC-83 glycopeptide probably decreased 
its mobility in the reverse-phase high pressure liquid 
chromatography profile (Mecham and Trent, 1982b). The first 
(most hydrophilic) of the three glycosylated tryptic 
peptides of TRD virus E2 was missing in the TC-83 virus E2 
chromatogram, and the second TC-83 peak was larger in area 
than the third TRD peak by an amount approximately equal to 
that of the first TRD peak (Mecham and Trent, 1982b). These 
profiles, in addition to the now available sequence 
information, indicate that the Thr-to-Ile change shifted the 
first glycopeptide peak of TRD virus E2 into the more 
hydrophobic third peak, and that the TRD and TC-83 virus E2 
proteins are equally glycosylated.
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All six of the RNase Tl-resistant oligonucleotide spot 
differences between the oligonucleotide fingerprints of TRD 
and TC-83 viruses (Trent et al., 1979) were found to occur 
in the 26S mRNAs of these viruses (Mecham and Trent,
1982a). The TC-83 virus mutations at 26S RNA nucleotide 
positions 1285 (E2 amino acid position 85), 1919 (E2-296), 
and 3874 (3'-noncoding region) occurred in RNase Tl- 
resistant oligonucleotides (containing only a single G 
nucleotide at the 3'-terminus) of 17, 23, and 38 nucleotide 
lengths, respectively. Mutations in these three 
oligonucleotides of TRD virus may have resulted in their 
altered gel migration, as observed in the fingerprint of VEE 
TC-83 virus. TC-83 virus mutations at 26S RNA nucleotide 
positions 1053 (E2-7), 1391 (E2-120), 1607 (E2-192), 1866 
(E2-278), 2947 (El-161), and 3099 (El-211) occurred in 
oligonucleotides 5 - 1 3  bases in length, which may not have 
been resolved clearly by oligonucleotide fingerprinting. 
Since oligonucleotide fingerprinting resolves only about 10% 
of the RNA genome as isolated, well-resolved oligonucleotide 
spots (Domingo et al., 1978), potential mutations in the 
genes encoding the nonstructural polypeptides, as well as in 
the genes encoding the structural proteins, may not be 
resolved by this technique.
Attenuation of a virulent virus may result from 
mutations in the virus structural proteins to affect virus 
morphogenesis, host cell tropism, and interaction with the 
host immune system, and/or from mutations in nonstructural 
proteins or noncoding regions of the genome, thereby
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affecting virus replication in infected cells. Only 9 
(0.2%) nucleotide mutations were detected in the TC-83 virus 
26S RNA (Table 7). Two of the mutations (one each in El and 
E2) were silent, resulting in no change in the encoded amino 
acid. It seems unlikely that the deletion of a single U 
nucleotide from the UUUUUU string in the A-T-rich 
3’-noncoding region of TRD virus is responsible for the 
attenuated phenotype of VEE TC-83 virus. However, reversion 
to virulence of polio type 3 vaccine virus occurred in one 
case via a single point mutation in the 5'-noncoding region 
of the genome (Evans et ^., 1985).
The conservative Leu-to-Ile change in the El 
glycoprotein of TC-83 virus may play a role in attenuation. 
Reversion of a mutation affecting the isoelectric point of 
the El protein of a temperature-sensitive mutant of VEE virus 
(subtype IE) occurred concomitantly with a reversion to 
virulence (Emini and Wiebe, 1981). Furthermore, Lustig et 
al. (1988) reported that a conservative Ala-to-Val 
substitution at SIN virus El amino acid position 72 resulted 
in attenuation of a neurovirulent SIN virus strain for 
weanling mice.
The nonconservative natures of the 5 amino acid 
substitutions in the VEE TC-83 virus E2 glycoprotein make 
them particularly attractive as potential molecular 
determinants of virulence. These changes occur in 
hydrophilic or weakly nonpolar domains of the E2 
glycoprotein (Fig. 26), and therefore may affect virus 
interaction with the environment. These mutations also
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result in alterations in the predicted secondary structure 
of the TC-83 virus E2 envelope protein (Fig. 27).
Alterations in VEE virus E2 envelope glycoprotein , 
which by monoclonal antibody analysis appears to be involved 
in virus adsorption to cells in vitro (Roehrig et al..
1988), may result in vivo in differential clearance rates of 
virulent and avirulent VEE virus strains from the plasma of 
hamsters and monkeys (Jahrling and Scherer, 1973c; Jahrling 
and Gorelkin, 1975; Jahrling et al., 1977), and in vitro in 
differential pH optima for adsorption to cells (Marker and 
Jahrling, 1979) or elution profiles from hydroxylapatite 
columns (Jahrling and Eddy, 1977). Since virulence in the 
VEE virus complex correlates most consistently with high 
levels of replication and high viraemias in virus-infected 
mice (Le Blanc ^  al., 1978), hamsters (Austin and Scherer, 
1971), guinea pigs (Scherer and Chin, 1977), and equines 
(Johnson and Martin, 1974; Walton et ^., 1972a), rapid 
adsorption of avirulent virus to, and clearance by, cells of 
the reticuloendothelial system (Jahrling and Gorelkin, 1975) 
may help prevent high viraemias and associated rapid 
destruction of haematopoietic cells and entry into the CNS.
Rapid clearance of avirulent VEE viruses is probably 
only one, albeit important, manifestation of the attenuated 
phenotype of VEE virus. A rapid clearance phenotype does 
not explain the benign replication of TC-83 virus in the 
hamster brain following i.e. inoculation (Austin and 
Scherer, 1971) or the lack of severe cytopathology following 
TC-83 or enzootic FIX (subtype 4) virus infection of the CNS
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of mice (Le Blanc et al», 1978). Although early differences 
in intracellular 26S mRNA production between TC-83 and TRD 
virus-infected cells may contribute to slower replication of 
TC-83 virus (Mecham and Trent, 1983), it is doubtful that 
this phenomenon accounts for the avirulence of the 
attenuated virus.
The basic mechanism of attenuation in VEE TC-83 virus 
likely involves altered cell tropisms due to mutations in E2 
and/or perhaps El, which may have multifaceted effects in 
vivo, both peripherally and in the CNS. Mutations in the 
envelope glycoproteins may alter the binding or penetration 
characteristics of the virus for certain target cells, or 
may result in restriction of virus maturation in cell types 
that are permissive for replication of virulent virus. 
Epizootic VEE virus strains and TC-83 virus replicate in 
monocytes isolated from the peripheral blood of donkeys, 
whereas enzootic VEE virus strains MUC, FIX, and 71D-1252 do 
not (Liprandi et al., 1986).
Virulent strains of another alphavirus, SF virus, 
replicate in the spleen, lymph nodes, and brains of infected 
mice, whereas avirulent SF virus strains lose the ability to 
enter the CNS or to damage neurons (reviewed by Atkins et 
al., 1985). Some avirulent SF virus strains fail to produce 
CFE in cultured mouse neuroblastoma cells (Atkins et al.. 
1985). The avirulent A7 mutant of SF virus synthesizes less 
RNA in three cell lines, including neuroblastoma cells, than 
do virulent strains (Atkins, 1983). Both the AR339 and AR86 
strains of SIN virus cause encephalitis in young mice by
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peripheral or i.e. routes (Taylor et al., 1955; Weinbren 
et al.. 1956; Reinarz et al», 1971), although mice become 
resistant to fatal SIN virus encephalitis after one week of 
age (Johnson et al., 1972; Griffin, 1976). Virulent SIN 
virus strains, which have conformational changes in the E2 
envelopeglycoprotein relative to less virulent strains 
(Olmsted et al., 1984; Baric et al., 1981; Stanley et al.. 
1985), replicate to higher titre in the CNS of infected mice 
(Griffin and Johnson, 1977). Since pathogenesis 
characteristics of attenuated and virulent phenotypes of SIN 
and SF viruses show some similarities to those of VEE 
viruses, molecular determinants of virulence that are 
defined in the SIN or SF virus model of encephalitis may be 
applicable to the VEE virus model as well.
Sequence analysis of a number of different 
neurovirulent and avirulent SIN virus strains, including in 
vitro recombinants derived from the infectious cDNA clone of 
SIN virus (Rice et al., 1987), have implicated a number of 
amino acid positions in the El and E2 glycoproteins as 
potential determinants of virulence and attenuation 
(Table 21). Lustig et (1988) found that loci in both 
El and E2 proteins of SIN virus were important for 
neurovirulence in adult mice and that a gradient of 
virulence, depending on the El and E2 loci involved, existed 
for neonatal mice. Studies with SIN virus (Lustig et al.. 
1988; Polo et al., 1988) indicate that neurovirulent and 
attenuated phenotypes of SIN virus are associated with 
various constellations of amino acid residues at 10 loci in
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Table 21. Summary of glycoprotein El and E2 amino acid
positions that have been associated with virulent 
and attenuated phenotypes in alphaviruses
Amino acid substitutions^ at indicated 
amino acid positions for viruses:
Amino Acid
Protein Position VEE^ SIN^ RR^
E2 1 S,A
E2 3 T,I
E2 7 K-N
E2 23 E,V
E2 55 H-Q Delë
E2 70 K,E
E2 85 H-Y
E2 114 S-R
E2 120 T-R
E2 172 G,R
E2 192 V-D
E2 209 G,R
E2 216 G,V
E2 251 V,A
E2 296 T-I
El 72 A,V
El 75 D,G
El 161 L-I
El 237 A,S
El 313 D,G
^(residue #1, residue #2) = both residues found in both 
virulent and attenuated phenotypes.
(residue #1 - residue #2) = residue #1 of virulent phenotype 
replaced by residue #2 of avirulent phenotype.
^Data from this thesis.
^Data from Lustig et (1988), and Polo et (1988). 
âüata from Vrati et al. (1986).
^Deletion (Del) of E2 residues 55-61 resulted in avirulent 
phenotype.
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E2 and 4 loci in El (Table 21). For most loci, phenotypic 
association of either residue of an amino acid pair found at 
a given locus is ambiguous; both residues of the amino acid 
pair are found in both virulent and avirulent phenotypes of 
SIN virus (Lustig et al., 1988; Polo et al., 1988).
However, the His-to-Gln and Ser-to-Arg mutations at SIN 
virus loci E2-55 and E2-114, respectively, are more 
consistently, although not absolutely, associated with 
virulent-to-avirulent phenotypic changes (Table 21; Lustig 
et al., 1988; Davis et al., 1986). A RR virus variant with 
a deletion of amino acids at positions 55 - 61 in E2 was 
attenuated for mice (Vrati et al., 1986). Sequence analyses 
of mutant SIN viruses that were selected for rapid 
penetration in vitro, with resulting attenuation for 
neonatal mice (Baric et ^ . , 1981; Olmsted et al., 1984), 
demonstrated the Ser-to-Arg substitution in E2 at position 
114 in the attenuated SB-RL strain of SIN virus (Davis et 
al.. 1986). The attenuated mutant elicited monoclonal 
antibodies that preferentially neutralized the mutant virus 
as opposed to the parent virus, although the antibody 
reacted similarly with both attenuated and parent viruses in 
binding assays (Olmsted et ^., 1986). The multiple 
association with penetration, Nt, and virulence phenotypes 
makes the E2 locus at amino acid position 114 a 
candidate as a virulence marker for SIN virus.
With the exception of the E2-120 locus, the El and E2 
mutations associated with attenuation of the VEE TC-83 virus 
do not so far appear to show positive correlations with
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potential virulence markers in SIN virus (Table 21). The 
Thr-to-Ser mutation at position E2-120 of TC-83 virus occurs 
in a very hydrophilic domain of E2 and is similar in amino 
acid character to the SIN virus (SB-RL strain) E2-114 
mutation (Davis et al., 1986). Recently, Johnston and Smith 
(1988) obtained seven rapid penetration isolates of VEE TRD 
virus that were avirulent for adult mice. Two of these were 
also avirulent for hamsters. Thus, at least two of the 
protein domains that are involved in virus penetration in 
vitro appear to be associated with virulent and avirulent 
phenotypes. These changes may alter tissue tropisms or 
virus-tissue interactions. Nucleotide sequence analysis of 
these TRD virus variants will undoubtedly prove to be 
interesting and informative.
Determinants of attenuated and virulent phenotypes have 
been identified on the surface envelope proteins of 
influenza virus (Webster et ^., 1982; Webster and Rott, 
1987; Sweet and Smith, 1980), rabies virus (Dietzschold et 
al., 1983; Coulin et al,, 1983), yellow fever virus 
(Schlesinger et al,, 1983; Hahn et al., 1987), and 
bunyaviruses (Gonzalez-Scarano al., 1985), as well as on 
surface proteins of nonenveloped reoviruses (Spriggs and 
Fields, 1982; Fields and Greene, 1982) and polio viruses 
(Omata et al., 1986). Analyses of recombinant polio type 1 
viruses obtained from infectious cDNA clones demonstrated 
that loci involved in attenuation were distributed in 
several regions of the genome and that alterations in
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antigenicity correlated poorly with virulence changes (Omata 
et al., 1986).
Although loss of epitopes involved in Nt of virulent 
virus has been associated with attenuation (Dietzchold 
et al.. 1983), this may not be the operative mechanism of 
attenuation in the TRD - TC-83 VEE virus pair. Of the 
12 epitopes identified on the envelope glycoproteins of VEE 
viruses, only one (E2*) was TC-83 virus-specific by ELISA 
(Roehrig et al.. 1982; Roehrig and Mathews, 1985). This 
epitope is defined by monoclonal antibody (5B4D-6) that has 
no HI or Nt activity. The remaining epitopes, including 
those involved in virus Nt, are conserved in both TRD and 
TC-83 viruses (Roehrig et ^., 1982, Roehrig and Mathews,
1985). Furthermore, Roehrig et (1988) have demonstrated 
that monoclonal antibodies which define epitopes spatially 
proximal to the E2^ Nt epitope are the most effective at 
blocking virus attachment in vitro.
Although this study has identified mutations that are 
associated with the attenuated phenotype of TC-83 virus, the 
relative contribution of each of the mutations remains to be 
assessed. The most direct route of investigation lies in 
recombination experiments utilizing infectious cDNA clones 
of VEE virus. Sequence analysis of rapid penetration 
mutants and variants selected under the pressure of 
monoclonal antibodies should prove invaluable in defining 
protein domains that may contribute to virulence and 
attenuation. Primer extension sequencing of other VEE lAB 
virus RNAs should be performed to determine if the TRD virus
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correlates of the TC-83 virus mutations are consistently 
found in epizootic VEE virus strains. In assessing the 
antigenic, immunogenic, and functional consequences of 
glycoprotein mutations, investigators should recognize that 
biologically active regions of the virion spike may be 
comprised of domains contributed by both El and E2 
glycoproteins, analogous to the influenza A virus "Ca" site, 
which forms an antigenic cleft between haemagglutinin 
subunits (Raymond et al., 1986; Wilson et al., 1971).
This study has focused on the 3'-one-third portion of 
the VEE virus genome, which encodes the structural proteins 
of the virus. Although amino acid mutations have been 
detected in the envelope glycoproteins of TC-83 virus, 
potential mutations in the remaining two-thirds of the 
genome encoding the nonstructural proteins of the virus may 
also play a role in the attenuated phenotype. The complete 
nucleotide sequences of the entire 42S mRNA molecules of 
both TRD and TC-83 viruses must be obtained in order to 
define all of the mutations associated with attenuation in 
this virus pair.
V. Recombinant VACC/VEE Virus
To investigate a eukaryotic expression system as an 
alternative vaccine against VEE virus disease, the cDNA 
inserts from recombinant pUC18 plasmids pTRD-1, pTC-5, and 
pTRD-20, each containing the structural protein genes of the 
respective VEE virus strain, were inserted into VACC virus.
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The VEE virus nucleocapsid protein as well as El, E2, and 
pE2 glycoproteins were expressed in CV-1 cells infected with 
recombinant vaccinia/TC-83 (VACC/TC-5A) or vaccinia/TRD 
(VACC/TRD-IA and VACC/TRD-20A) virus. As shown for 
recombinant VACC virus expressing the structural proteins of 
SIN virus (Rice et al., 1985), VEE virus mRNA apparently was 
transcribed in recombinant VACC/VEE virus-infected cells and 
was translated into a polyprotein precursor that was 
processed to yield VEE virus structural proteins as cleavage 
products, thereby effectively mimicking translation of the 
subgenomic 265 mRNA in cells infected with VEE virus.
Of the twelve epitopes (eight E2 and four El) that have 
been identified on the envelope glycoproteins of VEE virus,
IFA using monoclonal antibodies demonstrated authentic 
expression of E2*, E2^, E2®, E2^, E2®, El^, and 
El^ epitopes in cells infected with recombinant VACC/TC-5A 
or VACC/TRD-IA virus. The monoclonal antibody defining the 
E2^ epitope was not available for this study. Monoclonal 
antibodies 1A6C-3 (E2^) and 1A3B-7 (E2^) reacted equally 
well with detergent-disrupted, purified TRD and TC-83 
viruses by ELISA (Roehrig et al., 1985) and with TRD or 
TC-83 virus-infected CV-1 cells by IFA (Table 13), but 
reacted variably by IFA with acetone-fixed antigens in 
VACC/TC-5A or VACC/TRD-IA virus-infected cells (Table 13).
The reason for the reduced expression of the E2^ 
epitope in VACC/TRD-IA virus-infected cells is unknown. 
However, a possible explanation exists for the E2^ epitope 
discrepancy. The pTRD-1 cDNA clone encodes a Lys
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substitution in the E2 protein at amino acid position 209 
(Glu in TRD genomic RNA). It is possible that this cloning 
artifact may have altered the binding efficiency of 
anti-E2^ monoclonal antibody to the E2 polypeptide 
expressed in VACC/TRD-IA virus-infected cells. If this is 
the case, then recombinant VACC/TRD-IA virus may 
fortuitously have permitted identification of the location 
of the E2^ epitope on the VEE virus E2 glycoprotein. This 
contention should be pursued by IFA analysis of protein 
expression in VACC/TRD-20A virus-infected CV-1 cells and 
perhaps by partial sequencing of the cDNA contained in the 
recombinant pTRD-20 plasmid.
The El^ and El^ epitopes, which were evident by IFA 
in cells infected with VEE TC-83 or TRD virus, were not 
detected by IFA (under identical conditions) in recombinant 
virus-infected cells. The reason for the apparent lack of 
expression of these two El epitopes in recombinant 
virus-infected cells is as yet unknown.
Documentation of the expression of VEE virus 
glycoprotein epitopes in cells infected with recombinant 
VACC/VEE viruses has positive implications for the use of 
these recombinant viruses as alternative live, self- 
replicating virus vaccines. Expression of the E2^ epitope 
is especially important because it defines the critical Nt 
site of VEE virus (Roehrig et ^., 1982; Roehrig and 
Mathews, 1985). Earlier reports demonstrated that purified 
VEE virus E2 glycoprotein induces Nt and HI antibodies in 
immunized rabbits (France et ^ . , 1979; Trent et ^ . , 1979;
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Kinney ^  al., 1983). Epitopes E2^, E2^, E2®, and
E2^, which are defined by VEE virus-specific monoclonal
antibodies with different Nt activities,are located in the
same spatial domain on the glycoprotein spike (Roehrig and
Mathews, 1985). Furthermore, mice passively immunized with
monoclonal antibodies 1A4A-1 (E2^), 1A3A-9 (E2®), and
1A3B-7 (E2^), which efficiently block attachment of VEE
virus to cells in vitro (Roehrig et al., 1988), are
protected from lethal peripheral challenge with several
virulent VEE subtype viruses (Roehrig and Mathews, 1985). 
c hThe E2 and E2 epitopes are the most conserved epitopes 
of the E2 glycoprotein among viruses of the VEE virus 
antigenic complex, and antibodies elicited against these two 
epitopes should provide protection against heterologous VEE 
virus challenge.
Monoclonal antibody 3B2A-9 (El^) has low level Nt 
activity and protective capability against VEE virus in 
passively immunized mice (Roehrig et ^., 1982, Mathews and 
Roehrig, 1982). Passive administration of non-neutralizing 
anti-El^ monoclonal antibody can prevent lethal 
encephalitis in mice (Mathews and Roehrig, 1982; Schmaljohn 
et al.. 1982; Hunt and Roehrig, 1985). These results 
indicate that genetically engineered vaccines which express 
VEE virus epitopes El^ and El^, in addition to E2- 
specific epitopes, may be more effective immunogens than 
recombinant vaccines that express E2 antigenic determinants 
alone.
Immunization with recombinant VACC/TC-5A virus, which
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contains the structural protein genes of VEE TC-83 virus, 
protected three strains of mice against lethal i.p. 
challenge with virulent VEE TRD virus. Anti-VEE virus Nt 
titres in these recombinant virus-immunized mice correlated 
well with Nt titres elicited by TC-83 vaccine virus in 
equines (Jochim et al., 1973) and humans (Burke et al..
1977), and VACC/TC-5A virus-induced immunity appeared to be 
long lasting (Table 17). Two recombinant VACC viruses 
(VACC/TRD-IA and VACC/TRD-20A) containing the structural 
protein genes of VEE TRD virus also protected mice from i.p. 
TRD virus challenge (data not shown). Recombinant VACC 
virus expressing the structural proteins of another 
alphavirus, SIN virus, elicits Nt antibody in cattle.
(Franke et ^ . , 1985).
Epidemics of VEE virus disease have been caused by VEE 
subtype lAB and 1C viruses, which also cause clinical 
disease in experimentally infected monkeys (Monath et al.. 
1974) and horses (Henderson et al., 1971; Walton et al.. 
1973). Mosquito-transmitted human disease has occurred with 
VEE subtype 2 (Ehrankranz et al., 1970) and ID (Franck and 
Johnson, 1970; Johnson et al., 1968) viruses, and laboratory 
infection with the more distantly related VEE subtype 3A 
virus (MUC) has been reported (de Mucha-Macias and 
Sanchez-Spindola, 1965).
Pooled sera from mice immunized with TC-83 or 
recombinant VACC/TC-5A virus neutralized VEE TRD (lAB) and 
P676 (1C) viruses to high titre and EVE (subtype 2), 3880 
(ID), and Mena II (IE) viruses somewhat less effectively
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(Table 18). FIX (subtype 4) virus was not neutralized by 
sera from mice immunized with either vaccine. This pattern 
of cross-reactivity is typical of TC-83 virus-immunized 
humans (Burke et al., 1977; Fillis and Calisher, 1978) and 
equines (Walton et al., 1972a), of antiserum elicited 
against purified VEE TRD virus E2 envelope glycoprotein 
(France et ^., 1979), and of anti-E2 monoclonal antibody 
(Roehrig et ^ . , 1982). TC-83 and recombinant virus-
immunized mice survived an otherwise lethal i.p. challenge 
with high doses of VEE TRD, P676, 3880, and EVE viruses 
(Table 19) as well as Mena II virus (3 IPLD^^ dose), 
although only 50% of the nonimmunized control mice succumbed 
to Mena II virus challenge (data not shown). Apparently, 
even low levels of VEE virus-specific antibodies (Tables 15, 
16, and 18) protect mice against severe peripheral challenge 
with virulent VEE viruses. Chimpanzees immunized with 
recombinant VACC virus expressing the surface antigen of 
hepatitis B virus (HBV) were protected against challenge 
with HBV, even though they possessed no measurable (by 
radioimmunoassay) anti-HBV antibody. However, HBV challenge 
resulted in a measurable anamnestic-like anti-HBV antibody 
response, suggesting that immunologic priming had occurred 
in the immunized chimpanzees (Moss et ^., 1984). Low 
anti-ID and anti-IE VEE virus Nt titres induced in TC-83 
virus-immunized horses disappeared by 14 months 
postvaccination (Walton et ^., 1972a). For long-term 
immunity to ID, IE, and more distantly related VEE subtype 
viruses, other immunogens will probably be necessary.
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VACC/TC-5A virus-induced Nt titres were apparently 
lower in outbred Swiss NIH mice than in inbred A/J or C3H 
mice. Mice immunized with recombinant virus developed lower 
anti-VEE virus HI, ELISA, and Nt titres than did TC-83 
virus-immunized mice. This differential response to the two 
vaccines was expected since TC-83 virus replicates in most 
tissues of mice (Kundin, 1966; Le Blanc et ^., 1978).
TC-83 virus can be recovered in nasopharyngeal secretions of 
immunized humans (McKinney et al., 1963) and monkeys (Monath 
et al., 1974). Replication of TC-83 virus in the 
nasopharynx would be expected to stimulate local secretory 
immunity. This stimulation may account for mouse survival 
after i.n. challenge with TRD virus in TC-83 virus-immunized 
mice, whereas mice immunized with the VACC/TC-5A recombinant 
virus succumbed to i.n. TRD virus challenge (Table 20). 
Invasion of the olfactory tract by virulent VEE virus has 
been demonstrated in monkeys (Danes et al., 1973a, 1973b) 
and hamsters (Dill et al., 1973). Therefore, aerosol 
exposure may lead to CNS infection by a nonhaematogenous 
route. Although passive monoclonal Nt antibody 
(immunoglobulin G) protects mice from peripheral VEE virus 
challenge (Mathews and Roehrig, 1982), it has been 
demonstrated here that passive immunization with monoclonal 
3B4C-4 antibody (anti-E2^) does not protect mice from i.n. 
challenge. Locally stimulated production of immuno­
globulin A is also important in resistance to respiratory 
infection with rubella virus (Ogra et al., 1971), influenza
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virus (Waldman ^  al., 1970), and rhinovirus (Perkins 
et al., 1969).
Recombinant VACC (WR vaccinia strain) viruses encoding 
surface glycoproteins of human respiratory syncytial virus 
(RSV) (Elango et 1986; Wertz et al., 1987) and
influenza A virus (Smith et al., 1983) protected rodents 
from lethal i.n. challenge with RSV and influenza viruses, 
respectively. Replication of the challenge virus was 
inhibited to a greater extent in the lower respiratory tract 
(lungs) than in the upper tract (nasopharynx). Similarly, 
although passive administration of Nt antibody decreased 
replication of RSV in lungs of cotton rats, it had a reduced 
effect on RSV replication in nasal tissues (Walsh et al..
1984); passive antibody protected A/J mice from lethal 
influenza pneumonitis, but not tracheitis, after influenza A 
virus challenge (Ramphal et ^., 1971). Mice that were 
immunized intradermally with recombinant VACC virus 
expressing influenza A virus haemagglutinin developed serum 
anti-haemagglutinin antibodies that prevented lung, but not 
nasal, infection after i.n. challenge with influenza virus 
(Smith et ^., 1986). Unlike the i.d. route of 
immunization, which failed to induce nasal secretory 
antibody, i.n. administration of the recombinant VACC virus 
elicited both serum and nasal secretory anti-haemagglutinin 
antibodies and protected both the lung and upper respiratory 
tract against infection by the challenge virus (Smith et 
al., 1986). Thus, resistance to nasal infection appears to 
be dependent on nasal secretory antibody, whereas
-324-
circulating antibody may be adequate to protect the lower 
respiratory tract. It is possible that the WR VACC virus 
strain provides greater stimulation of mucosal immunity than 
does the Wyeth strain used in this study, since the WR 
strain is reported to be more invasive in mice (Buller 
et al.. 1985). Recently, Esposito et (1987) reported 
that mice immunized with recombinant VACC virus (Wyeth 
strain) expressing the rabies virus glycoprotein survived 
i.e. challenge with rabies virus. This would suggest that 
rabies virus may have been neutralized by immune serum at 
the inoculation site.
Although aerosol transmission of VEE virus may occur 
naturally under appropriate conditions (Kissling et al.. 
1956; Zarate and Scherer, 1968), VEE virus infection in 
equines and humans is usually acquired naturally through 
mosquito transmission. Both TC-83 and VACC/TC-5A virus 
vaccines protect mice against peripheral challenge with 
epizootic-epidemic VEE virus strains (lAB and 1C). However, 
the recombinant VACC virus vaccine is less effective than 
the attenuated live TC-83 virus vaccine in protecting mice 
from i.n. VEE virus challenge. Recombinant VACC/TC-5A virus 
elicits immunity that is more like immunity induced by the 
formaldehyde-inactivated C-84 VEE virus vaccine, which 
protects hamsters against peripheral, but not i.n., 
challenge with VEE TRD virus (Jahrling and Stephenson, 1984)
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VI. Prospects for VACC Virus-Vectored Vaccines
The structural proteins of both TC-83 and TRD viruses 
have been expressed in recombinant VACC viruses.
Recombinant VACC/TC-5A virus-immunized mice were protected 
against lethal peripheral, but not i.n., challenge with 
virulent VEE virus. Peripheral immunization with other 
recombinant VACC viruses, such as those expressing envelope 
glycoproteins of respiratory syncytial and influenza A 
viruses, also fails to elicit effective immunity against 
upper respiratory tract infection by challenge virus. The 
latter vaccines are effective in preventing serious clinical 
disease, as manifested by lower respiratory tract infection 
by challenge virus, despite upper respiratory tract 
infection following challenge. This level of immunity is 
probably unacceptable for laboratory workers at risk of 
aerosol infection with VEE virus, which may infect the CNS 
directly via the olfactory tract. It is possible that 
laboratory workers may be effectively immunized against VEE 
virus infection by combined i.d. vaccination with 
recombinant VACC/VEE virus and i.n. vaccination with an 
inactivated or (preferably) subunit VEE virus vaccine. 
Monkeys should be immunized with the recombinant VACC/TC-5A 
virus to determine if primate responses to the recombinant 
virus vaccine differ from those observed in rodents.
If the VACC/TC-5A virus is tested in equines and is 
efficacious, then the recombinant virus vaccine may be a 
viable alternative to the TC-83 virus vaccine in the field.
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However, the TC-83 virus vaccine is a proven effective 
immunogen for equines under actual epizootic field 
conditions (Walton et al., 1972b). During past epizootics 
of VEE virus, humans were protected indirectly through 
immunization of equines. The removal of susceptible 
amplifying hosts for the virus interrupted the transmission 
cycle and reduced the risk of mosquito-borne transmission of 
VEE virus to humans. If a severe VEE virus outbreak should 
occur in the future, it may be desirable to immunize humans 
at risk of VEE virus infection in epizootic areas. A 
genetically engineered vaccine, such as the recombinant 
VACC/TC-5A virus, may perhaps be safer for children, who are 
most susceptible to severe consequences of virulent VEE 
virus infection, than the TC-83 vaccine virus, which 
exhibits high reactogenicity rates even in adults (McKinney, 
1972; Alevizatos et al., 1967). Use of a genetically 
engineered vaccine would also eliminate the potential risk 
of introducing a virulent revertant of TC-83 virus into the 
environment.
During the 1969 - 1971 VEE virus epizootic, the TC-83 
virus vaccine induced anti-VEE virus antibodies in 29% - 
100% of vaccinated equines (Walton et al.f 1972a; Eddy et 
al.. 1972). Vaccine failures were attributed to heat 
inactivation of reconstituted TC-83 vaccine virus (Johnson 
and Martin, 1974). This problem can largely be overcome by 
utilizing vials containing fewer doses of vaccine. VACC 
virus, on the other hand, is remarkably heat-stable. During 
the smallpox campaign, vaccine was regarded as acceptable
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for use if its titre decreased from 10^ '^ PFU/ml to not 
lower than 10^ "^  PFU/ml after incubation for 1 h at 
100°C (Arita, 1973). Heat-stability of vaccines is an 
important aspect of vaccination in tropical regions of the 
world.
Although recombinant VACC viruses generally elicit 
somewhat lower levels of immunity than develop following 
natural infection, a growing body of literature confirms the 
immunogenic efficacy of these vaccines. Acceptance of 
recombinant vaccinia vaccines for human and animal use will 
certainly require resolution of several issues: (i) an
acceptably safe strain of vaccinia virus must be identified 
or developed. Vaccinia strains Lister, Elstree, New York 
City Board of Health (Wyeth), LC16mO, and LC16m8 are 
examples of relatively safe strains (Bernstein and Bierly, 
1973; Sugimoto et ^., 1985; Morita et al., 1977; Hashizume 
et al.. 1973). The WR strain, which has been extremely 
popular for laboratory investigations of recombinant virus 
vaccines (Table 2), is clearly a neurovirulent virus.
Despite the attenuation that occurs following insertional 
inactivation of the VACC virus TK gene (Buller et al..
1985), the WR VACC virus strain is probably unacceptable for 
human or animal use in the field. The wild-type WR strain, 
selected for neurovirulence in mice, is greater than a 
million-fold more virulent for BALB/cByJ mice by i.e. 
inoculation than the Wyeth strain (Buller et ^., 1985). 
During the smallpox campaign, immunization standards 
required that vaccine strains should not show greater
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tendency to produce generalized or CNS lesions in humans or 
animals than those vaccines that were currently in use, and 
that "neurovaccinia" virus strains should be excluded from 
use (World Health Organization, 1966). (ii) a generally 
acceptable insertion plasmid, cell line, and protocol for 
selective screening of recombinant VACC viruses must be 
defined. The universal practice of selection in the 
presence of the chemical mutagen BUDR is probably 
unacceptable. Falkner and Moss (1988) have constructed a 
new insertion vector that may overcome the deficiencies of 
the TK selection system. Mycophenolic acid (MPA), an 
inhibitor of purine metabolism, reversibly blocks 
development of VACC virus plaques. Expression of the 
E. coli gpt (xanthine-guanine phosphoribosyl transferase) 
gene under control of the 7.5K promoter in the presence of 
xanthine and hypoxanthine in the culture medium overcomes 
the MPA block and permits development of plaques due to the 
replication of recombinant VACC viruses which express both 
gpt and foreign gene insert (controlled by the Ilk 
promoter), (iii) the benefits of immunization with 
recombinant VACC virus, namely immunization against 
naturally acquired disease, must clearly outweigh the low, 
but definite risks associated with the recombinant virus 
vaccine (or any live vaccine). Recombinant VACC viruses 
expressing immunogens of hepatitis B or human 
immunodeficiency virus are possible candidates (Table 2). 
Use of multivalent recombinant virus vaccines, resulting in 
fewer incidences of risk, is probably desirable.
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Use of multivalent recombinant virus vaccines may be 
advisable to avoid VACC virus-immune host suppression of 
vaccine virus replication. Rooney et al, (1988) reported 
that a booster immunization of BALB/c mice with recombinant 
VACC virus expressing the D glycoprotein of herpes simplex 
virus (HSV) type 1, three months after primary immunization 
with the same vaccine virus, induced a 10-fold increase in 
anti-HSV antibody titre. However, immunization with this 
recombinant virus three months following prior immunization 
with recombinant virus expressing the haemagglutinin of 
influenza virus or the surface antigen of hepatitis B virus 
resulted in decreased anti-HSV Nt titres and decreased 
levels of protection against HSV challenge relative to 
animals that had received a single vaccination with the 
recombinant VACC/herpes virus alone (Rooney et al,, 1988). 
Thus, limited replication of recombinant VACC virus in VACC 
virus-immune individuals may be sufficient to elicit an 
anamnestic response against the expressed foreign antigen, 
but primary responses to recombinant VACC virus-vectored 
immunogens may be adversely affected in such individuals. 
However, humans are effectively immunized with 8 X 10^ 
(assuming delivery of 0.025 ml of vaccine virus with titre 
of 10^'^ PFU/ml using a bifurcated needle) or fewer PFU of 
VACC virus (Arita, 1973), and are therefore more sensitive 
to VACC virus than are mice (Table 15). Results obtained in 
recombinant VACC virus-immunized mice should be extrapolated 
to the human situation with caution.
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Simultaneous immunization with two different 
recombinant VACC viruses has been reported (Gillespie 
et al.. 1986; Spriggs et al., 1988). However, none of the 
studies listed in Table 2 involved investigation of bivalent 
or multivalent, single-vector constructs. Such constructs 
may be desirable in terms of readily achievable, high-titre, 
single vaccine dose, but they are technically intractable 
since expression of each heterologous gene must be 
controlled by a dedicated promoter and, perhaps, 
transcription termination signal. Franke and Hruby (1988) 
have expressed chloramphenicol acetyl transferase and 
neomycin genes in various orientations in recombinant VACC 
virus to show that expression of linked foreign genes is not 
sensitive to transcriptional interference from neighboring 
loci. If the VACC/TC-5A construct should prove to be an 
effective immunogen in horses, it may be desirable to 
construct a trivalent VACC virus-vectored vaccine for the 
three equine encephalitides caused by VEE, WEE, and EEE 
viruses. A multivalent recombinant virus vaccine for VEE 
subtype lAB, ID, and IE viruses may also be useful to 
provide more complete, long term protection against 
infection with the latter two virus strains.
VII. Conclusion
The genes encoding the structural proteins of the virulent 
VEE TRD virus and its vaccine derivative, strain TC-83, have 
been cloned and sequenced. Six amino acid mutations, one in
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the El envelope glycoprotein and five in the E2 
glycoprotein, were detected. Mutations in the TC-83 E2 
protein produced alterations in the predicted secondary 
structure of this protein relative to the E2 protein of the 
TRD parent virus. One of the mutations in E2, a Thr-to-Arg 
substitution at amino acid position 120, resembles a 
reported Ser-to-Arg mutation at amino acid position 114 in 
the E2 protein of SIN virus that appears to result in 
virulent-to-attenuated phenotypic drift of SIN virus. The 
other mutations identified in the El and E2 proteins of 
TC-83 virus do not appear to correlate with reported amino 
acid substitutions that have been associated with virulence 
and attenuation in SIN virus.
The genes encoding the structural proteins of VEE TC-83 
virus were inserted into a vaccinia virus expression 
system. The recombinant VACC/TC-5A virus immunized mice and 
protected them from fatal i.p. challenge with VEE subtype 
lAB, 1C, ID, and 2 viruses. Protection against VEE subtype 
IE virus was ambiguous due to the relative avirulence of 
this strain for 8-week-old mice. The TC-83 vaccine virus 
protected mice from i.n. challenge with TRD virus, but 
immunization with the VACC/TC-5A virus did not. Although 
humans may respond more favorably than mice to the 
recombinant VACC virus, the lack of protection against i.n. 
TRD virus challenge in recombinant virus-immunized mice does 
not bode well for the value of this vaccine in protecting 
laboratory workers from aerosols of infectious VEE virus. 
Further research is needed to determine the suitability of
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recombinant VACC virus vaccines for vaccinating equines, and 
perhaps humans, against naturally acquired, mosquito- 
transmitted VEE virus disease. Before a recombinant 
VACC/VEE virus vaccine can be tested in humans, safety 
considerations will require the engineering of a new 
vaccine, using an approved, relatively safe strain of VACC 
virus and a mutagen-free selection system.
In light of the initial successes with the infectious 
cDNA clone of SIN virus, the 5'-two-thirds portion of the 
VEE virus genome should be cloned and sequenced. Completion 
of this project would provide the entire complement of 
mutations associated with the attenuation of TC-83 virus and 
would provide cDNA clones with which to construct an 
infectious full-length clone of VEE virus. This construct 
would permit detailed investigations of protein function via 
in vitro mutagenesis and recombination, which may eventually 
lead to development of an improved VEE virus vaccine with 
low reactogenicity, full immunizing potential, and low 
probability of reversion to virulent phenotype.
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